| P1 | The identification of potent anti-tumor antibodies for ADC therapeutics from patients undergoing immunotherapy | Alexander Scholz, PhD; Jerald Aurellano; Michael Harbell, MS PhD; Danhui Zhang, MD PhD; Samantha O'Connor; May Sumi, BS; Beatriz Millare, BS; Felix Chu, MS; Sheila Fernandez; Cathrin Czupalla; Iraz T. Aydin, PhD; Amy Manning-Bog, PhD; Yvonne Leung, BS, PhD; Kevin Williamson, BS PhD; Chantia Carroll; Dongkyoon Kim, BS PhD; Xiaomu Chen, MS PhD; Sean M. Carroll, BS, PhD; Ish Dhawan, PhD; Ngan Nguyen, BS PhD; Shweta Thyagarajan; Mark Whidden; Gregg Espiritu Santo, BS PhD; Nicole Haaser, MS; Hibah Mahmood; Guy Cavet, PhD; Lawrence Steinman, MD; Tito A. Serafini, PhD; Wayne Volkmuth, BS PhD; Jonathan Benjamin, MD, PhD; William H. Robinson, MD; Norman M. Greenberg, PhD; Daniel Emerling, PhD; Jeff DeFalco | Antibody; B cell; Bioinformatics; Tumor antigens |
| P2 | Intratumoral application of hu14.18-IL2 for treatment of GD2+ pediatric malignancies: A novel immunotherapeutic approach aiming at in-situ vaccination | Romana Gugenberger, PhD; Zachary S. Morris, MD, PhD; Oliver Mutschlechner; Paul M. Sondel, MD, PhD; Hans Loibner, PhD | Antibody; Cytokine; Pediatric tumors; Solid tumors; Vaccine |
| P3 | Evaluating antibody-mediated cellular cytotoxicity and potency of antibody-drug conjugates within three-dimensional tumor models | Chris Langsdorf, BS; Bhaskar S. Mandavilli, PhD; Yi-Zhen Hu; Aimei Chen, Bachelor of Science; Marcy Wickett | Adoptive immunotherapy; Antibody; NK/NK T cell; Solid tumors; T cell; Tumor microenvironment |
| P4 | PBD-based anti-MICA/B antibody drug conjugate with a dual mechanism of action: direct tumor cell killing and restoration of NKG2D-mediated immunosurveillance | Florence Lhospice, Pharm D; Laurent Pouyet, PhD; Ester Morgado; Romain Remark, PhD; Delphine Bregeon, PhD; Adeline Montbel; Nadia Anceriz; Mathieu Blery, PhD; Ariane Morel, PhD; Manel kraiem; Kenneth Crook; Yannis Morel, PhD; Eric Vivier; | Antibody; Immune monitoring; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P5 | Anti-CD38 immunotherapy kills Treg (CD4+CD25+FoxP3+CD38hi) and Breg (CD19+CD24+CD38hi) cells and restores the anti-tumor T-cell repertoire in chronic lymphocytic leukemia (CLL). | Alak Manna, PhD; Sonikpreet Aulukh, MD; Laura J. Lewis-Tuffin, PhD; Taimur Sher, MD; Sikander Ailawadhi, MD; Rami Manuchakian, MD; Asher A. Chanan-Khan; Aneel Paulus, MD; Alak Manna, PhD; | Antigen presenting cells; B cell; Immune suppression; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor microenvironment |
| P6 | Anti-CD38 immunotherapy kills Treg (CD4+CD25+FoxP3+CD38hi) and Breg (CD19+CD24+CD38hi) cells and restores the anti-tumor T-cell repertoire in chronic lymphocytic leukemia (CLL). | Alak Manna, PhD; Sonikpreet Aulakh, MD; Laura J. Lewis-Tuffin, PhD; Taimur Sher, MD; Sikander Ailawadhi, MD; Rami Manuchakian, MD; Asher A. Chanan-Khan; Aneel Paulus, MD; | B cell; Immune adjuvant; Immune suppression; Immune tolerance; Immune toxicity; Leukemia/Lymphoma; Monocyte/Macrophage |
| P7 | Potent tumor-directed T cell activation and tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR™ bispecific antibody | Michelle H. Nelson, PhD; Gabriele Blahnik-Fagan; Robert Bader; Doreen Werchau, BS; Anneli Nilsson; Lill Ljung; Jeannette Bannink, BS; Danielle Mitchell; Lynda Misher; Catherine McMahan; Maria Askmyr; Anna Dahlman; Peter Ellmark, PhD; Gabriela Hernandez-Hoyos; Sara Fritzell; Sara Fritzell | Antibody; Costimulation; NK/NK T cell; T cell; Targeted therapy |
| P8 | Single-cell proteomic analysis of T cells stimulated by Bi-specific T-cell Engagers (BiTEs) shows robust and unique polyfunctional secretion profile | Sean G. Mackay, MBA; Patrick Paczkowski; Brianna Flynn, MS; Kevin Morse; Tiffany A. Coupet, BS; Claire Godbersen, B.S.; Charles L. Sentman; Jing Zhou, MD, PhD; | Antibody; Bioinformatics; Biomarkers; Chemokine; Cytokine; Proteomics; T cell; Targeted therapy; Tumor antigens |
| P9 | Identification and functional profiling of PD-L1 targeted engineered toxin bodies for antigen seeding technology and redirection of T cell response to tumors | Brigitte Brieschke, BS; Sara LeMar; Garrett L. Robinson; Aimee Iberg, Ph.D.; Shaoyou Chu, Ph.D.; Jack P. Higgins, Ph.D.; Erin K. Willert, Ph.D.; Hilario J. Ramos, Ph.D.; | Adoptive immunotherapy; Checkpoint blockade; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P10 | Local radiation with intratumoral anti-disialoganglioside (anti-GD2) and interleukin-2 (IL2) induces significant tumor responses with immunologic memory in a syngeneic murine NXS2 neuroblastoma model | Julie S. Voeller, MD; Amy K. Erbe, PhD; Kayla Rasmussen, Ms; Jacob Slowinski, Mr.; Sabrina VandenHeuvel; Ravi Patel, MD, PhD; Hans Loibner, PhD;Stephen D. Gillies, PhD; Jacquelyn A. Hank, PhD; Alexander L. Rakhmilevich, MD, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; Julie S. Voeller, MD; Julie S. Voeller, MD; | Antibody; Pediatric tumors; Radiotherapy; Solid tumors; Targeted therapy; Tumor antigens |
| P11 | A CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate shows potent anti-tumor activity in pre-clinical models of solid tumors either alone or in combination with a PD-1 inhibitor | Francesca Zammarchi, PhD; Karin Havenith, PhD; Francois Bertelli; Balakumar Vijayakrishnan; Patrick H. van Berkel, Ph.D; | Antibody; Checkpoint blockade; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P12 | Response and toxicity with immune checkpoint inhibition in older patients with non-small-cell lung cancer | Keval B. Yerigeri, BS; Kristen Marrone, MD; Jiajia Zhang, MD, MPH; Julie R. Brahmer, MD; Patrick Forde, MD; Christine L. Hann, MD, PhD; David S. Ettinger, MD; Ronan J. Kelly, MD MBA; Josephine L. Feliciano, MD; Sarah Sagorsky, PA-C; Michelle Turner, NP; Valerie Rowe, NP; Jarushka Naidoo, MD | Checkpoint blockade; Immune toxicity; Solid tumors |
| P13 | Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment | Charles W. Abbott, III, PhD; Sean M. Boyle, PhD; Eric Levy, PhD; Rena McClory; Sekwon Jang, MD; Richard Chen | Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Neoantigens; Tumor evasion; Tumor microenvironment |
| P14 | Durvalumab treatment-induced transcriptional changes in the tumor microenvironment associated with longer survival in patients with late stage Non-Small Cell Lung Cancer (NSCLC) | Ikbel Achour, PhD; Zachary A. Cooper, PhD; Sriram Sridhar; Maria L. Ascierto, PhD; Jixin Wang; Young S. Lee; Natasha Angra; Shaad E. Abedin, MD, FACP; Rajiv G. Raja, PhD; Brandon W. Higgs, PhD; Maria Jure-Kunkel | B cell; Biomarkers; Checkpoint blockade; Dendritic cell; Gene expression; Immune contexture; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P15 | Development of a Robust, Simplified Method to Measure Receptor Occupancy in Peripheral Blood from Patients Treated with a Novel Anti-PD-1 Agent, AB122 | Devika Ashok, PhD; Dana Piovesan, MSc; Sharon Zhao; Hema Singh; Steve W. Young, PhD; Matthew J. Walters, PhD; Lisa Seitz, MSc | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors; T cell |
| P16 | Better efficacy of PD-1 antibody predicted by immune-related adverse effects is impaired by high dose steroids | Xue Bai, MD; Michelle Kim; Gyulnara Kasumova; Tatyana Sharova; Justine V. Cohen, DO; Donald Lawrence, MD; Christine Freedman, RN; Riley Fadden, NP; Krista M. Rubin, MS, FNP-BC; Ryan J. Sullivan, MD; Keith T. Flaherty; Genevieve M. Boland, MD, PhD; | Biomarkers; Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity |
| P17 | Combined MAGE-A1,3/6,4, and 10 expression levels quantified in solid tumors by (BaseScope™) RNA in situ hybridization (ISH) identify targets for immunotherapy | Anshika Bajaj, PhD; Helly Xiao Yan Pimentel; Bingqing Zhang, PhD; Ruby Hsu, PhD; Peter Berglund, PhD; Jan H. Ter Meulen, MD, PhD | Adoptive immunotherapy; Biomarkers; Dendritic cell; Gene expression; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| P18 | Preliminary Evaluation of a Novel Whole Slide Multispectral Assessment of Seven Markers: Potential to Minimize Bias in the Characterization of the Tumor Immune Environment | Carmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Carla Coltharp, PhD; Kristin Roman, MS; Chichung Wang; Nikhil Lonberg, HSDG; Sebastian Marwitz; Tarsem L. Moudgil, MS; William L. Miller, BS; William L. Redmond, PhD; Yoshinobu Koguchi, MD, PhD; Carlo B. Bifulco, MD; Clifford C. Hoyt, MS; Bernard A. Fox, PhD | Biomarkers; Immune contexture; Immune monitoring; Immunoscore; Tumor microenvironment; Tumor stroma |
| P19 | Molecular determinants of response to PD-L1 blockade across tumor types | Romain Banchereau; Ning Leng; Edward E. Kadel, III, BS; Dorothee Nickles, PhD; Steve Lianoglou, BS, MSc, PhD; Oliver Zill; Sushit Jhunjhunwala; Luciana Molinero, PhD; Mahrukh Huseni; Marcin Kowanetz, Ph.D.; Richard Bourgon, BS, PhD; Craig Cummings, PhD; Sanjeev Mariathasan, PhD; Priti S. Hegde, PhD; Thomas Powles, MBBS, MD, MRCP | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Systems biology |
| P20 | A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging | Leeat Keren; Marc Bosse; Robert West; Sean C. Bendall, PhD; Michael Angelo, MD, PhD; | Bioinformatics; Biomarkers; Checkpoint blockade; Immune tolerance; Proteomics; Systems biology; Tumor microenvironment |
| P21 | Deep learning-based PD-L1 tumor cell (TC) scoring improves survival prediction compared to pathologists on durvalumab-treated NSCLC patients | Nicolas Brieu, PhD; Ansh Kapil; Aleksandra Zuraw, Dr.; Supporting Author - Abraham Silva, MD; Supporting Author - Marlon C. Rebelatto, DVM, PhD, DACVP; Supporting Author - Keith E. Steele, DVM, PhD; Presenting Author - Guenter Schmidt, PhD; | Bioinformatics; Biomarkers; Checkpoint blockade |
| P22 | Impact of tumor inherent interferons on immune reactivity and personalized therapy in triple negative breast cancer | Natasha K. Brockwell, BBiomed (Hons); Jai Rautela; Tim Molloy, PhD; Sandra O'Toole, MD, PhD; Vinod Ganju, MBBS, FRACP; Belinda S. Parker; | Biomarkers; Checkpoint blockade; Chemotherapy; Immune contexture; Immune monitoring; Immunoscore; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment; Tumor stroma |
| P23 | Centrifuge-less immunostaining of suspension cells for flow cytometry analysis by DA-Cell™ washer and plate for superior data and workflow | Namyong Kim, PhD; Melvin Lye | CAR T cells; Immune monitoring; Systems biology; T cell |
| P24 | Centrifuge-less red blood cell lysis and immunostaining of whole blood for flow cytometry using DA-Cell washer and plate | Melvin Lye; Namyong Kim, PhD | B cell; Biomarkers; CAR T cells; Immune monitoring; Immune tolerance; Immune toxicity |
| P25 | Consistent pharmacodynamics and immunological responses to the TLR9 agonist, SD-101, following intratumoral injection in multiple cancer types | Albert F. Candia, PhD; Cristiana Guiducci, PhD; Ezra Cohen, MD; Ronald Levy, MD; Mohammed Milhem, MBBS; Antoni Ribas, MD, PhD; Thomas Tuting, MD; Erick Gamelin, MD PhD; Robert S. Janssen, MD; Robert L. Coffman, Jr., PhD | Biomarkers; Checkpoint blockade; Clinical study; Dendritic cell; Gene expression; Immune monitoring; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P26 | High-dimensional flow cytometry of circulating immune cells predicts clinical responses to combination Immune Checkpoint Blockade (ICB) and Radiotherapy (RT) in Gastroesophageal Cancer (GEC) | Joseph Chao, MD; Wanqiu Hou; Yi-Jen Chen, MD, PhD; Helen Chen; Michael Tajon; Marwan Fakih, MD; Peter P. Lee, MD; | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Monocyte/Macrophage; Radiotherapy; Solid tumors; T cell |
| P27 | Tumor mutational burden assessment on FFPE samples using a targeted next-generation sequencing assay | Ruchi Chaudhary, PhD; Dinesh Cyanam, PhD; Vinay Mittal; Charles Scafe; Warren Tom, PhD; Janice Au-Young; Seth Sadis; Fiona Hyland | Bioinformatics; Biomarkers; Checkpoint blockade |
| P28 | Detection and validation of cancer immunotherapy biomarkers in blood and urine-based liquid biopsy | Simo Zhang; Shidong Jia; Amy Wang; Chen Xie | Bioinformatics; Biomarkers |
| P29 | Ensemble computational intelligence reveals novel molecular signatures of cancer biology and pan-cancer survival | Richard T. Williams; Thomas Chittenden; Nicholas A. Cilfone, x; Jeffrey R. Gulcher; | Bioinformatics; Biomarkers; Systems biology |
| P30 | Tracking the cancer immune response using neural network deep learning of serial inflammatory marker data for forecasting timing of therapy | Brendon J. Coventry, MD PhD; Mohsen Dorraki, MSc, BS; Anahita Fouladzadeh, BSc; Andrew Alison; Derek Abbott, PhD; Brendon J. Coventry, MD PhD; | Bioinformatics; Biomarkers; Immune monitoring; Inflammation; Solid tumors; Systems biology; Targeted therapy |
| P31 | Prevalence of high microsatellite instability in cancer patients in the real world | Razvan Cristescu, PhD; Kai-Li Liaw, PhD; Scott Pruitt, MD, PhD; Mark Ayers, PhD; Jianda Yuan, MD, PhD; Thao Vo, MD; Senaka Peter; Andrew Joe, MD PhD; Darcy Hille; Sun Young Rha; Torben Steiniche; Andrey Loboda, PhD | Biomarkers |
| P32 | Monitoring of M-MDSC vs. G-MDSC in clinical studies – which is more important? (monocytic versus granulocytic myeloid derived suppressor cells) | Henry Hepburne-Scott, PhD; Phoebe Bonner-Ferraby | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Granulocyte; Immune monitoring; Monocyte/Macrophage; Myeloid cells; MDSC |
| P33 | DNA damage detected by localized γH2AX is associated with elevated TILs and PD-L1 expression in human colorectal carcinomas. | Shruti Desai, PhD; Parker Sulkowski; Aravind N. Kalathil; Ranjini Sundaram; Ila J. Datar, PHD; Charles Fuchs, MD, MPH; Patricia LoRusso, DO; Ranjit S. Bindra; Kurt A. Schalper, MD, PhD | Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P34 | Clinical application of urinary cell free DNA as a marker for cancer | Jeffrey Ding; Debin Sun; | Biomarkers; Clinical study; Targeted therapy |
| P35 | Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928 | Daniel DiRenzo, PhD; Joanne BL. Tan, PhD; Devika Ashok, PhD; Amy Anderson, PhD; Jenna Jeffrey, PhD; Lisa Seitz, MSc; Manmohan R. Leleti, PhD; Steve W. Young, PhD; Jay P. Powers, PhD; Matthew J. Walters, PhD | Biomarkers; Gene expression; Tumor microenvironment |
| P36 | Defining the expression of Programmed Death-Ligand 2 in high grade glioma tumor microenvironment | Gifty A. Dominah; Victoria E. Sanchez, BS; John Lynes, MD; Nicholas Adamstein; Arnold Obungu, BS, BA; Xiang Wang, MS; Nancy Edwards, BA; Edjah K. Nduom, MD; | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor microenvironment |
| P37 | Multiplexed biomarker quantification to assay and characterize T-cell activation | Shilan Dong, MS; Jason G. Cahoon, BS; Rachit Ohri, PhD; Shilan Dong, MS; | Adoptive immunotherapy; Biomarkers; Costimulation; Cytokine; Immune monitoring; Immune suppression; Proteomics; T cell |
| P38 | Highly multiplex spatial immuno-profiling in FFPE tumor tissue with InSituPlex technology | Sean R. Downing, PhD; Abdul Mohammed, PhD; Abdul Mohammed, PhD; Gourab Chatterjee, PhD; Kevin Hwang, PhD; Julie Xia; Amanda J. Bares, PhD; Michael Murphy; Eloise Wheeler; Armen Changelian; Katir K. Patel, PhD; Bonnie Phillips, PhD; Mael Manesse, PhD | Antibody; Biomarkers; Immune contexture; Immune monitoring; Monocyte/Macrophage; Proteomics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P39 | PD-L1 expression on tumor versus antigen presenting cells investigated with multiplexed IHC using UltiMapper™ I/O assays | Amy Zhang, M.S.; Amy Zhang, M.S.; Alexis Wong, PhD; Max Rubinstein; Laura Sciarra, PhD; Chakib Boussahmain, Mr., B.S; Bonnie Phillips, PhD; Katir K. Patel, PhD; Sean R. Downing, PhD; Stephanie Hennek, PhD | Antibody; Antigen presenting cells; Biomarkers; Immune contexture; Immune monitoring; Immune suppression; Proteomics; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P40 | Intra-assay and inter-assay assessment of reproducibility and quantification of UltiMapperTM I/O PD-1 and PD-L1 immuno-oncology panels for tissue multiplexing | Bonnie Phillips, PhD; Bonnie Phillips, PhD; Katir K. Patel, PhD; Courtney Hebert; Jamie Buell; Sean R. Downing, PhD | Antibody; Biomarkers; Immune contexture; Immune monitoring; Monocyte/Macrophage; Proteomics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P41 | Characterization of circulating biomarkers in subjects with NSCLC using data independent acquisition mass spectrometry reveals host immune response mechanisms | Nicholas Dupuis, PhD; Jakob Vowinckel, PhD; Daniel Heinzmann; Claudia Escher | Biomarkers; Immune monitoring; Inflammation; Proteomics |
| P42 | Expanding insights into the colorectal cancer tumor proteome; unbiased protein profiling reveals multiple proteomic-based tumor subtypes | Jan Muntel; Roland Bruderer; Nicholas Dupuis, PhD; Lukas Reiter | Bioinformatics; Biomarkers; Gene expression; Proteomics; Solid tumors; Tumor microenvironment |
| P43 | The presence of exhausted CD8+ T cells identifies a subset of immunogenic ER+ breast cancer patient tumors | Colt Egelston, PhD; Christian Avalos; Diana L. Simons; Min Hui Lim; Peter P. Lee, MD | Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P44 | Discovery and screening of protein biomarkers with the FirePlex Technology Platform | Timothy P. Erps; Amy Perea, PhD; Russell Neuner, PhD; Bianca Heinrich, PhD; Wayne Austin; Conor Rafferty, PhD; Matt Camilleri; Long To; James Murray, PhD; Daniel Pregibon, PhD; Elnaz Atabakhsh, PhD | Bioinformatics; Biomarkers; Chemokine; Cytokine; Inflammation; Proteomics |
| P45 | Tumor infiltrating T cells: complete workflows allow faster and improved analysis | Cesar Evaristo, PhD; Ramona Siemer, BTA; Philipp Steinbrueck; Zhongjie Yu; David Agorku, BS; Olaf Hardt, PhD; Christian Dose, PhD; Anne Richter, PhD | Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P47 | Immune response in patients treated with autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC from the phase I, open label, dose escalation and cohort expansion study | Izak Faiena, MD; Nazy Zomorodian; Beata Berent-Maoz; Ankush Sachadeva; Adrian Bot, MD, PhD; Fairooz Kabinnavar; Jonathan Said; Gardenia Cheung-Lau; Jia Pang; Mignonette Macabali; Tinle Chodon; Xiaoyan Wang; Paula Cabrera; Paula Kaplan-Lezco; Sandy Liu; Begonya Comin-Anduix, PhD; Allan J. Pantuck, MD; Arie Belldegrun, MD, FACS; Karim Chamie, MD; Alexandra Drakaki, MD,PHD; Izak Faiena, MD; | Clinical trial; Dendritic cell |
| P48 | A high baseline neutrophil-to-lymphocyte ratio in patients receiving anti-PD-1 therapy for head and neck cancer associates with poor prognosis, tumor hypoxia, and tumor M2 macrophage predominance | Corey C. Foster, MD; Riyue Bao, PhD; Sara Kochanny, BA; Arun Khattri, PhD; Rajesh Acharya, MS; Allison Dekker, RN; Yi-Hung Carol Tan, PhD; Elaine Klema, BS; Ryan Brisson, BS; Vassiliki Saloura; Alexander T. Pearson, MD, PhD; Everett E. Vokes, MD; Rom Leidner, MD; Hisham Mehanna, PhD; Tanguy Seiwert, MD | Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; Monocyte/Macrophage; Solid tumors; Tumor microenvironment |
| P49 | Comprehensive immune and molecular analysis of a cohort of non-small cell lung cancer (NSCLC) patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1 | Joel Greshock; Ramaswamy Govindan, MD; Riley R. Curran; Rana Besada; Samantha J. Gates; Victoria Kohler; Meghan E. Bushway; Julian Scherer, PhD; Ying Sonia Ting; Yuting Huang, Master of Science; Yvonne Ware, Masters; April Lamb; Lisa D. Cleary; Melissa Moles; Joel Greshock; Richard B. Gaynor, MD; Matthew J. Goldstein, MD, PhD; Lakshmi Srinivasan | Antigen presenting cells; Biomarkers; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P50 | Characterization of T cell receptor repertoire from FFPE extracted RNA from glioblastoma patients by anchored multiplex PCR and next-generation sequencing | LAURA JOHNSON, PhD; Josh D. Haimes; Namitha M. Nair; Angelo Porciuncula, PhD; Kurt A. Schalper, MD, PhD; | Immune monitoring; T cell |
| P51 | Objective quantitative measurements of PD-L1 expression in tumor tissue by Phosphor Integrated Dots staining in patients with non-small cell lung cancer | Kazuyuki Hamada, MD, PhD.; Ryotaro Ohkuma, MD; Takehiro Takahashi, MD, PhD.; Takeshi Setogawa; Masaru Takahashi; Hisatake Okada; Hiroo Ishida; Yutaro Kubota, MD, PhD.; Hirotsugu Ariizumi, MD. PhD.; Etsuko Satoh, MD, PhD.; Yuya Hirasawa, MD; Yasutsuna Sasaki, MD, PhD.; Kiyoshi Yoshimura, MD, PhD.; Takuya Tsunoda, MD; Satoshi Wada, MD, PhD. | Biomarkers; Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs) |
| P52 | Emergence of an ICOShi CD4 T cell subset correlates with tumor reductions in subjects treated with the ICOS agonist antibody JTX-2011 | Amanda Hanson; Sean M. Lacey, MA Biostatistics; Courtney Hart; Ty McClure; Ellen Hooper, MD; Elizabeth G. Trehu, MD; Deborah Law, DPhil; Christopher Harvey, PhD | Biomarkers; Costimulation; Immune monitoring |
| P53 | X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor inflammatory status in the microenvironment of melanoma | Robert H. Andtbacka, MD, CM, FACS, FRCSC; Robert H. Pierce, Jr., MD; Jean S. Campbell, PhD; Melinda Yushak, MD, MPH; Mohammed Milhem, MBBS; Merrick Ross, MD; Katie Niland; Lu Gan, MD, PhD; Sudha Parasuraman, MD; Yan Wang, PhD | Antigen presenting cells; Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Immune suppression; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P54 | Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444 | Andrew Hotson, PhD; Stephen Willingham, PhD; Lawrence Fong, MD; John D. Powderly, II, MD, CPI; Jason J. Luke, MD, FACP; Mario Sznol, MD; Saby George, MD, FACP; Toni K. Choueiri; Marios Giannakis, MD, PhD; Brian I. Rini, MD; Shivaani Kummar, MD; Erik Evensen; Ian McCaffery, PhD; Chunyan Gu; Long Kwei, PhD; Ginna Laport; Joseph J. Buggy; Richard A. Miller, MD; | Biomarkers; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment |
| P55 | Within the secretome: Immunomodulatory role of extracellular vesicles in breast cancers. | Atousa khiabany, Mres; Fabian Flores-Borja, PhD; Ines García Carcedo; Felix Wong; Fabienne Beuron, PhD; Jose vicencio; Andrew Tutt; Tony Ng; SHEEBA IRSHAD, MD PhD | Immune tolerance; Inflammation; Tumor evasion; Tumor microenvironment |
| P56 | New Dextramer technology for T-cell epitope profiling, and single cell deep phenotyping using DNA barcodes, transcriptomic and genetic sequence analysis, on single cells | Kivin KJ. Jacobsen, PhD; Liselotte Brix, phd | Adoptive immunotherapy; Antigen presenting cells; Autoimmunity; Bioinformatics; Biomarkers; Carcinogenesis; Immune monitoring; Neoantigens; T cell; Tumor antigens |
| P57 | A rapid multi-color fluorescence imaging on frozen tissues | Dinesh Jaishankar, PhD; Cormac Cosgrove, PhD; Caroline Le Poole | Antibody; Immune monitoring |
| P58 | The use of low-coverage sequencing of cell-free DNA for monitoring response to immune checkpoint inhibitors throughout treatment | Taylor J. Jensen, Ph.D.; Aaron M. Goodman; Shumei Kato, MD; Mina Nikanjam; Christopher K. Ellison; Gregory A. Daniels, MD, PhD; Lisa Kim, M.S.; Kimberly Kelly, M.S.; Kerry Fitzgerald, Ph.D.; Erin McCarthy; Prachi Nakashe, M.S.; Amin R. Mazloom; Graham McLennan, M.S.; Daniel S. Grosu, MD, MBA; Mathias Ehrich; Razelle Kurzrock, MD | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Solid tumors; Systems biology |
| P59 | Assessment of consistency of multiplex fluorescent immunohistochemistry data across multiple users utilizing different quantitative analysis strategies | Shawn M. Jensen, PhD; Carmen Ballesteros Merino, PhD; Sebastian Marwitz; Nikhil Lonberg, HSDG; Bernard A. Fox, PhD | Biomarkers; Immune contexture; Immune monitoring; Immunoscore; Tumor microenvironment |
| P60 | Circulating tumor DNA assessment in plasma samples collected in Atezolizumab versus docetaxel in subjects with previously treated non-small-cell lung cancer (OAK) study | Yuqiu Jiang, PhD; Namrata S. Patil, Ph.D.; Johnny Wu; Wei Zou; Stephanie Yaung; Aarthi Balasubramanyam; Susan Flynn; Maureen Peterson; Eric Peters; Priti S. Hegde, PhD; Simonetta Mocci; Marcin Kowanetz, Ph.D.; John Palma | Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Solid tumors |
| P61 | Development of an exosome / EV analysis pipeline for tumor and immune monitoring | Joshua A. Welsh, PhD; Kevin C. Conlon, MD; Milos Miljkovic, MD, MSc; Julia Kepley, BS; Jennifer Marte, BS MD; Jason Savage, PhD; Veronica Galli, PhD; Katherine McKinnon, MS; Katherine Calvo, MD, PhD; Hong Zhang; Cynthia Masison; Fatima Karzai, MD; Fatah Kashanchi; Deborah Citrin; Steve C. Jacobson; James L. Gulley, MD, PhD, FACP; Genoveffa Franchini, PhD; Thomas A. Waldmann, MD; Kevin Camphausen, MD, PhD; Jennifer C. Jones, MD, PhD; Jennifer C. Jones, MD, PhD; | Immune contexture; Immune monitoring; Leukemia/Lymphoma; Radiotherapy; Systems biology; Tumor microenvironment |
| P62 | A Pan-cancer view of the immune landscape in the tumor microenvironment via RNA and their potential for biomarkers in clinical trials | Wendell Jones; | B cell; Biomarkers; Gene expression; Monocyte/Macrophage; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P63 | Estimation of Microsatellite Instability (MSI) by next-generation sequencing using a novel MSI classification method | Sameh El-Difrawy; Annie Kraitcheva; Alice Zheng; Simon Crawley; Asha Kamat, PhD; | Bioinformatics; Biomarkers; Solid tumors |
| P64 | Evaluation of PD-L1 and IRF-1 expression on circulating tumor cells as a predictive biomarker of checkpoint inhibitor response | Laura C. Kennedy, MD PhD; Lance U'Ren, DVM, PhD; Yao Sun; Petros Grivas, MD, PhD; Laura Q. Chow, MD; Vijayakrishna Gadi, MD, PhD; | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring |
| P65 | IDO/HLA-DR expression and tumor mutational burden are complementary predictive biomarkers of anti-PD-1 immunotherapy in squamous cell carcinoma of the head and neck | Arun Khattri, PhD; Ju Young Kim; Riyue Bao, PhD; Rajesh k. Acharya; Yi-Hung Carol Tan, PhD; Rom Leidner, MD; Hisham Mehanna, PhD; Nathan Roscoe; Christine A. Vaupel, PhD; Naveen Dakappagari; Tanguy Seiwert, MD; Sara Kochanny, BA; | Antigen presenting cells; Biomarkers; Checkpoint blockade; Immune monitoring; Neoantigens; Tumor infiltrating lymphocytes (TILs) |
| P66 | Evaluation of Immune – related Markers in circulating proteome and their association with atezolizumab efficacy in patients with 2L+ NSCLC | Marcin Kowanetz, Ph.D.; Ning Leng; Joanna Roder, PhD; Carlos Oliveira, PhD; Senait Asmellash, PhD; Krista Meyer, PhD; Heinrich Roder, DPhil; Marcus Ballinger, PhD; David Shames, Ph.D.; Marcin Kowanetz, Ph.D.; David Shames, Ph.D.; | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune suppression; Immunoscore; Inflammation; Proteomics; Solid tumors |
| P67 | Innovative combinatorial approach to characterize the immune landscape and analyze the tumor response after anti-PD-1 blockade in a 3D ex-vivo tumoroid system of non-small cell lung cancer | Melba Marie Page, Ph.D.; Melanie Mediavilla-Varela, PhD; Jenny Kreahling, PhD; Soner Altiok, MD, PhD | Antibody; Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P68 | Using high dimensional mass cytometry (CyTOF) and machine assisted analysis to detect biomarkers in the immunotherapy of cancer | Carsten Krieg, PhD; Silvia Guglietta; John M. Wrangle, MD; Luis E. Cardenas, B.S.; Mitchell Levesque; Reinhard Dummer, MD; Burkhard Becher;Mark P. Rubinstein, PhD; Mark Robinson; Carsten Krieg, PhD; | Biomarkers; Checkpoint blockade; Clinical trial; Cytokine; Immune monitoring; Inflammation; Monocyte/Macrophage; Myeloid cells; NK/NK T cell |
| P69 | Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy | Rachel Krupa, BS; Robin Richardson; Priscilla Ontiveros; Joseph Schonhoft; Yipeng Wang, PhD, MD; Jiyun Byun, MS; David Lu; Aaron Oh; Sean Nisperos; Mark Landers, MS; Ryan Dittamore, MS | Biomarkers; Checkpoint blockade; Immune monitoring; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P70 | CD4+FOXP3+ regulatory T cells in the periphery of HNSCC patients demonstrate high phenotypic diversity depending on Treg subtype | Cornelius Kürten, MD; Shanhong Lu; Tullia C. Bruno, PhD; Robert L. Ferris, MD, PhD | Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Systems biology; Tumor evasion; Tumor microenvironment |
| P71 | Characterization of tumor mutational burden (TMB) and homologous recombination repair (HRR) mutations to assess correlation with immune checkpoint inhibitors (ICIs) response in renal cell carcinoma | Matthew K. Labriola, MD; Jason Zhu, MD; Rajan Gupta; Shannon J. McCall, MD; Jennifer JJ. Jackson, PhD; James White, PhD; Elizabeth Weingartner; Eric Kong; Peter Simone, Ph.D.; Eniko Papp, Ph.D.; Kelly Gerding, Ph.D.; Eun-Hae Kim, Ph.D.; John K. Simmons, PhD; Daniel J. George, MD; Tian Zhang, MD; Tian Zhang, MD; | Biomarkers; Checkpoint blockade; Solid tumors |
| P72 | Biomarker and preliminary pharmacodynamic evaluations of the PD-1 inhibitor ABBV-181 from an ongoing phase 1 clinical trial in patients with advanced solid tumors | Stacie L. Lambert; Gregory Vosganian, MD; Fiona Harding, PhD; James Sheridan; Stefan Englert, Dr.; Sara Siggelkow; Apurvasena Parikh, PhD; Betty Wang; Kinjal Hew; Jaishree Bankoti; Marcia Stickler; Eileen Lee; Merriam Mcclellan; Daniel Afar, PhD; Anita Reddy, PhD; Stacie L. Lambert; | Biomarkers; Checkpoint blockade; Clinical trial; Solid tumors; T cell |
| P73 | Analysis of survival and mRNA expressivity in the tumor microenvironment of adenocarcinoma via K-means clustering algorithm | Seongwon Lee, PhD; Andrew Baird, MD; Jillian Dolan, BS; Stuart Baird; Fateeha Furqan, MD; Shinyoung Park, MS; Sunyoung S. Lee, MD, PhD; | Gene expression; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P74 | Validation the immune contexture as prognostic biomarkers in high-grade serous ovarian cancer | Shin Wha Lee, MD; Ju-hyun Kim; Soo-Jung Kim; Yong-Man Kim | Immune contexture; Immunoscore |
| P75 | Development of a next-generation sequencing-based microsatellite instability assay (MSI-NGS) for solid tumor testing | Sean T. Glenn, PhD; Sarabjot Pabla, MSc, PhD, BS; Jonathan Andreas, MS; Blake Burgher, BS, RN; Jacob Hagen; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Vincent Giamo, BS, MS; Felicia L. Lenzo; Maochun Qin, MD, MS; Yirong Wang, M.S.; Mark Gardner; Carl D. Morrison, MD, DVM | Biomarkers; Solid tumors |
| P76 | Analysis of the complex immune-cell milieu of tumors from patients treated with immunotherapy to better understand clinical response | Shumei Kato, MD; Ryosuke Okamura; Mina Nikanjam; Ramez N. Eskander, MD; Paul Fanta, MD; Suzanna Lee; Sean T. Glenn, PhD; Devin Dressman, PhD; Sarabjot Pabla, MSc, PhD, BS; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Felicia L. Lenzo; Mark Gardner; Carl D. Morrison, MD, DVM; Razelle Kurzrock, MD | Biomarkers; Gene expression; Solid tumors; T cell; Tumor microenvironment |
| P77 | Identifying major immune-related subsets of GI tumors for clinical purposes | Amy P. Early, MD; Sarabjot Pabla, MSc, PhD, BS; Jeffrey Conroy, BS; Mary Nesline, MS; Sean T. Glenn, PhD; Felicia L. Lenzo; Antonios Papanicolau-Sengos, MD; Blake Burgher, BS, RN; Vincent Giamo, BS, MS; Jonathan Andreas, MS; Yirong Wang, M.S.; Carl D. Morrison, MD, DVM | Biomarkers; Immune monitoring; Solid tumors; Tumor microenvironment |
| P78 | More sensitive identification of T-cell receptor beta rearrangements with an augmented transcriptome method | Sean M. Boyle, PhD; Eric Levy, PhD; Gabor Bartha; Pamela Milani; Robin Li; Shujun Luo; Rena McClory; John S. West, MBA; Richard Chen | Bioinformatics; Biomarkers; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P79 | Change in neutrophil to lymphocyte ratio during treatment with immune checkpoint inhibitors predicts survival in patients with advanced cancer | Dan Spakowicz, PhD, MS; Jarred Burkart; Sandip Patel; Marium Husain, MD, MPH; Kai He, MD, PhD; Carolyn Presley; Erin Bertino; Peter Shields; David P. Carbone, MD, PhD; Claire Verschraegen, MD; Greg Otterson; Kari Kendra; Mingjia Li, MD; Dwight Owen | Biomarkers; Checkpoint blockade; Immune monitoring; Inflammation |
| P80 | Day-to-day profiling of T cell activation by measuring cellular markers and secreted cytokines in a rapid multiplexed cell/bead mixture assay | Zhaoping Liu, Ph.D.; | Adoptive immunotherapy; Biomarkers; CAR T cells; Checkpoint blockade; Cytokine; Immune monitoring; Immune suppression; Immune tolerance; T cell; Tumor evasion |
| P81 | Germline encoded TRBV polymorphism predicts adverse events during checkpoint blockade immunotherapy | Timothy Looney, PhD; Geoffrey M. Lowman, PhD; Asha Kamat, PhD; Fiona Hyland | Autoimmunity; Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Immune monitoring; Immune toxicity; T cell |
| P82 | Peripheral blood TCRB repertoire convergence and clonal expansion predict response to anti-CTLA-4 monotherapy for cancer | Timothy Looney, PhD; Li Zhang, MD PhD; David Y. Oh, MD, PhD; Denise S. Topacio-Hall, BS, MA; Lawrence Fong, MD | Bioinformatics; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; T cell; T cell lineages; Tumor antigens |
| P83 | T cell receptor beta immune repertoire sequencing in several FFPE tissue types – Interrogation of the tumor microenvironment in archived tissue samples | Denise S. Topacio-Hall, BS, MA; Lauren Miller, BS; Elizabeth Linch, BS; Alice Zheng, PhD; Geoffrey M. Lowman, PhD; Timothy Looney, PhD; Mark Andersen, PhD | Biomarkers; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P84 | Quantitative evaluation of tumor-infiltrating lymphocyte subsets and PD-L1 expression in lung cancer brain metastases | Benjamin Y. Lu, MD; Richa Gupta; Hailey Wyatt; Matthew Ribeiro; Tyler Stewart; Veronica Chiang, MD; Joseph Contessa; Adebowale Adeniran; Harriet Kluger, MD; Lucia Jilaveanu, MD; Kurt A. Schalper, MD, PhD; Sarah B. Goldberg, MD, MPH | Immune monitoring; Immune suppression; Inflammation; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P85 | Correlation of clinical response and pathologic treatment effect after 4 weeks of preoperative PD-1 blockade in primary head and neck squamous cell carcinoma (HNSCC) | Adam Luginbuhl, MD; Jennifer Johnson, MD; Madalina Tuluc, MD; Stacey Mardekian, MD; Chandala Chitguppi, MD; Larry Harshyne, PhD; Ralph G. Zinner, MD; Joseph Curry, MD; David Cognetti, MD; Ulrich Rodeck, MD PhD; Athanassios Argiris, MD PhD | Checkpoint blockade; Clinical trial; Immune monitoring; Immunoscore; Solid tumors; Surgery; Tumor microenvironment |
| P86 | T-cell receptor (TCR) repertoire features associated with disease-free survival following infusion with marrow-infiltrating lymphocytes (MILs) | Eric R. Lutz, PhD; Alex Hopkins, PhD; LAKSHMI RUDRARAJU, MS; Elizabeth DeOlivera; Ido Weiss, PhD; Rachel Gittelman, PhD; Erik Yusko, PhD; Kathryn G. Boland, DVM, PhD; Ivan M. Borrello, MD; Kimberly A. Noonan, Ph.D.; | Adoptive immunotherapy; Biomarkers; Immune monitoring |
| P87 | Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial | Susan K. Lyman; Judi Gordon; Amy DuPage; Preeti Pramanik; Bruce Howng; Michael B. Winter; Irina K. Popova; Olga Vasiljeva; James Jones; Kenneth R. Wong, MA; Victoria Singson; Jennifer H. Richardson, PhD; Beiyao Zheng, PhD; Mark Stroh, PhD; Lori Carman, RN; Vanessa Huels; Karen Autio, MS, MD; Valentina Boni; Daniel C. Cho, MD; Javier Garcia-Corbacho; Iván Victoria Ruiz; Omid Hamid, MD; Nataliya Uboha; Elisabeth de Vries; Anthony El-Khoueiry, MD; Alexander I. Spira, MD, PhD, FACP; Rachel E. Sanborn, MD; Fiona Thistlethwaite, MD, PhD; Hendrik-Tobias Arkenau; Johanna Bendell; Patrick A. Ott, MD, PhD; Naiyer A. Rizvi, MD; Matthias Will, MD; W. Michael Kavanaugh, MD; Aung Naing, MD, FACP; Luc R. R. Desnoyers, Ph. D. | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune monitoring; Leukemia/Lymphoma; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P88 | Quantitative assessment and standardization of the programmed death 1 ligand 1 (PD-L1) immunohistochemistry companion diagnostic assays | Sandra Martinez-Morilla, PhD; John McGuire; Patricia Gaule, PhD; Lauren Moore; Balazs Acs; Delphine Cougot; David L. Rimm, MD, PhD; | Antibody; Biomarkers; Checkpoint blockade; Targeted therapy |
| P90 | Using artificial intelligence to predict response to immunotherapy | Joseph S. Krueger, BS PhD; Karen Ryall, PhD, BS; Navi Mehra; Jenifer Caldara, BS; Will Paces, BS; Kelsey Weigel, PhD | Biomarkers; Checkpoint blockade; Clinical trial; Immune contexture; Immune suppression; Immune tolerance; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P91 | It’s pan-o’clock: Tumor and circulating lymphocytic pan-pathology targets of the failed immune response | Anne Monette, PhD; Antigoni Morou, PhD; Nadia Al-banna; Louise Rousseau, RT; Jean-Baptiste Lattouf, MD, FRCSC; Sara Rahmati; Tomas Tokar; Daniel Kaufmann, MD; Jean-pierre Routy; Igor Jurisica, PhD; Rejean Lapointe, PhD | B cell; Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P92 | Predictive plasma proteomic biomarkers of immunotherapy toxicity in patients (pts) with metastatic melanoma (MM) | Meghan J. Mooradian, MD; Xuesong Gu; Donald Lawrence, MD; Justine V. Cohen, DO; Tatyana Sharova; Genevieve M. Boland, MD, PhD; Towia A. Libermann; Ryan J. Sullivan, MD; | Biomarkers; Immune monitoring; Immune toxicity; Proteomics; Solid tumors |
| P93 | Pre-analytical variables affect myeloid-derived suppressor cell quantitation by flow cytometry | Chihiro Morishima, MD; Amy E. Wright; Angela M. Riggins; Chihiro Morishima, MD; Minjun Apodaca | Biomarkers; Immune monitoring; Myeloid cells; MDSC |
| P94 | Measurement of adenosine and other immunomodulators in the tumor microenvironment by in vivo microdialysis | Nadege Morisot, PhD; Julien Roeser, PhD; Holden Janssens, PhD; Arash Rassoulpour, PhD | Biomarkers; Immune contexture; Immune monitoring; Solid tumors; Tumor microenvironment |
| P95 | Modulation of adenosine levels in the tumor microenvironment following treatment with anti-PD1 antibodies and oxaliplatin: an in vivo microdialysis study | Arash Rassoulpour, PhD; Nadege Morisot, PhD; Julien Roeser, PhD; Holden Janssens, PhD | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; Targeted therapy; Tumor microenvironment |
| P96 | Assessment of RNA turbulence and PD-L1 expression on tumor-infiltrating lymphocytes in breast cancer | Apoorva L. Mylavarapu, BS; Scott Morris; Maulik Patel, PharmD, PhD; Sandip P. Patel, MD | Biomarkers; Gene expression; Tumor infiltrating lymphocytes (TILs) |
| P97 | Different functionality of CD8 PD-1-positive CD28-negative T cells in the periphery and in the tumor of lung cancer patients | Belinda Palermo; Ornella Franzese; Mariangela Panetta; Giulia Campo; Fabiana Cecere; Virginia Ferraresi; Gabriele Alessandrini; Francesco Facciolo; Gennaro Ciliberto, MD; Paola Nistico', MD | Checkpoint blockade; Coinhibition; Costimulation; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P98 | High gene expression of estrogen and progesterone receptor is associated with increased T cell infiltration in patients with NSCLC | Michael S. Oh, MD; Jonathan Anker, MD; Young Kwang Chae, MD; | Gene expression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P99 | RRx-001 is a Phase 3-Ready small molecule dual inhibitor of CD47 and SIRPalpha | Pedro Cabrales, PhD; Bryan Oronsky, MD PhD; Tony Reid, MD PhD; Corey A. Carter, MD; | Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P100 | Exploring dissociated human tissues as an alternative to fresh tissue for multiple downstream applications | Shawn Fahl, Ph.D.; | B cell; Biomarkers; Myeloid cells; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P101 | Evaluation of ctDNA mutations detected in plasma as potential correlate of immunotherapy efficacy in NSCLC patients | Namrata S. Patil, Ph.D.; Yuqiu Jiang, PhD; Wei Zou; Johnny Wu; Stephanie Yaung; Susan Flynn; Maureen Peterson; Eric Peters; Priti S. Hegde, PhD; Marcin Kowanetz, Ph.D.; John Palma; Namrata S. Patil, Ph.D.; David Shames, Ph.D.; Yuqiu Jiang, PhD; Namrata S. Patil, Ph.D.; | Biomarkers; Clinical trial; Neoantigens |
| P102 | Localized measurement and clinical significance of OX40 and OX40L expression in human non-small cell lung cancer (NSCLC) | Angelo Porciuncula, PhD; Micaela Morgado; Sima Zacharek, PhD; Maria Toki, MD, MSc; Kostas Syrigos; Vamsidhar Velcheti, MD FACP; Joshua Frederick, PhD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD | Costimulation; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P103 | Bulk and single-cell TCR and transcriptome profiling reveals significant phenotypic, spatial and temporal heterogeneity in the TIL repertoire of pancreatic cancer and melanoma patients | Chin Leng Tan; Ignacio Heras-Murillo, MSc.; Katharina Lindner; Aaron Rodriguez Ehrenfried; Lena Appel; Anna-Katharina Koenig; Markus Buechler; Ugur Sahin, MD; Jessica Hassel; Oliver Strobel; Michael Flossdorf; Rienk Offringa, PhD; Isabel Poschke, PhD | Adoptive immunotherapy; Immune contexture; Immune monitoring; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P104 | Radiomic features that can predict response to PD-1 inhibitors in late-stage Non-Small Cell Lung Cancer are also associated with tissue-derived measures of immune response | Prateek Prasanna, PhD; Mohammadhadi Khorrami, PhD; Pradnya Patil; Kaustav Bera, MBBS; Vamsidhar Velcheti, MD FACP; Anant Madabhushi, PhD; | Biomarkers; Immune monitoring; Tumor infiltrating lymphocytes (TILs) |
| P105 | Response to immunotherapy in hepatocellular carcinoma, a single-institutional analysis | Petra Prins; Bhavana P. Singh, MD; AIwu He | Biomarkers; Chemotherapy; Solid tumors; Targeted therapy |
| P106 | Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment (TME) across tumor types | Jason Ptacek, PhD; Rachel Finck; Murat Aksoy; Jay Tarolli; Jessica Finn; | Biomarkers; Immune monitoring; Immune suppression; Monocyte/Macrophage; Proteomics; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P107 | A comparative study of the PD-L1 IHC 22C3 and 28-8 assays in melanoma samples | Gabriel S. Krigsfeld, Ph.D.; Kim Zerba; James Novotny Jr; Shuntae Williams; Michael Matthews, M.S.; Hytham Al-Masri, PhD; David Gold; James White | Antibody; Biomarkers; Checkpoint blockade; Solid tumors |
| P108 | HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumab | Anton Safanov; John Pluta; Lu Qian; Ravi Amaravadi; Allison Applegate; Elizabeth Buchbinder, MD; Justine V. Cohen, DO; Claire Friedman, MD; Ruth Halaban, PhD; F. Stephen Hodi, Jr., MD; Christine E. Horak, PhD; Douglas B. Johnson, MD, MSCI; John M. Kirkwood, MD; Tara C. Mitchell; William A. Robinson, MD, PhD; Lynn M. Schuchter, MD; Jeffrey A. Sosman, MD; Mario Sznol, MD; Megan Wind-Rotolo, PhD; Jedd D. Wolchok, MD, PhD; Mingyao Li; Peter Kanetsky; Katherine L. Nathanson | Antigen presenting cells; Autoimmunity; Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Immune toxicity; Tumor microenvironment |
| P109 | Clinical efficacy of immune checkpoint inhibitors in patients with small cell lung cancer is associated with high tumor mutational burden and development of immune-related adverse events | Biagio Ricciuti, MD; Suzanne Dahlberg; Sasha Kravets; Safiya Subegdjo; Renato Umeton; Adem Albayrak, M.S.; Lynette M. Sholl; Mark M. Awad | Biomarkers; Checkpoint blockade; Immune toxicity |
| P110 | Modular repertoire analysis of blood transcriptomic immune response in metastatic renal cell carcinoma patients treated with Pazopanib | Darawan Rinchai, PhD; Elena Verzoni; Agata Cova; Paola Squarcina; Loris D. Cecco; Paolo Grassi; Raffaele Ratta; Veronica Huber; Matteo Dugo; Monica Rodolfo; Jessica Roelands, Master; Damien Chaussabel; Giuseppe Procopio; Davide Bedognetti, MD, PhD; Licia Rivoltini, MD; | Bioinformatics; Clinical study; Gene expression; Immune monitoring; Immune suppression; Systems biology |
| P111 | Streamlined human immune monitoring with mass cytometry: 29 markers in a single tube with automated data analysis | Christina Loh, PhD; Thiru Selvanantham, PhD; Leslie Fung; Michelle M. Poulin; C. Bruce Bagwell; Margaret Inokuma; Clare Rogers, MS; Greg Stelzer, PhD; Steven Lott, PhD | B cell; Bioinformatics; Biomarkers; CAR T cells; Immune monitoring; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; Proteomics; T cell |
| P112 | Proteomic profiling of biomarkers for response to checkpoint immunotherapy in melanoma patients | Marijana Rucevic, PhD; | Biomarkers; Checkpoint blockade; Immune monitoring; Proteomics |
| P113 | Digital spatial profiling of bone-marrow infiltrating immune cells in acute myeloid leukemia. | Sergio Rutella, MD, PhD, FRCPath; Jayakumar Vadakekolathu, PhD; Sarah E. Church; Heidi Altmann; Elena Viboch, MS; Jorn Meinel, MD; Yan Liang, MD PhD; Joseph M. Beechem, PhD; Alessandra Cesano, MD, PhD; Sarah Warren, PhD; Gerhard Enhinger, MD; Marc Schmitz, MD; Martin Bornhauser, MD; Sergio Rutella, MD, PhD, FRCPath; | Gene expression; Immune contexture; Immune suppression; Immune tolerance; Leukemia/Lymphoma; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment |
| P114 | ImmunoINTEL, a flow cytometry based platform that identifies and quantifies the most critical cell subsets and related functional potential in dissociated solid tumors | Konstantin Salojin, PhD; Christine Hauther; Dai Liu; Santosh Putta; Norman B. Purvis, Jr., PhD; Matt Westfall, PhD | Biomarkers; Immune monitoring; Immunoscore; Monocyte/Macrophage; MDSC; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P115 | Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma | Robert Holt, PhD; David Micklem, PhD; Anthony Brown; Cornelia Schuster; Oddbjørn Straume; James Lorens, PhD | Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Coinhibition; Cytokine; Targeted therapy |
| P116 | Quantitative measurement of CD8, CD68 and PD-L1 expression in a novel multiplex assay and associations of overall survival in non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 Therapy | Fahad S. Shabbir, MD; Jon Zugazagoitia, MD; Yuting Liu, PhD candidate; Katir K. Patel, PhD; Brian S. Henick, MD; Scott N. Gettinger, MD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD | Antibody; Biomarkers; Checkpoint blockade; Immune monitoring; Monocyte/Macrophage; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P117 | Host immune response in undifferentiated pleomorphic sarcoma – 10-year retrospective analysis | Joseph Sheridan; Andrew Horvai; Ross Okimoto; Rosanna Wustrack; | Immune monitoring; Solid tumors; Surgery; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P118 | Immunosuppression involving MDSC and IL-17 is associated with decreased levels of serum rapid turnover protein and shorter survival in patients with gastrointestinal cancer | Masahiko Shibata, MD; Kenji Gonda, MD, PhD; Takahiro Nakajima; Tatsuo Shimura; Koji Kono; Seiichi Takenoshita; | Biomarkers; Cytokine; Immune suppression; Immune tolerance; Inflammation; Myeloid cells; MDSC |
| P119 | Fab-selective proteolysis coupled with liquid chromatography-mass spectrometry for monitoring therapeutic antibodies in circulation | TAKASHI SHIMADA, PhD; Noriko Iwamoto, PhD | Antibody; Biomarkers; Immune monitoring |
| P120 | Validated next generation sequencing assay for the characterization of the T-cell repertoire from RNA | Jennifer K. Sims; Martin Buchkovich, PhD; Jason Powers; Victor J. Weigman, Jr.; John Pufky; Jennifer Mason, PhD; Patrick Hurban, PhD | Biomarkers; Immune monitoring; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P121 | Interaction of immune checkpoints in tumor-stromal microenvironment of primary and chemoreduced retinoblastoma | Lata Singh, Ph.D.; Mithalesh K. Singh; Seema Kashyap; Seema Sen, MD; Moshahid A. Rizvi, PhD; | Chemotherapy; Pediatric tumors; Tumor microenvironment; Tumor stroma |
| P122 | Validated next generation sequencing RNA-based assay of the IGHV mutation status and repertoire diversity | Jeran Stratford; Jennifer K. Sims; Patrick Hurban, PhD; Victor J. Weigman, Jr.; | Antibody; B cell; Bioinformatics; Biomarkers; Immune monitoring |
| P123 | Peripheral blood lymphocyte responses in patients with renal cell carcinoma treated with high-dose interleukin-2 | Rupal Bhatt, MD, PhD; Lei Sun, Ph.D; William J. Slichenmyer, MD; Sean Rossi; Juan C. Alvarez, PhD; Wenxin Xu, MD; Heather C. Losey, PhD | Biomarkers; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P124 | Quantitative multichannel immunofluorescence imaging to assess the immune composition of the T cell-inflamed tumor microenvironment in bladder cancer | Randy F. Sweis, MD; Ken Hatogai; Danny Kim; Yuanyuan Zha, PhD; Alexander T. Pearson, MD, PhD; Gary D. Steinberg, MD; Thomas F. Gajewski, MD, PhD; | Antigen presenting cells; Biomarkers; Checkpoint blockade; Dendritic cell; Immune contexture; Immune monitoring; Inflammation; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P125 | DNA methylation biomarkers for noninvassive detection of hepatocellular carcinoma | David J. Taggart, PhD; Dhruvajyoti Roy, PhD; Gen Li; Dan Liu; Lianghong Zheng; Kang Zhang; | Biomarkers; Clinical study; Solid tumors |
| P126 | Peripheral immune monitoring identifies biomarkers of response and toxicity after neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanoma | Ahmad A. Tarhini, MD, PhD; Ghanashyam Sarikonda; Arjun Khunger, MD; Jack El-Sawada, MD; Christian Laing; Christine A. Vaupel, PhD; Naveen Dakappagari | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Immune monitoring; MDSC; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P127 | Characterization of changes in tumor immune microenvironment after treatment with neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanoma | Arjun Khunger, MD; Jennifer Bordeaux, PhD; Ju Young Kim; Christine A. Vaupel, PhD; Naveen Dakappagari; Ahmad A. Tarhini, MD, PhD | Biomarkers; Checkpoint blockade; Immune monitoring; MDSC; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P128 | Multiplexed immunofluorescent assay development for study of the PD-1/PD-L1 checkpoint in the tumor immune microenvironment (TIME) | Sneha Berry, MS; Nicolas A. Giraldo, MD PhD; Peter Nguyen, MS; Benjamin Green, BS; Haiying Xu; Aleksandra Ogurtsova; Abha Soni, DO; Farah Succaria, MD; Daphne Wang, MS; Charles Roberts; Julie E. Stein, MD; Elizabeth L. Engle, MSc; Drew M. Pardoll, MD, PhD; Robert A. Anders, MD, PhD; Tricia Cottrell, MD, PhD; Janis M. Taube, MD, MSC | Biomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment |
| P129 | Simultaneous single cell analysis of multiple analytes resolves T cell populations at high resolution | Sarah Taylor, PhD; Katherine A. Pfeiffer; Michael JT. Stubbington, PhD; Josephine Y. Lee; Jerald Sapida; Liselotte Brix, phd; Kivin KJ. Jacobsen, PhD; Bertrand Yeung; Xinfang Zhao; Tarjei Mikkelsen; Deanna M. Church, PhD | Antigen presenting cells; Gene expression; Immune monitoring; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P130 | A measurable immune response in the tumors and lymph nodes of patients with lymph node positive and lymph node negative breast cancer. | Archana Thakur, PhD; Dana L. Schalk; Tayson Lin; Griffin R. Calme, B.S.; Johnson Ung; Lawrence G. Lum, MD, DSc; Lydia Choi | Biomarkers; Immunoscore; T cell; Tumor infiltrating lymphocytes (TILs) |
| P131 | High-plex predictive marker discovery for melanoma immunotherapy treated patients using NanoString® Digital Spatial Profiling | Maria Toki, MD, MSc; Pok Fai Wong, MD, MPhil; James W. Smithy, MD, MHS; Harriet Kluger, MD; Chris Merritt, PhD; Giang Ong, MS; Sarah Warren, PhD; Joseph M. Beechem, PhD; David L. Rimm, MD, PhD | Biomarkers; Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P132 | RNA sequencing of rare antigen-specific T cells and tissue micro-regions using the RareCyte platform | Lance U'Ren, DVM, PhD; Rebecca Podyminogin; Nolan Ericson; Eric Kaldjian, MD; Tad George, PhD | Biomarkers; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P133 | Spatially resolved and multiplexed immunoprofiling of NSCLC using imaging mass cytometry reveals distinct functional profile of CD4 and CD8 TILs associated with response to immune checkpoint blockers | Franz Villarroel-Espindola, Ph.D.; Miguel F. Sanmamed, MD, PhD; Jonathan Patsenker; Ya-Wei Lin; Brian S. Henick, MD; Jovian Yu; Mark Verburg; Tayf Badri; Jon Zugazagoitia, MD; Daniel E. Carvajal-Hausdorf, MD; Ruth Montgomery, Ph.D.; Roy S. Herbst, MD, PhD; Lieping Chen, MD, PhD; David L. Rimm, MD, PhD; Tal Shnitzer, Ph.D.; Ronen Talmon, Ph.D.; Yuval Kluger, Ph.D.; Kurt A. Schalper, MD, PhD; | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P134 | Prognostic and predictive value of baseline biomarkers in advanced non-small cell lung cancer (NSCLC) | Huifen Wang, PhD; Robert McEwen; Ketan Patel, PhD; Binbing Yu; J Carl Barrett; Kris Sachsenmeier, PhD | Adoptive immunotherapy; Biomarkers |
| P135 | Integrative genomic and proteomic analysis identifies cancer subtypes and signaling networks associated with aberrant tumor expression of VISTA | Duncan Whitney, PhD; Anna W. Ma, MS; Ramachandra Mu. Katabathula, Ph.D.; Timothy Wyant; Jefferson Parker; Salendra Singh, MS; David Tuck; Vinay Varadan, PhD; | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Tumor stroma |
| P136 | Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumab | Breelyn A. Wilky, MD; SuFey Ong; Sarah Warren, PhD; Alessandra Cesano, MD, PhD; Despina Kolonias; Eric Wieder, PhD; Deukwoo Kwon, PhD; Andrew Rosenberg, MD; Jonathan C. Trent, MD, PhD; Krishna Komanduri, MD | Angiogenesis; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors |
| P137 | A systematic literature review (SLR) of tumor mutational burden (TMB) and efficacy with immunotherapy (IO) in lung cancer | Connor Willis, PharmD; Michelle Fiander; Dao Tran, PharmD; Beata Korytowsky; John-michael Thomas, PharmD; Signe Fransen; Florencio Calderon; Teresa Zyczynski; Lisa Siegartel; Diana Brixner; David Stenehjem; Connor Willis, PharmD; | Biomarkers; Checkpoint blockade; Solid tumors |
| P138 | Quantitative assessment of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma | Pok Fai Wong, MD, MPhil; Wei Wei, MD, PhD; Swati Gupta, PhD; James W. Smithy, MD, MHS; Harriet Kluger, MD; David L. Rimm, MD, PhD | Biomarkers; Checkpoint blockade; Clinical study; Solid tumors; Tumor microenvironment; Tumor stroma |
| P139 | Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of T-cell activation (VISTA) and PD-L1 | Timothy L. Wyant, PhD; Hongwei Wang, MD, PhD; David Tuck; Yung-Jue Bang, MD PhD; Anna W. Ma, MS; Jeffrey A. Sosman, MD; Adil Daud, MBBS MD; John D. Powderly, II, MD, CPI; Javier Garcia-Corbacho; Manish R. Patel, MD; James J. Lee, MD, PhD; Kyu-Pyo Kim; Joshua Brody, MD; Sun Young Rha; Erika P. Hamilton, MD; Marta Gil Martin; Santiago Ponce Aix, MD; Radhakrishnan Ramchandren, MD; Myung-Ju Ahn; James Spicer, MD, PhD; Simon Pacey; Gerald S. Falchook, MD; Funda Meric-Bernstam, MD | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| P140 | Deep profiling of Asian NSCLC to identify the tumor antigen-specific T cells and the predictive potential of the patients treated with PD-1/PD-L1 blockade | Joe P. Yeong, MBBS, PhD; Lisda Suteja; Yannick Simoni; Kah Weng Lau; Sherlly Lim; Jie Hua, Josh Loh; Angela Takano; Eng Huat Tan, MD; Kiat Hon, Tony Lim; S. W., Daniel Tan; Evan W. Newell, PhD; | Adoptive immunotherapy; Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P141 | Circulating tumor DNA ( ctDNA) a novel biomarker for immunotherapy response in advanced lung cancer | Ebenezer O. Appah, MD; Katherine B. Neblett; Clive D. Morris; Greg Jones; Vincent Plagnol; Paul R. Walker, MD; Meera Yogarajah, MD | Checkpoint blockade; Immune monitoring |
| P142 | The immunogenomic impact of indoximod on the tumor microenvironment of melanoma patients | Jiayi Yu, PhD; Gabriela R. Rossi, PhD; Ravindra Kohle, MD, PhD; David H. Munn, MD; Yousef Zakharia, MD; Nicholas Vahanian, MD; Eugene P. Kennedy, MD, FACS; Charles Link, Jr., MD | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors; Tumor microenvironment |
| P143 | Rational combination of GITR agonism with PD-1 blockade in cancer patients | Roberta Zappasodi, PhD; Cynthia Sirard, MD; Yanyun Li, PhD MD; Sadna Budhu, PhD; Moshen Abu-Akeel; Cailian Liu, MD; Xia Yang; Hong Zhong, BS; Walter Newman, PhD; Jingjing Qi; Phillip Wong, PhD; David Schaer; Henry Koon, MD; Vamsidhar Velcheti, MD FACP; Michael Postow, MD; Margaret K. Callahan, MD, PhD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; | Biomarkers; Checkpoint blockade; Costimulation; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P144 | A fully-automated multiplex fluorescence IHC assay with whole slide multispectral imaging on mouse tissue: phenoptics™ quantitative pathology solutions translational workflow | Yi Zheng, PhD; Carla Coltharp, PhD; Ryan Dilworth, PhD; Rachel Schaefer; Linying Liu; Victoria Duckworth; William Kennedy; Darryn Unfricht, PhD; Peter Miller, MS; Milind Rajopadhye, PhD; | Biomarkers; Regulatory T cell (Treg cell); Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma |
| P145 | Computational assessment of IDO1 feedback modulation | JIAN ZHU, PhD; Rebecca L. Zhu | Bioinformatics; Biomarkers; Immune suppression; MDSC; NK/NK T cell; Regulatory T cell (Treg cell); Systems biology; Tumor infiltrating lymphocytes (TILs) |
| P146 | Cell proliferation improves prediction for immune checkpoint inhibitors (ICIs) response in PD-L1 positive TMB high non-small cell lung cancer (NSCLC) | Jason Zhu, MD; Matthew K. Labriola, MD; Daniele Marin, MD; Shannon J. McCall, MD; Edwin Yau, MD, PhD; Grace K. Dy; Sarabjot Pabla, MSc, PhD, BS; Sean T. Glenn, PhD; Carl D. Morrison, MD, DVM; Daniel J. George, MD; Tian Zhang, MD; Jeffrey M. Clarke, MD | Biomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment |
| P147 | Quantitative assessment of co-expression of PD-L1 and CMTM6 in the tumor microenvironment in non-small cell lung cancer (NSCLC) patients treated with PD-1 pathway blockade | Jon Zugazagoitia, MD, PhD; Fahad S. Shabbir, MD; Yuting Liu, PhD candidate; Brian S. Henick, MD; Scott N. Gettinger, MD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD; | Biomarkers; Checkpoint blockade; Tumor microenvironment; Tumor stroma |
| P148 | Viral based vaccine for personalized neoantigen-directed cancer therapies | Christian Ottensmeier, MD PhD FRCP; Natalia Savelyeva; Katy McKann; Chuan Wang; Jason Greenbaum; Finn C. Nielsen; Chantal Hoffmann; Huguette Schultz; Nathalie Silvestre; Jean-Baptiste jb. Marchand, pHD; Maud Brandely-Talbot, MD, PhD; Eric Quemeneur, PharmD, PhD; Kaidre Bendjama, .; Kaidre Bendjama, . | Bioinformatics; Biomarkers; Immune adjuvant; Neoantigens; T cell; Tumor antigens |
| P149 | A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies | Ana B. Blazquez, PhD; Alexander Rubinsteyn, PhD; Julia Kodysh, MSc; John Finnigan; Thomas U. Marron, MD PhD; Rachel L. Sabado, PhD; Marcia Meseck, MS, JD; Timothy O'Donnell; Jeffrey Hammerbacher, BA; Michael Donovan; John Holt; Millind Mahajan; John Mandeli, PhD; Krysztof Misiukiewicz; Eric Genden; Brett Miles, DDS MD; Hooman Khorasani; Peter Dottino; Hanna Irie; Amy Tiersten, MD; Elisa Port; Andrea Wolf, MD; Hearn J. Cho, MD, PhD; Ashutosh Tewari, MD; Samir Parekh, MD; Sujit Nair; Matthew D. Galsky, MD; William K. Oh, MD; Sacha Gnjatic, PhD; Eric Schadt; Philip Friedlander, MD PhD; Nina Bhardwaj, MD, PhD; Nina Bhardwaj, MD, PhD; | Clinical trial; Immune adjuvant; Immune monitoring; Solid tumors; T cell; Tumor antigens; Vaccine |
| P150 | A Phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission | Anna C. Pavlick, MD, MBA; Ana B. Blazquez, PhD; Marcia Meseck, MS, JD; Michael Donovan; Mireia Castillo-Martin; Tin Htwe Thin, Ph.D.; Rachel L. Sabado, PhD; John Mandeli, PhD; Sacha Gnjatic, PhD; Philip Friedlander, MD PhD; Nina Bhardwaj, MD, PhD | Clinical trial; Dendritic cell; Immune adjuvant; Immune monitoring; Solid tumors; T cell; TLR; Vaccine |
| P151 | Improving neoantigen identification for therapeutic and diagnostic use in immuno-oncology using mass spectrometry and machine learning | Sean M. Boyle, PhD; Eric Levy, PhD; Gabor Bartha; Jason Harris; Rena McClory; John S. West, MBA; Richard Chen | Immune monitoring; Neoantigens; Proteomics; Solid tumors; Tumor microenvironment |
| P152 | Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy for cancer treatment | Ying Xuan Chua, PhD; Antonia Susnjar; Jeremy Ho; Jessica R. Rhudy; Priya Jain, B.S.; Marco Folci; Andrea Ballerini; Shailbala Singh; Carly S. Filgueira, Ph.D.; Cassian Yee, MD; Brian Butler; Alessandro Grattoni | Antibody; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P153 | Vaccination with HSP70iQ435 DNA elicits a broad, functional antibody response that may contribute to tumor control of melanoma | Cormac Cosgrove, PhD; I Caroline Le Poole; Emilia Dellacecca; Steven W. Henning | Antibody; Autoimmunity; Dendritic cell; T cell; Vaccine |
| P154 | Empiric profiling of neoantigen-specific T cell responses in NSCLC patients with ATLAS™ reveals unexpected neoantigen and inhibitory antigen profiles | Kyle Ferber, PhD, BS; Michael O'Keeffe; Crystal Cabral, BS, MSc; Christopher Warren; Erick Donis; Mariya Croll, MS; James Loizeaux; Melissa W. Hayes, PhD; James Perry; Wendy Broom, PhD; Pamela Carroll; Jessica B. Flechtner, PhD; Jason R. Dobson, PhD, BS; | Antigen presenting cells; Dendritic cell; Neoantigens; Regulatory T cell (Treg cell); T cell; Tumor antigens |
| P155 | A DNA-based CSPG4 cancer vaccine designed by SynCon® technology is highly immunogenic and extends survival in a mouse model of melanoma | Bradley Garman, MS; Bradley Garman, MS; Jewell N. Walters, BS PhD; Elizabeth K. Duperret, BS, PhD; Aspen Trautz; Jaemi Chu; Jian Yan, BS PhD; Laurent M. Humeau, BS, MS, PhD; David B. Weiner, BS, MS, PhD | Angiogenesis; Checkpoint blockade; Immune tolerance; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P156 | Developing a cross-reactive heteroclitic peptide cancer vaccine targetting poorly immunogenic mutant calreticulin in myeloproliferative neoplasms | Mathieu Gigoux, PhD; Shannon Elf, Ph.D.; Michele Ciboddo; Roberta Zappasodi, PhD; Stephane Pourpe, M.Sc.; Nouran Abdelfattah, M.Sc.; Timothy A. Chan, MD, PhD; Omar Abdel-Wahab, M.D.; Ann Mullally, M.D.; Taha Merghoub, PhD; Jedd D. Wolchok, MD, PhD | Antigen presenting cells; Neoantigens; T cell; Tumor antigens; Vaccine |
| P157 | ISA101 and nivolumab for HPV-16+ Cancer: Updated clinical efficacy and immune correlates of response | Bonnie S. Glisson; Erminia Massarelli, MD, PhD, MS; William William, MD; Faye M. Johnson, MD, PhD; Renata Ferrarotto, MD; Ming Guo; Lei Feng; J Jack Lee; Hai Tran; Jaime Rodriguez-Canales, MD; Tomas Zecchini Barrese; Ignacio Wistuba, MD; Jing Wang; Sjoerd H. van der Burg, PhD; Kimal Rajapakshe, PhD; Cornelis J. Melief, MD, PhD; Michael A. Curran, PhD; | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P158 | IFN-α and 5’-Aza-2’-deoxycytidine enhance the anti-tumor efficacy of a dendritic-cell targeting MIP3α-Gp100-Trp2 DNA vaccine by affecting T-cell recruitment and tumor microenvironment gene expression | James Gordy, PhD; Richard Markham, BS MD | Chemokine; Cytokine; Dendritic cell; Gene expression; Immune adjuvant; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P159 | Correlation between response and HLA type in a randomized phase IIb trial of NeuVax + trastuzumab in HER2 low-expressing breast cancer patients to prevent recurrence | Annelies T. Hickeron; Guy T. Clifton, MD, FACS; Tommy Brown, MD; John W. Myers, III, MD; Jessica L. Campf, MD; Kaitlin Peace, MD; Jennifer K. Litton; Rashmi Murthy; Timothy J. Vreeland, BS MD; Diane F. Hale, MD; Garth S. Herbert, MD; Jason Lukas, MD/PhD; Nicholas J. Sarlis; Jarrod P. Holmes; Elizabeth A. Mittendorf; George E. Peoples, MD, FACS | Antigen presenting cells; Clinical trial; Solid tumors; T cell; T cell lineages; Vaccine |
| P160 | Engineering a T cell stimulating extra-cellular matrix for immunotherapy | John Hickey, BS; Yi Dong; Hai-Quan Mao, PhD; Jonathan P. Schneck, MD, PhD; | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma |
| P161 | The effects of IGF-1R antisense on cells of the glioma tumor microenvironment promotes immunostimulatory antigen release | Rhonda Kean, MS; Aurore LeBrun, PhD; Emily Bongiorno; David W. Andrews, MD; D. Craig Hooper, PhD; Samantha A. Garcia, PhD | Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Metabolism; Solid tumors; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| P162 | Single cell sequencing to identify TCRs that recognize autologous tumor cells after vaccination with allogeinic DRibble vaccine | Hong-Ming Hu, PhD; Christopher C. Paustian, PhD; Zhifa Wen; Tarsem L. Moudgil, MS; Traci L. Hilton, PhD; Sam Bookhardt, BA; Guangjie Yu; Eric Tran, PhD; Venkatesh Rajamanickam; Walter J. Urba, MD, PhD; Rachel E. Sanborn, MD; Bernard A. Fox, PhD | Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P163 | Humoral immune responses elicited by Globo H vaccine and the impact of Globo H expression levels on clinical response to Globo H vaccine in metastatic breast cancer | Jung-Tung Hung; I-Ju Chen; Wei-Chien Tang; Shir-Hwa Ueng; Tsai-Hsien Hung; Fei-Yun Lo; Hope Rugo, MD; Chiun-Sheng Huang; Alice L. Yu, MD, PhD | Antibody; Clinical trial; Immune monitoring; Solid tumors; Tumor antigens; Vaccine |
| P164 | Personalized cancer vaccines based on peptide-TLR-7/8a conjugates induce CD8 T cell responses to neoantigens in primates that are dependent on TLR-7/8a potency | Andrew S. Ishizuka, DPhil; Andrei Ramirez-Valdez; Hide Yamane, PhD; Yaling Zhu, PhD; Vincent Coble; Faezzah Baharom; Kennedy Tobin; Brennan Decker; Geoffrey Lynn; Robert A. Seder, MD | Bioinformatics; Immune adjuvant; Neoantigens; T cell; T cell lineages; TLR; Tumor antigens; Vaccine |
| P166 | Ex vivo ATLAS-identified inhibitory neoantigens promote mouse melanoma tumor progression | Hanna Starobinets, PhD; Kyle Ferber, PhD, BS; Jason R. Dobson, PhD, BS; Michael O'Keeffe; Crystal Cabral, BS, MSc; Matthew Lanchantin, BS; Erick Donis; Peri Matatia; Erik Carter; Adrienne Li, PhD; James Loizeaux; Jamie Foti, PhD; Wendy Broom, PhD; Pamela Carroll; Paul Kirschmeier; Jessica B. Flechtner, PhD; Hubert Lam, PhD; | Antigen presenting cells; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Neoantigens; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor antigens |
| P167 | Characterization of antigen specific immune responses from a first-in-human study evaluating the anti-ASPH cancer vaccine SNS-301 in biochemically relapsed prostate cancer patients | Michael S. Lebowitz, PhD; Kanam Malhotra; M S. Walker; Hong Dai, MD, PhD; Steven Fuller, PhD; Amir Shahlaee, MD; James J. Elist, MD; Neal Shore, MD; Luke T. Nordquist, MD, FACP; Hossein A. Ghanbari, PhD | B cell; Clinical study; Immune tolerance; NK/NK T cell; Solid tumors; T cell; Tumor antigens |
| P168 | Induction of chemokine receptor and suppression of inhibitory receptors of CD8 T cell controlled effectively cervicovaginal tumor in mouse | Daewoo Lee, MD; Daeun Nam; Sungjong Lee, PhD, MD; | Chemokine; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P169 | In-Depth Characterization of Immune Responses Induced Against Patient-Specific Neoantigens using NEO-STIM™ | Brian McCarthy; Divya R. Lenkala; Michael Nelson; Rachel Debarge; Janani Sridar; Yusuf S. Nasrullah, Master's in Biological Research, United Kingdom; Jessica Kohler, PhD; Matthew J. Goldstein, MD, PhD; Richard B. Gaynor, MD; Marit M. Van Buuren, PhD; | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Dendritic cell; Neoantigens; T cell |
| P170 | Identification of breast cancer neoantigens exposed by radiation therapy | Claire Lhuillier, PhD; Nils-Petter Rudqvist, PhD; Takahiro Yamazaki, PhD; Tuo Zhang, PhD; Lorenzo Galluzzi, PhD; Sandra Demaria, MD | Neoantigens; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P171 | Safety and immunogenicity of a DNA vaccine encoding PSA and PSMA in patients with biochemically recurrent prostate cancer | Neal Shore, MD; Elisabeth Heath; Matthew P. Morrow, PhD; Kimberly Kraynyak, BS PhD; Kamal Bhatt, LCEH MS; Trevor McMullan; Jessica Lee, MS, MPH; Brian Sacchetta; Samantha Rosencranz; Ildiko Csiki, BS MD, PhD; Mark Bagarazzi, MD; Li Liu, PhD; | Clinical study; T cell; Vaccine |
| P172 | Personalized cancer vaccines based on self-assembling nanoparticles co-delivering peptide antigens and TLR-7/8 agonists (SNP-7/8a) enhance the breadth and magnitude of anticancer CD8 T cell immunity | Geoffrey Lynn; Faezzah Baharom; Yaling Zhu, PhD; Ramiro A. Ramirez-Valdez, BA Cantab; Tobin Kennedy; Vincent Coble; Brennan Decker; Hide Yamane, PhD; Andrew S. Ishizuka, DPhil; Robert A. Seder, MD | Immune adjuvant; T cell; Targeted therapy; TLR; Tumor antigens; Vaccine |
| P173 | Early results of a phase I clinical trial of a HER2 dendritic cell cancer vaccine | Hoyoung Maeng, MD; Lauren V. Wood, MD; Lee England, PA-C; Brenda Roberson, BSN, RN, OCN; Santhana Webb; Brittni Moore; David F. Stroncek, MD; John C. Morris, MD; Jay A. Berzofsky, MD, PhD; | Antigen presenting cells; Clinical trial; Dendritic cell; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| P174 | A phase 1/2a study to evaluate the safety, tolerability, immunogenicity, and anti-tumor activity of GEN-009 adjuvanted neoantigen vaccine in adult patients with selected solid tumors | Roger Cohen; Michael S. Gordon, MD; Wendy Hill; Lisa K. McNeil, PhD; Tingting Ge, PhD; Arthur P. DeCillis, MD; Melissa L. Johnson, MD; Mark Awad, MD PhD; | Antigen presenting cells; Checkpoint blockade; Clinical study; Cytokine; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P175 | Targeting arginase in tumor microenvironment | Evelina Martinenaite, MSc; Shamaila Munir Ahmad; Simone Kloch Bendtsen, M.Sc; Mia Aaboe Jørgensen; Stine Emilie Weis-Banke; Inge Marie Svane, MD; Mads H. Andersen, PhD | Autoimmunity; Dendritic cell; Immune suppression; Immune tolerance; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P176 | Identification and analysis of critical immune molecules and signaling pathways to improve the immunogenicity of dendritic cell vaccines | Deena M. Maurer, MS; Patricia M. Santos, PhD; John M. Kirkwood, MD; Ahmad A. Tarhini, MD, PhD; Hussein A. Tawbi, MD, PhD; David F. Stroncek, MD; Ping Jin, PhD; Lisa H. Butterfield, PhD; | Antigen presenting cells; Checkpoint blockade; Costimulation; Dendritic cell; Metabolism; Targeted therapy; Vaccine |
| P177 | Boosting T cell immunity against IDO1: Proof of concept for a novel cancer vaccine approach | Alexander J. Muller, PhD; Souvik Dey, PhD; Erika Sutanto-Ward, BS; Katharina L. Kopp, BS; Mai-Britt Zocca, PhD; Ayako W. Pedersen, PhD; Mads H. Andersen, PhD | Immune contexture; Metabolism; T cell; T cell lineages; Tumor microenvironment; Vaccine |
| P178 | Identification of shared phosphopeptide tumor targets in colorectal carcinoma for novel off-the-shelf vaccine development | Paisley T. Myers, PhD; Erin D. Jeffery, PhD; Benjamin Morin, PhD; Christine Brittsan, MA; Bishnu Joshi; Antoine Tanne, PhD; Karen Smith, BS; Albert Hurwitz; Kara L. Cummings, PhD; Amanda M. Lulu; Daniel L. Levey, PhD; Linh Mach; Mark A. Findeis, PhD; Gayle C. Hunt, PhD; Jeffrey Shabanowitz, PhD; Donald F. Hunt, PhD; Arthur A. Hurwitz; Robert N. Stein, MD PhD; Alex Duncan, PhD; Dennis Underwood, PhD | Epidemiology; Neoantigens; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| P179 | Use of Jurkat T cells for high throughput screening of chimeric antigen receptor constructs | Scott McComb, Ph.D; Risini D. Weeratna, PhD; Tina Nguyen, Ph.D. | CAR T cells; T cell |
| P180 | From infectious disease to personalized cancer vaccines: Integrated CD4, CD8, and regulatory T cell neo-epitope screening platform for the design of safe and customized vaccines | Guilhem Richard, PhD; Randy F. Sweis, MD; Leonard Moise, PhD; Matthew Ardito, BA; William Martin, BA MD; Gad Berdugo, MSc, MBA; Gary D. Steinberg, MD; Anne S. de Groot, MD | Antigen presenting cells; Bioinformatics; Biomarkers; Immune tolerance; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens |
| P181 | Pseudocowpox virus (PCPV), a potent tumor antigen-independent viral vector for cancer immunotherapy | Karola Rittner, PhD; Caroline Tosch, engineer; Thioudellet Christine; Christelle Remy-Ziller, Engineer; Marie-Christine Claudepierre, Ms; Benoit Sansas; Johann Foloppe; Philippe Erbs; Kaïdre Bendjama; Eric Quemeneur, PharmD, PhD; | Chemokine; Cytokine; Monocyte/Macrophage; Tumor antigens; Tumor microenvironment; Vaccine |
| P182 | Identification of prevalent immunogenic tumor antigens in microsatellite unstable patients with uterine corpus endometrial carcinoma. | Vladimir Roudko, PhD; Cansu Cimen Bozkus, PhD; Orfanelli Theofano, MD; Stephanie V. Blank, MD; Benjamin D. Greenbaum, PhD; Nina Bhardwaj, MD, PhD | Bioinformatics; Biomarkers; Neoantigens; Vaccine |
| P183 | Immunogenicity and specificity of neoantigens derived from tumor-specific mutations in gastric cancer | Tetsuro Sasada, MD, PhD; Junya Ohtake; Susumu Iizumi; Taku Kouro, MD, PhD; Yuka Igarashi; Mamoru Kawahara; Erika Yada | Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P184 | High tumour burden mandates a cancer vaccine targeting many neoantigens combined with check point inhibition | Elisa Scarselli, MD; Anna Morena D'Alise; Guido Leoni; Gabriella Cotugno; Fulvia Troise; Francesca Langone; Imma Fichera; Maria De Lucia; Rosa Vitale; Adriano Leuzzi; Veronica Bignone; Elena Di Matteo; Fabio Tucci; Lidia Avalle; Valeria Poli; Armin Lahm; Maria Teresa Catanese; Antonella Folgori; Stefano Colloca; Alfredo Nicosia; Elisa Scarselli | Checkpoint blockade; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P185 | CUE-101, a novel Fc fusion protein comprised of HLA-A*0201-bound HPV16 E7 peptide and IL-2, for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies | Mary C. Simcox, Ph.D.; Steven N. Quayle; Dharma R. Thapa, Ph.D.; Sandrine Hulot, Ph.D.; Alyssa Nelson, B.S.; Lauren Kraemer, B.S.; Zohra Merazga, M.S.; Robert Ruidera, MSc; Dominic Beal, Ph.D.; Gurpanna Saggu, Ph.D.; Maria Hackett, MSc; Mark Haydock, B.S.; Jonathan Soriano, MSc; Joey Lee; Luke Witt, B.S.; Kelly Malone; Jessica Ryabin, B.S.; Simon Low, MSc; Natasha Girgis, Ph.D.; Emily Spaulding, Ph.D.; John F. Ross, Ph.D.; Anish Suri, Ph.D.; Rodolfo Chaparro, Ph.D.; Ronald Seidel, Ph.D.; Kenneth J. Pienta, MD; | Costimulation; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P186 | A multi-center study of hTERT immunotherapy in adults with solid tumors at high risk of relapse post-standard therapy: updated results from complete patient set | Anthony F. Shields, MD PhD; Autumn J. McRee, MD; Jennifer Johnson, MD; Weijing Sun, MD, FACP; Ashish Chintakuntlawar, MBBS, PhD; Naseem Prostak, BS MS; Kimberly Kraynyak, BS PhD; Matthew P. Morrow, PhD; Jeffrey M. Skolnik, MD; Robert H. Vonderheide, MD, DPhil | Clinical study; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P187 | Preclinical evidence for the potency and tumor selective activation of a novel EpCAM-CD3 Protease-Triggered Immune Activator (ProTIA) T-cell bispecific therapeutic | Bee-Cheng Sim; Desiree Thayer; Fan Yang; Tillman Pearce, MD; Zach Lange; Ulrich Ernst, PhD; Volker Schellenberger | Antibody; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P188 | Patient’s autologous T cells recognize tumor specific neoantigens in PDX models of ovarian cancer | Muzamil Y. Want, PhD; Anna Konstorum, PhD; Ruea-Yea Huang, PhD; Richard C. Koya, MD, PhD; Sebastiano Battaglia, PhD | Adoptive immunotherapy; Bioinformatics; Neoantigens; T cell |
| P189 | A phase 1 study of safety and tolerability of AutoSynVax™ vaccine in patients with advanced cancer. | Robert Wesolowski, MD; Breelyn A. Wilky, MD; Allison O'Neill; Ana M. Gonzalez, MD PhD; Elise E. Drouin, PhD; Edward Dow; Mohamed Uduman; Antoine J. Tanne; Maria Agarwal, PhD; Bishnu Joshi; Benjamin Morin, PhD; Mark A. Findeis, PhD; Sandra Craig; Igor Proscurshim, MD; Ricardo Soto; Jennifer S. Buell, PhD; Robert N. Stein, MD PhD; John C. Castle; Daniel L. Levey, PhD | Clinical study; Solid tumors; Tumor antigens; Vaccine |
| P190 | Identification of antigenic epitopes of EGFR for lung cancer vaccine development | Juhua Zhou, PhD; Ge Guo; Jianzhong Zhang; Shaoyan Huang; Yanmin Li | Bioinformatics; Cytokine; Neoantigens; Solid tumors; Tumor antigens; Vaccine |
| P191 | Combination of Sorafenib and anti-PD-1 for advanced hepatocellular carcinoma- real world experience | San-chi Chen, MD; Muh-Hwa Yang; Yee chao; | Checkpoint blockade; Solid tumors |
| P192 | A case of nivolumab-induced gastrointestinal toxicity treated with vedolizumab in the context of metastatic non-small cell lung cancer | Cynthia N. Tran, MD; Yinghong Wang, MD, PhD; Wenyi Luo, MD; | Checkpoint blockade; Immune toxicity |
| P193 | Exceptional response of MSH6-null castration-resistant prostate cancer patient with myelophthisic pancytopenia to pembrolizumab | Panagiotis J. Vlachostergios, MD, PhD; Julia T. Geyer, MD; Ana M. Molina, MD; David M. Nanus, MD; Himisha Beltran, MD; Scott T. Tagawa, MD, MS; | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors |
| P194 | Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis | Yinghong Wang, MD, PhD; Hamzah Abu-Sbeih, M.D.; Diana Wiesnoski; Beth Helmink, MD PhD; Vancheswaran Gopalakrishnan, MPH, PhD; Kati Choi, MD; Hebert DuPont, MD; Zhi-Dong Jiang; Michael T. Tetzlaff, MD PhD; Jennifer A. Wargo, MD, MMSc; Robert Jenq, MD; | Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity; Inflammation; Microbiome; T cell |
| P195 | Transcriptomic profiling of specific populations of T-cells in Acute Myeloid Leukemia | Milad Abolhalaj, MSc; Henrik Lilljebjörn; Carl Sandén; Karin Hägerbrand; Peter Ellmark, PhD; Carl Borrebaeck; Thoas Fioretos; Kristina Lundberg, PhD; | Biomarkers; Gene expression; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell |
| P196 | Comparison of culture media for in citro T cell assays and expansion | PONNI ANANDAKUMAR; Anne Lodge, PhD; Benjamin A. Tjoa, Ph. D.; | Adoptive immunotherapy; Antigen presenting cells; Biomarkers; CAR T cells; Chemokine; Cytokine; Metabolism; T cell; Tumor antigens |
| P197 | Modulating hexokinase 2 as a novel approach for simultaneous targeting of the tumor and its immunosuppressive microenvironment | Vered Behar, PhD; Reut Yosef, PhD; Eyal Dor-On, PhD; Nofar Amsalem, MSc; Yuval Ariel, MSc; Oren M. Becker, PhD | Immune suppression; Monocyte/Macrophage; Metabolism; Solid tumors; Targeted therapy; Tumor microenvironment |
| P198 | IDH1-R132H, a rate determining mutation in the timeline of anaplastic astrocytoma | Jonathan W. Fraser, MD; Mikhail Prosniac, PhD; Larry Harshyne; David W. Andrews, MD; D. Craig Hooper, PhD; | Angiogenesis; Chemokine; Cytokine; Gene expression; Immune suppression; Monocyte/Macrophage; Myeloid cells; Metabolism; Solid tumors; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P199 | Myo-inositol up-regulates PD-L1 in non-small cell lung cancer | Eileen Fung, PhD; Jane Yanagawa; Jessica Kim | Checkpoint blockade; Solid tumors; Tumor evasion |
| P200 | Cell competition and flower code regulates competitive interactions between tumor and its microenvironment | Rajan Gogna, PhD, MS, MBA; Esha Madan, PhD, MS, MBA; Masaki Nagane; Christopher Pelham; Taylor Parker; Antonio Beltran; Carlos Carvalho, MD; | Adoptive immunotherapy; Antibody; Carcinogenesis; Chemotherapy; Gene expression; Immune adjuvant; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment; Tumor stroma |
| P201 | Cell competition genes drive donor cell leukemia in AML patients | Rajan Gogna, PhD, MS, MBA; Esha Madan, PhD, MS, MBA; Christopher Pelham; Taylor Parker; | Antigen presenting cells; Biomarkers; Chemotherapy; Gene expression; Immune suppression; Leukemia/Lymphoma; MDSC; Stem cell/cancer-initiating cell; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P202 | Targeting the stress response kinase GCN2 to restore immunity in the tumor microenvironment | Lisa A. Marshall; Buvana Ravishankar; Lavanya Adusumilli; Mikhail Zibinsky, PhD; Deepa Pookot; Emily Huang; Oezcan Talay, PhD; Silpa Suthram; Jeffrey Jackson; Grant Shibuya; Akinori Okano; Paul Leger; Scott Jacobson, BS; Steve Wong; Sherra Johnson; Parcharee Tivitmahaisoon; Angela Wadsworth, BA; Jerick Sanchez; Martin Brovarney; David Chian, BA; Abood Okal, PhD; Delia Bradford; Christophe Colas; Andrea Kim; Gene Cutler, PhD; Jacob Schwartz; David J. Wustrow, PhD; Paul D. Kassner, PhD; Dirk Brockstedt; | Immune suppression; Immune tolerance; Myeloid cells; MDSC; Metabolism; T cell; Tumor microenvironment |
| P203 | Immunomodulatory effects through inhibition of monocarboxylate transporters in melanoma | Satish R. Noonepalle, PhD; Jennifer Kim, PhD; Namratta Manhas, PhD; Sophiya Ephrame, BS; Erica Palmer, BS; Melissa Hadley, MS; Vincent Sandanayaka, PhD; Alejandro Villagra, PhD | Checkpoint blockade; Costimulation; Cytokine; Immune suppression; Metabolism; NK/NK T cell; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| P204 | Characterization of novel dual A2A_A2B adenosine receptor antagonists for cancer immunotherapy | Mateusz Nowak; Michal Galezowski; Paulina Wegrzyn; Aneta Bobowska; Katarzyna Dziedzic; Joanna Szeremeta-Spisak; Marcin Nowogrodzki; Grzegorz Satala; Alicja Obara; Iwona Lozinska; Marcelina Dudek; Anita Janiga; Jacek Reus; Marek Wronowski; Magdalena Zastawna; Grzegorz Statkiewicz; Maciej Rogacki; Mateusz Swirski; Jakub Woyciechowski; Magdalena Ziembik; Karolina Grycuk; Foteini Soukou; Agnieszka Adamus; Karolina Wiatrowska; Natalia Lewandowska; Aniela Golas; Olga Pierzchala; Roderick Porter; Krzysztof Brzozka; Mateusz Nowak | Immune suppression; Metabolism; Tumor evasion; Tumor microenvironment |
| P205 | Preclinical and initial phase I clinical characterization of CPI-006: an anti-CD73 monoclonal antibody with unique immunostimulatory activity | Emily C. Piccione, PhD; Andrew Hotson, PhD; Glen Mikesell, BS; Barbara Daine-Matsuoka, BS; Chunyan Gu; Trang Dao-Pick; Craig M. Hill, PhD; Antonett Madriaga; Jennifer Rudnick; Liang Liu; W B. Jones; Linda Hammerich, PhD; Joshua Brody, MD; Ginna Laport; Richard A. Miller, MD; Joseph J. Buggy; | Antibody; B cell; Clinical trial; Costimulation; Immune suppression; Metabolism; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P206 | Using clear cell like-RenCa and papillary like-RenCa models of Kidney Cancer to study metabolic influences on the microenvironment and metastasis | Katy Beckermann; W. K. Rathmell, MD, PhD; Bradley I. Reinfeld, BA; Peter J. Siska; Jeffrey C. Rathmell, PhD; Melissa M. Wolf; Kirsten Young; Gabriella Andrejeva, PhD; Jamie Weyandt | Immune suppression; Immune tolerance; Metabolism; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P207 | Chronic T cell activation and metabolic stress promote the exhausted T cell state by inducing epigenetic inflexibility | Nicole E. Scharping, BS; Natalie Rittenhouse; Ashley Menk, BS; Ronal Peralta; Paolo Vignali, BA; Roderick J. O'Sullivan; Amanda Poholek; Greg M. Delgoffe, PhD; | Bioinformatics; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P208 | Metabolic reprogramming augments CAR T cell function | Yiyang Wang; Greg M. Delgoffe, PhD; Jason Lohmueller, PhD; McLane Watson, BS; Dayana B. Rivadeneira, PhD | CAR T cells; Metabolism; Tumor microenvironment |
| P209 | Antagonism of peroxisome proliferator activated receptor alpha by TPST-1120 suppresses tumor growth and stimulates anti-tumor immunity | Chan C. Whiting, PhD; Nick Stock, PhD; Davorka Messmer, PhD; Austin Chen, PhD; Lisa Rahbaek, PhD; Allison Gartung, PhD; Karin Stebbins, PhD; Traci Olafson; Alex Broadhead; Ryan Clark, PhD; Catherine Lee, MS; Chris Baccei; Dan Lorrain, PhD; Alicia Levey, PhD; Derek Metzger, BA; Amanda Enstrom, PhD; Jennifer McDevitt, PharmD, PhD; David e. Spaner, MD, PhD; Peppi Prasit, PhD; Dipak Panigrahy, MD | Antigen presenting cells; Checkpoint blockade; Chemotherapy; Cytokine; Dendritic cell; Gene expression; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Metabolism; T cell; Tumor microenvironment |
| P210 | PD-1-positive tumor-infiltrating lymphocytes (TIL) for the next generation of adoptive T cell therapy | Michelle R. Abelson, PhD; Kenneth D'Argio; Angel Cedano-Hilton; Ian Frank; Krit Ritthipichai, DVM, PhD; Cecile Chartier; Michelle R. Abelson, PhD; | Adoptive immunotherapy; Clinical study; Inflammation; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P211 | Oxygen and pressure promote primary T cell expansion and can regulate population dynamics and cytokine release | Yunmin Li, Ph.D; Zachary Pappalardo; Mauricio Montano; Ann Lu; Bruce Adams | Adoptive immunotherapy; Cytokine; T cell; Tumor microenvironment |
| P212 | Preinfusion product doubling time is associated with CAR T cell expansion and outcomes in ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma | Frederick L. Locke, MD; John M. Rossi, MS; Caron Jacobson, MD; David Miklos, MD; Armin Ghobadi, MD; Olalekan O. Oluwole, MBBS, MPH; Lazaros J. Lekakis, MD; Patrick Reagan, MD; Yizhou Jiang, PhD; Lianqing Zheng, PhD; William Go, MD, PhD; Adrian Bot, MD, PhD; | Adoptive immunotherapy; CAR T cells; Clinical study; Clinical trial; Leukemia/Lymphoma; Targeted therapy |
| P213 | CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule | Sophie AGAUGUE, PhD; Alexandre E. Michaux, PhD; Eytan Breman, MSc; Sebastien Mauen, PhD; David E. Gilham, PhD | Adoptive immunotherapy; CAR T cells; Solid tumors |
| P214 | Development of allogeneic gene-edited CAR T-cells: from preclinic to clinical proof of concept | Beatriz Aranda Orgilles, PhD; Agnes Gouble; Roman Galetto, PhD; Julianne Smith; Philippe Duchateau; David Sourdive; Laurent Poirot, PhD; Stephane depil | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Solid tumors; T cell |
| P215 | Preclinical evaluation of Deep™ IL-15 Primed PMEL cells demonstrates highly improved safety compared to systemic administration of IL-15 | Philip D. Bardwell, PhD; Elena Geretti; Xiaoyan Liang; Santina Caruso; De-Kuan Chang, Ph.D; Jesse Lyons; Carlos Tassa; Sanela Bilic; Janice Lanista; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Thomas L. Andresen, PhD | Adoptive immunotherapy; Cytokine; Immune toxicity; Solid tumors; T cell |
| P216 | Select metabolic and costimulatory bolt-on transgenes enhance chimeric receptor-bearing T cell activity against solid tumors | Luke Barron, Ph.D.; Kathleen Whiteman; Madaline Gilbert; Tapasya Pai; Megan Snyder, BS; Michael Fray; Allison Nelson; Tyler Johnson; Kelsey Lakeman; John Shin; Ryan Boomer; Seth Ettenberg; Kathleen McGinness; Greg Motz | Adoptive immunotherapy; CAR T cells; Costimulation; Metabolism; Solid tumors; T cell; Tumor microenvironment |
| P217 | Small molecule control of inducible MyD88/CD40 regulates Natural Killer cell expansion and anti-tumor activity | Joseph H. Bayle; Xiaomei Wang, PhD; Wei-Chun Chang, PhD; Daniel J. Jasinski, PhD; Jan L. Medina; Aaron E. Foster, PhD; David M. Spencer, PhD; | Adoptive immunotherapy; CAR T cells; NK/NK T cell; Targeted therapy |
| P218 | Endogenous DAP10 provides optimal co-stimulation to NKG2D-based CAR T cells | Jennifer Bolsée; Eytan Breman, MSc; Thuy Nguyen; Sophie AGAUGUE, PhD; David E. Gilham, PhD | Adoptive immunotherapy; CAR T cells; Costimulation |
| P219 | SQZ’ing cells to engineer next generation antigen presenting cell (APC) therapies | Matthew G. Booty, PhD; Scott M. Loughhead; Kelan A. Hlavaty; Ildefonso Vicente-Suarez; Katarina Blagovic, PhD; Melissa Myint; Brittany Stokes, MS; Defne Yarar; Howard Bernstein, MD, PhD; Armon Sharei | Adoptive immunotherapy; Antigen presenting cells; Immune adjuvant; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P220 | Generating allogeneic CAR T cells without gene editing | Simon Bornschein, PhD; Alexandre E. Michaux, PhD; Susanna Raitano, PhD; Eytan Breman, MSc; Céline Jacques-Hespel; Fanny Huberty; Laura Saerens; Dorothée Daro; Steven R. Lenger, Ph.D.; Hidevaldo B. Machado, PhD; Jonathan D. Moore, PhD; Sophie AGAUGUE, PhD; David E. Gilham, PhD; | Adoptive immunotherapy; CAR T cells; Gene expression; T cell |
| P221 | The co-expression of a single shRNA targeting MICA and MICB with a NKG2D-CAR (CYAD-01) generates CAR-T cells resistant to target driven fratricide and improves CYAD-01 cell persistence in vivo | Simon Bornschein, PhD; Susanna Raitano, PhD; Jérôme Marijsse; Dorothée Daro; Steven R. Lenger, Ph.D.; Hidevaldo B. Machado, PhD; Jonathan D. Moore, PhD; Sophie AGAUGUE, PhD; David E. Gilham, PhD | Adoptive immunotherapy; CAR T cells; Gene expression; T cell; Targeted therapy; Tumor antigens |
| P222 | Genetic engineering of tumour infiltrating lymphocytes (TIL) with a novel recombinant growth factor receptor for treatment of solid tumours | John S. Bridgeman, BSc, MSc, PhD; Michelle L. Le Brocq; Joanne McCaffrey; Tania Katopodi, PhD; Gemma L. Owens, MB BCh, BSc, MRes; Aysha Patel; Ryan Guest; Robert E. Hawkins; | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P223 | In vitro analysis of Tumour Infiltrating Lymphocytes engineered with costimulatory antigen receptors delivering targeted costimulation | John S. Bridgeman, BSc, MSc, PhD; Michelle L. Le Brocq; Aysha Patel; Martina Sykorova; Tania Katopodi, PhD; Joanne McCaffrey; Ryan Guest; Robert E. Hawkins | Adoptive immunotherapy; Granulocyte; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P224 | Adoptive cell therapy using tumor infiltrating lymphocytes for the treatment of bladder cancer | Brittany Bunch, PhD; Matthew Beatty, PhD; Jennifer Morse, MS; Michael Kidd; MacLean Hall; Autumn Joerger; Charles C. Peyton; Mayer N. Fishman, MD, PhD; Amod A. Sarnaik, MD; Michael Poch; Shari A. Pilon-Thomas, PhD | Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P225 | Adoptive cell transfer with NY-ESO-1 specific TCR T cells (TBI-1301) results in persistence, cytokine release syndrome and anti-tumor activity | Marcus O. Butler, MD; Valentin Sotov; Megan Nelles; Sarah Boross-Harmer; Luisa Bonilla; Sawako Elston; Michael Fyrsta; Diana Gray, MSc; Abha Gupta; Sevan Hakgor; Ausmeema Hossain; Michael X. Le; Darya Lemiashkova; Diane Liu; Charlotte S. Lo; Mark Comacho; Aaron Hansen; David Hogg, MD, FRCPC; Habeeb Majeed; Kiichi Murakami; Jessica Nie; Marc Ouellette; Albiruni R. Razak; Kendra Ross; Adrian Sacher, MD; Sam Saibil; Elizabeth Scheid; Anna Spreafico, MD PhD; Brendan Van As; Jennifer Y. Yam; Pamela S. Ohashi, PhD; Shuichi Takahashi; Shinya Tanaka; Linh Nguyen, PhD; Naoto Hirano, MD, PhD | Adoptive immunotherapy; Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Solid tumors; T cell; Tumor antigens |
| P226 | DeepTM IL-15 primed multi-targeted T cells demonstrate potent antigen-specific cytotoxic activity against human cancer cells | Shawn P. Carey, PhD; Beth Pearce; Darren Smith; Pengpeng Cao, PhD; Christine M. McInnis, PhD; Amy M. Shaw; Jonas Bruun, PhD; FABIO FACHIN, PhD; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Thomas L. Andresen, PhD; Andy Rakestraw, PhD; | Adoptive immunotherapy; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P227 | Tethering IL-12 to the surface of T cells induces a broad immune activation and potent anti-tumor activity in mice without inducing systemic toxicities | De-Kuan Chang, Ph.D; Gulzar Ahmad; Jonathan Nardozzi, PhD.; Thomas L. Andresen, PhD; Douglas Jones, PhD | Adoptive immunotherapy; Cytokine; Solid tumors; T cell |
| P228 | Novel electroporation method for T cells enables quick CAR-T cell manufacture | Jian Chen, PhD; Xiaofeng Xia, PhD | CAR T cells; Gene expression |
| P229 | Adapter mediated transduction with lentiviral vectors: A novel tool for cell-type specific gene transfer | Nicole Cordes, Master of Science; Carolin Kolbe; Thomas Schaser; Andrew Kaiser; | Adoptive immunotherapy; CAR T cells; Gene expression; T cell; Targeted therapy |
| P230 | Identification of CD4+ and CD8+ T lymphocyte-epitopes from the cancer testis antigen Lactate dehydrogenase C | Hibah Shaath; Remy Thomas; Salman M. Toor; Eyad Elkord, PhD; Julie Decock, PhD; | Adoptive immunotherapy; Biomarkers; T cell; Targeted therapy; Tumor antigens |
| P231 | Uncovering the phenotype, the functional and homing properties of NKG2D CAR T cells | Benjamin Demoulin; Eytan Breman, MSc; Sophie AGAUGUE, PhD; David E. Gilham, PhD; Panagiota Sotiropoulou, PhD; | CAR T cells; Chemokine; Leukemia/Lymphoma; T cell; Targeted therapy |
| P232 | Differential effects of target ligands upon NKG2D CAR T cell activation. | Eytan Breman, MSc; Martina Fontaine, PhD; Nancy Ramelot; Sophie AGAUGUE, PhD; David E. Gilham, PhD; Panagiota Sotiropoulou, PhD | CAR T cells; T cell; Targeted therapy; Tumor antigens |
| P233 | CD8+ tumor-infiltrating lymphocytes expanded from a NSCLC immunosuppressive environment display neoantigen-specific recognition | Lorenzo Federico, PhD; Andrea Ravelli; Cara Haymaker, PhD; Marie-Andrée Forget, Ph.D.; Tatiana Karpinets, MS; Jason Roszik, PhD; Donastas Sakellariou-Thompson, BS; Young Uk Kim, PhD; Ankit Bhatta, MSc; May Celestino, BS, MA; Alexandre Reuben; Annikka Weissferdt; Ara A. Vaporciyan, MD; Mara B. Antonoff, MD; Garret Walsh; Phillip Andrew Futreal, PhD; Ignacio Wistuba, MD; Jack Roth; Zhang Jianjun; Emily Roarty, PhD; Lara Alvarez de Lacerda-Landry; Stephen G. Swisher, MD; Tina Cascone, MD, PhD; Gregory A. Lizee, PhD; John V. Heymach; Boris Sepesi, MD; Don Gibbons, MD; Chantale Bernatchez | Immune contexture; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P234 | NF-κB p50 deficient immature myeloid cell (p50-IMC) adoptive cell transfer activates the tumor microenvironment to slow tumor growth | Rahul Suresh, PhD; Theresa Barberi, PhD; David Barakat, PhD; Kenneth J. Pienta, MD; Alan D. Friedman, MD | Adoptive immunotherapy; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| P235 | STACT-TREX1: A novel tumor-targeting systemically-delivered STING pathway agonist demonstrates robust anti-tumor efficacy in multiple murine cancer models | Laura H. Glickman, PhD; Justin Skoble, PhD; Chris S. Rae, PhD; Anastasia M. Makarova, PhD; Marc A. D'Antonio; Andrew J. McGeehan; Christopher Thanos, PhD | Checkpoint blockade; Immune adjuvant; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P236 | Flower-code: A novel Immunotherapy target | Rajan Gogna, PhD, MS, MBA; Christopher Pelham; Taylor Parker; Esha Madan, PhD, MS, MBA; Carlos Carvalho, MD; Antonio Beltran; | Antibody; Carcinogenesis; Chemotherapy; Costimulation; Gene expression; Immune adjuvant; Immune tolerance; Pediatric tumors; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P237 | CAR-modified killer MSC targeting GD2-positive Ewing sarcoma | Giulia Golinelli, PhD; Massimo Dominici; Giulia Grisendi; Carlotta Spano; Filippo Rossignoli; Malvina Prapa; Angela d'Esposito | CAR T cells; Pediatric tumors; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P238 | Regulation of in vivo anti-tumor activity of adoptively transferred CAR-T cells using FDA approved small molecule drugs | Brian M. Dolinski, BS; Scott Heller, MS; Mara Inniss; Abhishek Kulkarni; Dan Jun Li, MD; Christopher Reardon; Dexue Sun; Karen Tran, MS; Michelle L. Ols, PhD; Jennifer L. Gori, PhD; Vipin Suri; Celeste Richardson; Steven Shamah, Ph.D. | Adoptive immunotherapy; CAR T cells; Gene expression; Leukemia/Lymphoma; T cell |
| P239 | Novel solid tumor gene therapy approach mediated by engineered Bifidobacterium longum generates efficient tumor-derived IL-12 expression and results in local and systemic anti-tumor immunity | Sheetal Raithatha; Umesh Ramachandran; Melissa Dennis; Elena Topchy; Steven Zhao; Alexander Graves; | Adoptive immunotherapy; Cytokine; Gene expression; Microbiome; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P240 | Autologous Epstein-Barr virus (EBV)-specific T cells (baltaleucel T): preliminary results from a multicenter, multinational phase 2 study for treatment of EBV-associated NK/T cell lymphoma | Kurt C. Gunter, MD; Yasuhiro Oki, MD; Won Seog Kim; Kirit Ardeshna, MB BChir MA MD FRCP FRCPath; Yi Lin, MD PhD; Jia Ruan, MD, PhD; Pierluigi Porcu, MD; Jonathan Brammer, MD; Eric Jacobsen, MD; Dok Hyun Yoon, MD; Cheolwon Suh, MD PhD; Felipe Suarez, MD PhD; John Radford, MD; Lihua E. Budde, MD PhD; JIN SEOK Kim, MD PhD; Gilles Salles, MD; Hun Ju Lee, MD; Catherine Bollard, MD; Arnaud Jaccard, MD PhD; Hye Jin Kang, MD PhD; Shannon Inman, BS; Maryann Murray; Katherine E. Combs, RN; Kurt C. Gunter, MD; Daniel Y. Lee, MD PhD; Ranjana Advani, MD; M. Rooney, PhD; Helen E. Heslop, MD | Adoptive immunotherapy; Clinical study; Clinical trial; Leukemia/Lymphoma; T cell |
| P241 | Melanoma-derived human CD4+ tumor-infiltrating lymphocytes (TIL) demonstrate a functional response to autologous tumor | MacLean Hall; Autumn Joerger; Ellen Scott; Ben Schachner; Allison Richards; Valerie Stark; Jeani Rich; Amy M. Weber, .; Doris Wiener; Krithika N. Kodumudi, PhD; Matthew Beatty, PhD; Amod A. Sarnaik, MD; Shari A. Pilon-Thomas, PhD; | Adoptive immunotherapy; Cytokine; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P243 | Tumour infiltrating lymphocyte therapy: clinical outcomes in pre-treated metastatic melanoma patients and biomarker correlations | Manon Pillai, MB BS MD; Ryan Guest; Natallia Kirillova; Paul Lorigan; Michelle L. Le Brocq; John S. Bridgeman, BSc, MSc, PhD; Robert E. Hawkins, MD, PhD; | Adoptive immunotherapy; T cell; Tumor infiltrating lymphocytes (TILs) |
| P244 | Reactive myelopoiesis triggered by lymphodepletion limits the efficacy of adoptive T cell therapy | Patrick Innamarato, B.S.; Shari A. Pilon-Thomas, PhD; Krithika N. Kodumudi, PhD; Amy M. Weber; Amod A. Sarnaik, MD; Doris Weiner; Jennifer Morse, MS; Michael Kidd; Patrick Verdugo | Adoptive immunotherapy; Chemotherapy; Clinical trial; Immune suppression; Myeloid cells; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P245 | Enrichment of rare antigen-specific CD8+ T cells directly from splenocytes improves output and throughput | Ariel Y. Isser; John Hickey, BS; Kayla Gee; Sebastian Salathe; Yi Dong; Jonathan P. Schneck, MD, PhD; | Adoptive immunotherapy; T cell |
| P246 | Targeting novel tumor-associated antigens with TCR-engineered T Cells | Mamta Kalra, PhD; Ali Mohamed, PhD; Zoe Coughlin; Thorsten Demberg, PhD; Amir Alpert, BS; Leoni Alten; Sebastian Bunk, PhD; Claudia Wagner; Jens Fritsche, PhD; Oliver Schoor, PhD; Agathe Bourgogne; Yannick Bulliard, PhD; Geoffrey Stephens; Dominik Maurer, PhD; Harpreet Singh, PhD; Carsten Reinhardt, MD, PhD; Tony Weinschenk; Steffen Walter, PhD | Adoptive immunotherapy; Clinical trial; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P247 | Potent ex vivo expanded, human CD34+ cord blood-derived natural killer cells for glioblastoma immunotherapy | Lin Kang, Ph.D.; Shuyang He; William van der Touw; Bhavani Stout; Valentina Rousseva; Rathna Ravishankar; Robert Hariri; Xiaokui Zhang; | Adoptive immunotherapy; Cytokine; NK/NK T cell; Solid tumors |
| P248 | IL-2, IL-15 and IL-21 expanded tumor-infiltrating lymphocytes (TIL) for the treatment of patients with solid cancer | Dragan Kiselicki; Julia Karbach; Martin Rao, PhD; Ernest Dodoo; Evgueni Sinelnikov; Akin Atmaca; Markus Maeurer; Elke Jaeger | Adoptive immunotherapy; Immune contexture; Immune monitoring; Tumor infiltrating lymphocytes (TILs) |
| P249 | Glypican-1 (GPC-1) specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD1 antibody therapies | Daiki Kato, DVM; Tomonori Yaguchi, MD, PhD; Kenji Morii, MS; Satoshi Serada; Tetsuji Naka; Takayuki Nakagawa; Ryohei Nishimura; Yutaka Kawakami, MD PhD | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Solid tumors; T cell; Tumor antigens; Tumor microenvironment |
| P250 | Shorter ex vivo expansion of Th17 cells mediates potent anti-tumor regression in melanoma | Hannah Knochelmann; Michelle H. Nelson, PhD; Jacob S. Bowers; Megan Wyatt, MS; Aubrey S. Smith; Connor J. Dwyer, PhD; Chrystal M. Paulos, PhD | Adoptive immunotherapy; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| P251 | Tumor-infiltrating lymphocytes (TIL) for the adoptive treatment of patients with pancreatic cancer | Joana Lérias, DVM; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Martin Rao, PhD; Nuno Couto; Davide Valentini; Mireia Castillo-Martin; Antonio Beltran; Evgueni Sinelnikov; Hans Hofmeister; Ana Vieira; Javier Martin-Fernandez; Andreia Maia; Dário Ligeiro; Carlos Carvalho; Dragan Kiselicki; Akin Atmaca; Julia Karbach; Elke Jäger; Markus Maeurer; Joana R. Lerias, PhD; | Adoptive immunotherapy; Clinical study; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P252 | Fast quality gauging of tumor-infiltrating lymphocytes (TIL) for the treatment of patients with solid cancer | Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Joana Lérias, DVM; Martin Rao, PhD; Mireia Castillo-Martin; Antonio Beltran; Evgueni Sinelnikov; Hans Hofmeister; Javier Martin-Fernandez; Andreia Maia; Dário Ligeiro; Carlos Carvalho; Dodoo Ernest; Dragan Kiselicki; Julia Karbach; Elke Jäger; Ana Vieira; Markus Maeurer; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; | Adoptive immunotherapy; Cytokine; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P253 | B cell structural diversity in early cultured tumor-infiltrating lymphocytes | Dario D. Ligeiro, PhD; Dário Ligeiro; Hélder Trindade; Joana Lérias, DVM; Georgia Paraschoudi, M.Sc. in Cell and Molecular Biology, Sweden; Andreia Maia; Catarina V. de Oliveira; Javier Martin-Fernandez; Martin Rao, PhD; Carlos Carvalho, MD; Mireia Castillo-Martin; Markus Maeurer; Dário Ligeiro; | Adoptive immunotherapy; B cell; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P254 | Natural Killer cells propagated under pressurized culture conditions show enhanced tumor killing activity | James Lim; Ann Lu; Nick Wilson; Albert Wong | Adoptive immunotherapy; CAR T cells; Immune monitoring; Metabolism; NK/NK T cell; Stem cell/cancer-initiating cell; Solid tumors; Tumor microenvironment |
| P255 | Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors | Sylvie Rottey, MD; Mateusz Opyrchal, MD PhD; Kunle Odunsi, MD, PhD; Jean-Pascal Machiels, MD, PhD; Solmaz Sahebjam, MD; Leila Shaza, MD; Sandrine Aspeslagh; Marc Van den Eynde, MD; Jean-Luc Canon, MD; Javier Carrasco; Ahmad Awada; Eytan Breman, MSc; Panagiota A. Sotiropoulou, PhD; Sarah Snykers, PhD; Nathalie Braun; Caroline Lonez, PhD; Anne Flament; Bikash Verma, MD; Frédéric F. Lehmann, MD; Alain Hendlisz, MD | Adoptive immunotherapy; CAR T cells; Clinical study; Clinical trial; Solid tumors; Tumor microenvironment |
| P256 | Evaluation of therapeutic T cell manufacture using long amplicon TCRβ immune repertoire sequencing | Geoffrey M. Lowman, PhD; Lauren Miller, BS; Timothy Looney, PhD; Tor Espen Stav-Noraas; Reidun Hartberg, PhD; Hilde Almåsbak; Mark Andersen, PhD; Sjoerd H. van der Burg, PhD; Elizabeth (Els) ME. Verdegaal, PhD; Noel F. de Miranda, PhD | Adoptive immunotherapy; CAR T cells; Immune monitoring; Leukemia/Lymphoma; T cell |
| P257 | Natural Killer and TCR gamma-delta T-cells are present in the tumor microenvironment and can be expanded for adoptive immunotherapy for epithelial cancer | Andreia Maia; Joana Lérias; Catarina de Oliveira; Javier Martin-Fernandez; Georgia Paraschoudi, M.Sc.; Martin Rao, PhD; Dário Ligeiro; Tin Htwe Thin, Ph.D.; Ana Isabel Vieira; Carlos Carvalho, MD; Markus Maeurer; Mireia Castillo-Martin | Adoptive immunotherapy; Antibody; Biomarkers; Cytokine; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P258 | sd-rxRNA to enhance NK cell activity for adoptive cell transfer | Melissa Maxwell, MS; James Cardia; Dingxue Yan, PhD; Gerrit Dispersyn, PhD | Adoptive immunotherapy; Checkpoint blockade; Gene expression; NK/NK T cell |
| P259 | Regional delivery of chimeric antigen receptor (CAR)-engineered T cells with 4-1BB co-stimulation effectively targets TAG72-positive peritoneal ovarian tumors | John P. Murad, BS, MS; Anna K. Kozlowska, MSc, PhD; Maya Ramamurthy; Wen-Chung Chang, MS; Paul Yazaki, PhD; David Colcher, PhD; John Shively, PhD; Mihaela Cristea, MD; Stephen J. Forman, MD; Saul Priceman, BS PhD; | CAR T cells; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor evasion |
| P260 | Automated perfusion-based systems for research- and clinical-scale dendritic cell generation | Andrew Kozbial, BS, PhD; Lekhana Bhandary, BS, PhD; Shashi Murthy, BS, PhD | Dendritic cell; Monocyte/Macrophage; Neoantigens; Vaccine |
| P261 | Identification and pre-clinical development of tumour-reactive T-cell receptors from tumour-infiltrating lymphocytes | Natasha Myhill, MRes; John Bridgeman, Dr.; | Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P262 | AIM ACT, a novel nanoparticle-based technology that generates therapeutic numbers of functional tumor-specific CD8+ T cells with central and effector phenotype in 14 days | Mathias Oelke, Ph.D.; Sojung Kim; Juan Varela; Tatsuya Yoshida; Jeffrey S. Weber, MD, PhD; Lauren Suarez; Emily Lu; Celine Walmacq; Daniel Dembrow; Daniel Bednarik; Kenneth Carter, PhD; Kristi Jones; Scott P. Carmer, MBA; | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Dendritic cell; Leukemia/Lymphoma; Neoantigens; T cell; Targeted therapy; Tumor antigens |
| P263 | IL13RA2 as a new target for T-cell based therapies of melanoma brain metastases | Maria C. Ramello, PhD; Ismahene Benzaid, PhD; Maritza Lienlaf; Vincent Law; Nikhil I. Khushalani, MD; Amod A. Sarnaik, MD; Inna Smalley, PhD; Keiran S. Smalley, PhD; Peter A. Forsyth, MD; Daniel Abate-Daga, PhD | Adoptive immunotherapy; CAR T cells; Solid tumors |
| P264 | Identification of tyrosine phosphorylation sites in CD28 domain and their role in CAR-T cell function | Maria C. Ramello, PhD; Bin Fang, PhD; John Koomen, PhD; Eric Haura, MD; Daniel Abate-Daga, PhD | Adoptive immunotherapy; CAR T cells; Solid tumors |
| P265 | Inhibiting immune evasion in CNS tumors by reversing epigenetic gene silencing of chemoattractant cytokines | Nivedita M. Ratnam, PhD; Heather M. Sonnemann; Amber J. Giles, PhD; Mark R. Gilbert | Chemokine; Cytokine; Gene expression; T cell |
| P266 | Improving T cell functionality for adoptive cell transfer therapy in metastatic colon cancer | Sruthi Ravindranathan, PhD; Mohammad Raheel Jajja; Sruthi Ravindranathan, PhD; Christopher Petersen; Ramireddy Bommireddy; Periasamy Selvaraj; Lily Yang; Bassel El-rayes, MD; Brianna Flynn, MS; Edmund K. Waller, MD, PhD, FACP; Sruthi Ravindranathan, PhD; | Adoptive immunotherapy; Solid tumors |
| P267 | Hijacked CAR19 T cells have potent activity against solid tumors | Paul Rennert, PhD; Fay Dufort, PhD; Lihe Su, PhD; Lan Wu, PhD; Alyssa Birt; Roy Lobb, PhD; Christine Ambrose, PhD | CAR T cells; Leukemia/Lymphoma; Solid tumors; Tumor antigens |
| P268 | Heterogeneity of pancreatic cancer tumor-infiltrating T cells at the single cell level | Donastas Sakellariou-Thompson, BS; Aislyn Schalck; Mark Hurd, PhD; Gauri Varadhachary; Milind Javle, MD; Anirban Maitra, MBBS; Nicholas Navin, PhD; Cara Haymaker, PhD; Chantale Bernatchez | Gene expression; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P269 | Global phosphoproteomic analysis of chimeric antigen receptor and T cell receptor signaling enables design of modified receptors with distinct properties | Alexander I. Salter, BS; Richard G. Ivey; Anusha Rajan; Jacob J. Kennedy; Valentin Voillet, PhD; Jeffrey R. Whiteaker; Raphael Gottardo, PhD; Amanda G. Paulovich, MD, PhD; Stanley R. Riddell, MD | Adoptive immunotherapy; CAR T cells; Proteomics; T cell |
| P270 | A novel, human sdAb-based, CAR against CD33, effectively targets AML in vitro and in vivo, and spares hematopoietic stem cells | Dina Schneider, PhD; Ying Xiong, PhD; Peirong Hu; Darong Wu, MS; Weizao Chen; Tianlei Ying; Zhongyu Zhu; Dimiter Dimitrov, PhD; Boro Dropulic, PhD, MBA; Rimas J. Orentas, PhD | Adoptive immunotherapy; Antibody; CAR T cells; Leukemia/Lymphoma; Pediatric tumors; T cell; Tumor antigens |
| P271 | Titratable and reversible regulation of IL12 or IL15 with FDA-approved drugs enhances CAR-T therapy | Brian M. Dolinski, BS; Kutlu Elpek; Tucker Ezell; Michelle Fleury; Jennifer L. Gori, PhD; Jia Gwee; Scott Heller, MS; Mara Inniss; Abhishek Kulkarni; Meghan Langley, BS; Dan Jun Li, MD; Grace Olinger, MS; Michelle L. Ols, PhD; Benjamin Primack; Christopher Reardon; Michael Schebesta; Dexue Sun; Zoe Tarasiewicz, BA; Karen Tran, MS; Michael Briskin; Celeste Richardson; Vipin Suri; Steven Shamah, Ph.D. | CAR T cells; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P272 | A fully-closed, high efficiency manufacturing technology platform for the production of T cell therapies targeting multiple tumor antigens | Christine M. McInnis, PhD; Amy M. Shaw; Shawn P. Carey, PhD; Jonas Bruun, PhD; Rachel Klaski; Pengpeng Cao, PhD; Elisabeth Brown; Andy Rakestraw, PhD; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Thomas L. Andresen, PhD; FABIO FACHIN, PhD | Adoptive immunotherapy; Antigen presenting cells; Clinical trial; Cytokine; Dendritic cell; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P273 | T cells cultured in the presence of TLR9 agonist gain a CD25(high)CD39(low), pro-inflammatory phenotype and regress melanoma in vivo | Hannah Knochelmann; Connor J. Dwyer, PhD; Aubrey S. Smith; Aubrey S. Smith; Megan Wyatt, MS; Chrystal M. Paulos, PhD; Michelle H. Nelson, PhD; | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR |
| P274 | Functional screening of different anti-B7H6 CAR designs | Lorraine P. Springuel; Benjamin Demoulin; Martina Fontaine, PhD; Adam Hargreaves, Dr; Dorothée Daro; Jennifer Bolsée, PhD; Céline Jacques-Hespel; Valérie Steenwinckel, PhD; David E. Gilham, PhD; Sophie Agaugué, PhD | CAR T cells; Solid tumors; Tumor antigens |
| P275 | Pooling signaling and costimulatory domains in a flexible CARpool design | Lorraine P. Springuel; Amélie Velghe; Sophie AGAUGUE, PhD; David E. Gilham, PhD; Jennifer Bolsée, PhD | Adoptive immunotherapy; CAR T cells; Costimulation |
| P276 | Characterization of systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T-cells in synovial sarcoma (NCT01343043) | Justina Stadanlick; Indu Ramachandran, PhD; Daniel Lowther; Rebecca Dryer-Minnerly, PhD; Ruoxi Wang; Svetlana Fayngerts; Daniel Nunez; Natalie Bath, MSc; Gareth Betts, PhD; Karen Chagin, MD; Thomas H. Faitg, PhD; Wayne Higgins; Malini Iyengar, PhD; Luca Melchiori; Siva Samavedam; Jonathan D. Silk, PhD; Alex J. Tipping, PhD; Trupti Trivedi, MS; Erin Van Winkle; Lilli Wang; Rafael Amado, MD; Gwendolyn K. Binder; Samik Basu, MD; Samik Basu, MD; | Adoptive immunotherapy; Clinical trial; Immune contexture; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P277 | Genetic modification of IL13Rα2-CAR T cells to express secretory or membrane-bound IL-15 enhances their anti-glioma activity without discernible differences | David H. Steffin, MD; Haley Houke; Tim Sauer, MD; Irina V. Balyasnikova, Ph.D.; Stephen Gottschalk; M. Rooney, PhD; Giedre Krenciute, PhD | CAR T cells; Cytokine; Solid tumors |
| P278 | Identification of senescent T-cell subsets that impact gene-engineered T cell manufacturing success and product consistency | Jeffrey J. Teoh, PhD; Daniel Cossette; Sara Cooper; Ryan P. Larson, PhD | Adoptive immunotherapy; Biomarkers; CAR T cells; Leukemia/Lymphoma; T cell |
| P279 | CRISPR/Cas9 enables the efficient production of allogeneic CAR-T cells engineered to contain multiple genome edits to enhance therapeutic T-cell function | Ashley Porras, BA; Dan Henderson; Sushant Karnik; Katie Levitsky, BS; Demetrios Kalaitzidis, Ph.D.; Jason Sagert, PhD; Zinkal Padalia, MS; Mary Lee Dequeant, PhD; melanie allen, BS; Hanspeter Waldner; Henia Dar, PhD; Chandirasegaran Massilamany, PhD; Paul Tetteh; Dakai Mu, BA; Elaine Huang, PhD; Thao Nguyen; Sarah Spencer, PhD; Kelly Maeng; Jonathan Terrett, PhD | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Solid tumors |
| P280 | IL-12 cytokine priming of low avidity tumor specific T cells enhances tumor clearance and prevents exhaustion | Christopher G. Tucker, BS; Jason Mitchell; Brian Fife | Adoptive immunotherapy; Checkpoint blockade; Cytokine; T cell |
| P281 | Endogenous MHC class II restricted CD4+ T cell responses to recurrent driver mutations in melanoma and non-small cell lung cancer (NSCLC) | Joshua R. Veatch, MD, PhD; Brenda Jesernig, MS; Sylvia Lee; Stanley R. Riddell, MD | Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P282 | Pathogen-reduced human platelet lysate as a serum replacement maintains CAR T cells in a less-differentiated phenotype associated with superior anti-tumor function | Alejandro Torres Chavez; Emanuele Canestrari, PhD; Christina T. Dann, Ph.D; Ann Leen; Juan Vera; Norihiro Watanabe, Ph.D; Norihiro Watanabe, Ph.D; | Adoptive immunotherapy; CAR T cells |
| P283 | Allogeneic CAR T-cells resistant to both T- and NK-cell cytotoxicity | Alan Williams; Laurent Poirot, PhD; Philippe Duchateau; brian Busser; julien Valton; Alexandre juillerat; Stephane depil; Sonal Temburni-Blake, MS | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; T cell |
| P284 | Importance of the enzymatic activity of CD26 expressed on tumor-specific Th17 cells for adoptive cell therapy | Chrystal M. Paulos, PhD; Megan Wyatt, MS; Stefanie Bailey; Hannah Knochelmann; Aubrey S. Smith; Connor J. Dwyer, PhD; Michelle H. Nelson, PhD; | Adoptive immunotherapy; Gene expression; T cell |
| P285 | A clinical study on CD33-directed chimeric antigen receptor modified NK cells | Leiming Xia; Jing Zhang; Liu Liu; Bin Li; Tan Li; Yi Wang; Lin Yang; Yangyi Bao; Alfred Chang; Max S. Wicha, MD; Qiao Li, PhD | Adoptive immunotherapy; Clinical trial; Cytokine; Leukemia/Lymphoma; NK/NK T cell |
| P286 | Combination of PD-1 blockade and RetroNectin-activated cytokine-induced killer cells in pre-heavily treated NSCLC: a retrospective study | Lingdi Zhao; Lu Han; Yong Zhang; Tiepeng Li; Yonghao Yang; Wei Li; Yiman Shang; Hongwei Lin; Quanli Gao | Adoptive immunotherapy; Checkpoint blockade; Coinhibition |
| P287 | HyPeR: A phase 1, dose escalation study of Guadecitabine (SGI-110) a second generation hypomethylating agent in combination with Pembrolizumab (MK3475) in patients with refractory solid tumours | Malaka Ameratunga, MBBS; Maxime Chénard-Poirier; Sanjena Mithra; Ricardo Morilla; Ruth Riisnaes; Penny Flohr; Rita Pereira, BSc; Ana Ferreira, MSc; Ines Figueiredo; Suzanne Carreira; Claudia Bertan; Wei Yuan; David Dolling; Mateus Crespo; Bora Gurel; Bob Brown; Naina Patel; Joanna Dawes; Toby Prout; Mona Parmar; Alison Turner; Holly Tovey; Emma Hall; Anna Minchom; Udai Banerji; Nina Tunariu; Juanita Lopez; Dionysis Papadatos-Pastos; Johann S. De Bono, MD; | Checkpoint blockade; Clinical study; Clinical trial |
| P288 | IMAGE 1 (Immune Modulation And Gemcitabine Evaluation 1), a randomized, open-label phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer. | Angus G. Dalgleish, MD, PhD; | Chemotherapy; Clinical trial; Costimulation; Immune suppression; NK/NK T cell; Solid tumors; TLR; Tumor microenvironment |
| P289 | Initial results from a phase 1a/b study of etigilimab (OMP-313M32), an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody, in advanced solid tumors | Sunil Sharma, MD; Kathleen N. Moore; Niharika B. Mettu; Ignacio Garrido-Laguna; Susanna V. Ulahannan, MD, MMed; Vivek Khemka, MD; Ann Kapoun; Leonardo Faoro; Johanna Bendell, MD | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell |
| P290 | Immunologic biomarkers in a multi-center, single arm, open label Phase II clinical trial of mFOLFOX6 and pembrolizumab in patients with advanced colorectal cancer | Matthew R. Farren, Ph.D.; Yan Tong; Ziuye Liu; Bert O'Neil; Tanios Bekaii-Saab, MD; Anne Noonan; Christopher W. McQuinn, MD; Thomas Mace, PhD; Walid L. Shaib, MD; Christina Wu, MD; Bassel El-rayes, MD; Safi Shahda, MD; Gregory B. Lesinski, PhD, MPH; Matthew R. Farren, Ph.D. | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; Solid tumors |
| P291 | A targeted modified IL-2 (NHS-IL2) combined with stereotactic body radiation therapy (SBRT) in patients with advanced melanoma refractory to checkpoint inhibitors: Results from a Phase IIa trial | Omid Hamid, MD; David H. Lawson, MD; Karl D. Lewis, MD; Jose Lutzky, MD, FACP; C. Lance Cowey; Beatrice Brunkhorst; Meng Li; Wanping Geng; Christine Hicking; Vijay Kasturi, MD; Howard Kaufman | Antibody; Biomarkers; Clinical study; Clinical trial; Cytokine; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors |
| P292 | Changes in intra- and perinodular heterogeneity patterns on serial computed tomography are associated with overall survival in Nivolumab-treated non-small cell lung cancer | Mohammadhadi Khorrami, PhD; Prateek Prasanna, PhD; Vamsidhar Velcheti, MD FACP; Anant Madabhushi, PhD; | Biomarkers; Immune monitoring; Solid tumors; Tumor microenvironment |
| P293 | Autologous tumor cell vaccination combined with systemic CpG-B and IFNα promotes activation of dendritic cells and T cells and induces clinical responses in metastatic Renal Cell Carcinoma | Bas D. Koster, MD; Saskia Santegoets; Jorien J. Harting, MD; Arnold Baars, MD, PhD; Marieke van Ham, PhD; Rik J. Scheper, PhD; Erik Hooijberg, PhD; Alfons JM. van den Eertwegh, MD, PhD; Tanja D. de Gruijl, PhD | Clinical study; Clinical trial; Dendritic cell; Immune adjuvant; Immune monitoring; Solid tumors; T cell; TLR |
| P294 | Confirmatory study validates a MALDI prognostic signature for IL-2 response and the adverse prognostic role of the serum apoptotic marker Hepatocyte Growth Factor (HGF) in Renal Cell Carcinoma (RCC) | Michael T. Lotze, MD; Shuyan Zhai, PhD; Daniel P. Normolle, PhD; Ryan J. Sullivan, MD; Heinrich Roder, DPhil; Joanna Roder, PhD; David F. McDermott, MD; Theodore F. Logan, MD; Marc S. Ernstoff, MD; Thomas Olencki, DO; David Friedland, MD; Rahul A. Parikh, MD, PhD; Jodi K. Maranchie, MD; Mary Jo Buffo, BS; Lisa H. Butterfield, PhD; Leonard J. Appleman, MD, PhD; | Clinical study; Clinical trial; Cytokine; Immune contexture; Solid tumors |
| P295 | A Phase 1, open-label, multicenter, dose escalation study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection to patients with advanced malignancies | Shilpa G. Gupta, MD; Todd M. Bauer, MD; Ryan J. Sullivan, MD; Robert H. Andtbacka, MD, CM, FACS, FRCSC; Ding Wang, MD; Geoffrey Shapiro, MD, PhD; Khanh T. Do, MD; Kurt A. Schalper, MD, PhD; Patricia Gaule, PhD; Tal Zaks, MD, PhD; Joshua Frederick, PhD; Lisa Johansen; Kristen Hopson, PhD; William Randolph; Sima Zacharek, PhD; Robert S. Meehan, MD; Antonio Jimeno, MD, PhD; | Biomarkers; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell |
| P297 | Systemic activation and polyclonal expansion of CD8 T cells in cancer patients on Pegilodecakin alone or in combination with anti-PD-1 | Aung Naing, MD, FACP; Jeffrey R. Infante, MD; Kyri P. Papadopoulos; Ivan Chan, PhD; Cong Shen; Navneet Ratti, BS, MBA; Bianca Rojo, MSc; Karen Autio, MS, MD; Deborah J. Wong, MD PhD; Manish R. Patel, MD; Patrick A. Ott, MD, PhD; Gerald S. Falchook, MD; Shubham Pant, MBBS; Annie Hung, BA; John B. Mumm, PhD; Matthew Adamow; Scott McCauley, BA; Phillip Wong, PhD; Peter Van Vlasselaer, PhD; Joseph Leveque; Edward B. Garon, MD; Nizar M. Tannir, MD, FACP; Martin Oft, MD; Martin Oft, MD; | Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; T cell |
| P298 | T cell response induced by the addition of IL-7 treatment following sipuleucel-T immunotherapy in metastatic castration resistant-prostate cancer | Russell Pachynski, MD; Russell Szmulewitz, MD; Lauren Harshman, MD; Leonard J. Appleman, MD, PhD; Paul Monk, MD; Rhonda Bitting; Omer Kucuk, MD; Frederick Millard, MD; John Seigna; Steven P. Fling, PhD; Nirasha Ramchurren, PhD; Bruce Hess, BS; Leonard D'Amico, PhD; Andreanne M. Lacroix, BS; Judith C. Kaiser, MBA, BSN, RN; Michel Morre, DVM, MSc.; Anne GREGOIRE, phD; Martin A. Cheever, MD; Evan Y. Yu, MD; Lawrence Fong, MD | Adoptive immunotherapy; Antigen presenting cells; Clinical trial; Cytokine; Immune adjuvant; Immune monitoring; Solid tumors; T cell |
| P299 | Combination of subcutaneously administered TLR9 agonist lefitolimod with CTLA-4 checkpoint inhibitor ipilimumab - A phase I trial in patients with advanced solid tumors | Matthew J. Reilley, MD; Casey Ager, BS; Martin Meng; Apostolia M. Tsimberidou, MD, PhD; Sarina A. Piha-Paul, MD; Timothy A. Yap, MD; Siqing Fu, MD, PhD; Aung Naing, MD, FACP; Jordi Rodon; Ly Nguyen; Priya Bhosale, MD; Manuel Schmidt, MSc; Matthias Baumann; Funda Meric-Bernstam, MD; Michael A. Curran, PhD; David Hong, MD | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors; T cell; T cell lineages; TLR; Tumor microenvironment |
| P300 | First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors | Kohei Shitara, MD; Satoshi ueha; Shigeyuki Shichino; Hiroyasu Aoki; Haru Ogiwara, M.D., Ph.D.; Tetsuya Nakatsura; Toshihiro Suzuki; Manami Shimomura; Toshiaki Yoshikawa; Kayoko Shoda; Shigehisa Kitano; Makiko Yamashita; Takayuki Nakayama; Akihiro Sato; Sakiko Kuroda; Masashi Wakabayashi; Shogo Nomura; Satoru Ito; Kouji Matsushima; Toshihiko Doi, MD, PhD | Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; T cell; Targeted therapy |
| P301 | MLH1/ MSH2 expression and the prognosis of colorectal cancer in 978 Chinese patients | Yu Wang, MD; shuiming wang; youping deng | Surgery |
| P302 | Phase II trial of reirradiation (ReRT) plus Pembrolizumab for locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (SCCHN): Analysis of early toxicity | Dan P. Zandberg, MD; Tejan Diwanji, MD; Robert Morales, MD; Tiffani Tyer; James Snider, MD; Alexander Engelman, MD; Soren M. Bentzen, PhD; Thomas DeMora, MD; Robert Malyapa, MD; Navid Saeidi; Ana Ponce Kiess, MD; Josh Lubek, MD; Robert Ord, MD; Donita Dyalram, MD; Kyle Hatten, MD; Jeffrey S. Wolf, MD; rodney Taylor, MD; John Papadimitriou, MD, PhD; Ranee Mehra, MD; Harry Quon, MD; Hyunseok Kang, MD, MPH; John A. Ridge, MD, PhD; Jessica Bauman, MD; William F. Regine, MD; Mohan Suntharalingam, MD; Scott E. Strome, MD; Kevin Cullen, MD; | Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors |
| P303 | Correlation between prior surgery and immune related gastrointestinal toxicity among women receiving olaparib and tremelimumab for the treatment of recurrent ovarian cancer | Jaryse Harris, BA; Carolyn Muller, MD; Teresa Rutledge; Olivier Rixe, MD, PhD; Aisha Sethi; Phyllis Gimotty, PhD; Katherine T. Morris, MD, FACS; Sarah F. Adams, MD; | Checkpoint blockade; Clinical trial; Immune toxicity; Surgery |
| P304 | A phase 1 study of MGD007, a humanized gpA33 x CD3 DART® protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed/refractory metastatic colorectal cancer | Richard Kim, MD; David P. Ryan, MD; Stacey Stein, MD; James Cleary, MD, PhD; Liqin Liu, PhD; Ralph F. Alderson, PhD; Francine Z. Chen, MD; Peter Lung, BS, HT (ASCP); Allan Reduta, BA; Syd Johnson, PhD; Jan Baughman, MPH; Ezio Bonvini; Paul Moore, PhD; Joanna Lohr, PhD; Jon M. Wigginton, MD; Jan Davidson-Moncada, MD, PhD; John D. Powderly, II, MD, CPI | Checkpoint blockade; Clinical trial; T cell; Targeted therapy |
| P305 | A phase 1, open label, dose escalation study of MGD009, a B7-H3 x CD3 DART® protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors | Alexander I. Spira, MD, PhD, FACP; Stacie Goldberg, MD; James Strauss, MD; Johanna Bendell, MD; Gregory Cote; E E. Rahma, MD; Marwan Fakih, MD; Ralph F. Alderson, PhD; Liqin Liu, PhD; Ross La Motte-Mohs, PhD, BS; Amy Worth; Ashley Lowe; Jan Baughman, MPH; Tony Wu, PhD; Syd Johnson, PhD; Ezio Bonvini; Paul Moore, PhD; Jon M. Wigginton, MD | Checkpoint blockade; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P306 | A phase 1/2, first-in-human, dose escalation study of MGC018 (anti-B7-H3 antibody-drug conjugate) alone and in combination with MGA012 (anti-PD-1 antibody) in patients with advanced solid tumors | John D. Powderly, II, MD, CPI; Deryk Loo; Anthony Joshua, MD; Johanna Bendell, MD; Alexander I. Spira, MD, PhD, FACP; Joanna Lohr, PhD; Pepi Pencheva, MD; Jichao Sun, PhD; Jan Baughman, MPH; Ezio Bonvini; Jennifer Brown; Nehal Lakhani, MD, PhD; Jon M. Wigginton, MD | Antibody; Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors; Targeted therapy |
| P307 | An open-label, phase 1B study of NEO-PV-01 + CD40 agonist antibody (APX-005M) or Ipilimumab with Nivolumab in patients with advanced or metastatic melanoma | Omid Hamid, MD; David R. Spigel, MD; Patrick A. Ott, MD, PhD; Siwen Hu-Lieskovan, MD, PhD; Karl D. Lewis, MD; Michael S. Gordon, MD; Lisa D. Cleary; Melissa Moles; Richard B. Gaynor, MD; Matthew J. Goldstein, MD, PhD; Les H. Brail; Keith Flaherty, MD; | Checkpoint blockade; Clinical trial; Immune monitoring; Neoantigens; Vaccine |
| P308 | A Phase 1 study of MEDI5752, a bispecific antibody that preferentially targets PD-1 and CTLA-4 expressing T cells, in patients with advanced solid tumors. | Jeffery Brubaker; Ben Tran; Mark Voskoboynik; James C. Kuo; Yung-Lue Bang, MD; Hyun-Cheo Chung, MD, PhD; Myung-Ju Ahn; Sang-We Kim; Ayesh Perera; Daniel Freeman; Ikbel Achour, PhD; Raffaella Faggioni, PhD; Feng Xiao; Charles Ferte, MD, PhD; Charlotte R. Lemech, MBBS BSc(med) MD(res) | Antibody; Checkpoint blockade; Clinical study; Coinhibition; Solid tumors |
| P309 | Phase I dose-finding study of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced solid tumors or lymphomas | Funda Meric-Bernstam, MD; Theresa Werner; Stephen Hodi; Wells Messersmith, MD; Nancy Lewis; Craig Talluto; Mirek Dostalek; Aiyang Tao; Sarah McWhirter; Damian Trujillo; Jason J. Luke, MD, FACP | Antigen presenting cells; Clinical trial; Immune adjuvant; T cell |
| P310 | NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater TNBC and head & neck SCC | Mira Kistler, MD; Patrick Soon-Shiong, MD, FRCS, FACS; John Lee, MD; Chaitali Nangia, MD; Leonard Sender; Frank Jones, PhD | Adoptive immunotherapy; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Cytokine; NK/NK T cell; T cell; Tumor antigens; Vaccine |
| P311 | Positive identification of neoepitope specific T cell by tumor-normal DNA & RNA sequencing from breast cancer patient leading to yeast-based vaccine phase 1 trial delivering tumor specific neoepitopes | Peter A. Sieling, PhD; Steve Benz; Zach Sanborn, PhD; Kayvan Niazi; Tom King; Shahrooz Rabizadeh, PhD; Andrew Nguyen; | Clinical study; Clinical trial; Neoantigens; Proteomics; T cell; Tumor antigens; Vaccine |
| P313 | INCMGA 0012-201: A phase 2 study of INCMGA00012 in patients with metastatic Merkel cell carcinoma (mMCC) | Geoffrey T. Gibney, MD; Inderjit Mehmi, MD; Sadhna Shankar; Jeffrey Marine; Chuan Tian; Igor Puzanov, MD, MSCI, FACP | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P314 | An open-label, phase 1B study of NEO-PV-01 with Pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous Non-small Cell Lung Cancer | Mark Awad, MD PhD; David R. Spigel, MD; Lisa D. Cleary; Melissa Moles; Richard B. Gaynor, MD; Matthew J. Goldstein, MD, PhD; Ramaswamy Govindan, MD; | Chemotherapy; Clinical study; Neoantigens; Vaccine |
| P315 | Phase I/II study of the anti–LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies | Gareth P. Gregory; Pier L. Zinzani; John Palcza, MS; Jane Healy; Robert J. Orlowski, MD; Arun Balakumaran, PhD, MD; Philippe Armand | Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; Tumor evasion |
| P316 | Phase 1b dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-301 (Camidanlumab Tesirine) in patients with advanced solid tumors | Rose Hales; Igor Puzanov; Shivaani Kummar, MD; Patricia LoRusso, DO; Kyri P. Papadopoulos; Francesca Zammarchi, PhD; Hans G. Cruz; Jens U. Wuerthner, MD PhD; Johanna Bendell, MD; | Antibody; Clinical study; Immune tolerance; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P318 | HITM-SURE: Phase Ib CAR-T hepatic artery infusion trial for stage IV adenocarcinoma using Pressure-Enabled Drug Delivery technology | Steven C. Katz, MD; Prajna Guha, PhD; John C. Hardaway, MD, PhD; Ethan Prince, MD; Ashley E. Moody, BSN, RN; Jill E. Slansky, PhD; Kimberly R. Jordan, PhD; Richard D. Schulick, MD, FACS; Robert Knight, MD; Jerry Zeldis, MD, PhD; Vincent A. Armenio, MD; N. Joseph Espat, MD, FACS; Richard P. Junghans, PhD, MD | CAR T cells; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| P319 | PD-1 Blockade with pembrolizumab during concurrent chemoradiation for locally advanced non-small cell lung cancer | Salma K. Jabbour, MD; Abigail Berman; Roy H. Decker, MD PhD; Andrew Zloza; Steven Feigenberg; Scott N. Gettinger, MD; Charu Aggarwal, MD MPH; Corey J. Langer, MD; Charles B. Simone, II, MD; Jeffrey Bradley; Yong Lin; Salma K. Jabbour, MD; Jyoti Malhotra, MD | Checkpoint blockade; Chemotherapy; Clinical trial; Radiotherapy; Solid tumors |
| P320 | A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with breast or gynecologic malignancies | Paul de Souza, MBBS, MPH, PHD, FRACP; Chee Khoon Lee; Katrin Sjoquist; Shu Pan; Amanda Idan; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Lisa Seitz, MSc; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc | Antibody; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P321 | A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with gastrointestinal malignancies | Paul de Souza, MBBS, MPH, PHD, FRACP; Chee Khoon Lee; Katrin Sjoquist; Shu Pan; Amanda Idan; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Lisa Seitz, MSc; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc; | Antibody; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P322 | A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with carboplatin/pemetrexed and pembrolizumab in lung cancer patients | Paul de Souza, MBBS, MPH, PHD, FRACP; Chee Khoon Lee; Katrin Sjoquist; Shu Pan; Amanda Idan; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Lisa Seitz, MSc; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc | Antibody; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P323 | A phase 1 study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, with AB122, a programmed cell death-1 inhibitor, in patients with advanced malignancies | Lisa Seitz, MSc; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P324 | A phase II clinical trial of Ipilimumab/Nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine and gynaecological malignancies | Oliver Klein; Kee Damien; Ben Markman; Rachael Chang Lee, FRACP; Siddharth Menon; Jodie Palmer, BA/BSc, PhD, Grad Dip Law (IP); Andreas Behren, PhD; Jonathan S. Cebon, MD, PhD | Checkpoint blockade; Clinical trial; Immune contexture; Immune monitoring; Solid tumors |
| P325 | A phase 1 dose escalation study of TSR-033, an anti-LAG3 monoclonal antibody, in patients with advanced solid tumors | Kelly Stratton, MD; Aurélien Marabelle, MD PhD; Geoffrey Shapiro, MD, PhD; Jong Chul Park, MD; Solmaz Sahebjam, MD; Srimoyee Ghosh, PhD; Jian Chen; Taylor Eves; Ying Wang; Amita Patnaik, MD FRCP© | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Immune tolerance; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P326 | GARNET: Preliminary safety, efficacy, pharmacokinetic, and biomarker characterization from a phase 1 clinical trial of TSR-042 (anti-PD-1 monoclonal antibody) in patients with recurrent/advanced NSCLC | Desamparados Roda Perez, PhD, MD; Janakiraman Subramanian; Joanna Pikiel; Maria-Pilar Barretina-Ginesta; José Trigo, MD; Wei Guo; Sharon Lu; David Jenkins, PhD; Kai Yu Jen; Hadi Danaee; Steven Dunlap; Ellie Im; Victor Moreno, PhD, MD | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; Solid tumors |
| P327 | Higher dose single-agent intratumoral G100 (a TLR4 agonist) results in increased biomarker activity and improved clinical outcomes in patients with follicular lymphoma | Christopher Flowers, MD, MS; Carlos Panizo; Weiyun Ai, MD, PhD; Iris Isufi, MD; Alex Herrera, MD; Nancy Bartlett, MD; Craig Okada, MD, PhD; Bela Kis, MD, PhD; Luis de la Cruz Merino Sr.; Javier Briones; Jorge Chaves, MD; Elizabeth Cull; Locke J. Bryan, MD; Roch Houot, MD, PhD; Kim Linton, PhD; Ian Chau; Gottfried von Keudell; Hailing Lu, MD, PhD; Frank Hsu, MD; Ahmad S. Halwani, MD | B cell; Biomarkers; Clinical study; Clinical trial; Gene expression; Leukemia/Lymphoma; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Vaccine |
| P328 | Preoperative window of opportunity trial of nivolumab with or without tadalafil in patients with squamous cell carcinoma of the head and neck | Adam Luginbuhl, MD; Jennifer Johnson, MD; Larry Harshyne; Joseph Curry, MD; Rita Axelrod, MD; Ralph G. Zinner, MD; Benjamin Leiby, PhD; Madalina Tuluc, MD; Christopher M. Snyder; David Cognetti, MD; Ulrich Rodeck, MD PhD; Athanassios Argiris, MD PhD | Checkpoint blockade; Clinical trial; Solid tumors; Surgery; Tumor microenvironment |
| P329 | Phase 3 KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma | Jason J. Luke, MD, FACP; Paolo A. Ascierto, MD; Matteo S. Carlino, MBBS, PhD, BMedSC, F; Alexander MM. Eggermont; Jean-Jacques Grob, MD; Axel Hauschild; John M. Kirkwood, MD; Georgina Long, MBBS, PhD, BSc, FRAC; Peter Mohr; Caroline Robert; Jeffrey E. Gershenwald, MD; Andrew Poklepovic, MD; Merrick Ross, MD; Richard A. Scolyer; James Anderson; Sama Ahsan; Nageatte Ibrahim, MD PhD; Vernon K. Sondak | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune adjuvant; Solid tumors |
| P330 | Harnessing the power of lymphodepletion and checkpoint blockade: A Nivolumab/Ipilimumab-primed immunotransplant for relapsed/refractory diffuse large B cell lymphoma patients | Thomas U. Marron, MD PhD; Netonia Marshall, PhD; Dana Ostrowski, BA; Amir Steinberg, MD; Linda Hammerich, PhD; Sacha Gnjatic, PhD; Nina Bhardwaj, MD, PhD; Joshua Brody, MD; | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma |
| P331 | A phase 1a clinical trial of NLG802, a prodrug of indoximod with enhanced pharmacokinetic properties | Olivier Rixe, MD, PhD; Thomas George, MD; Heloisa Soares; Agnieszka Marcinowicz; Nicholas Vahanian, MD; Charles Link, Jr., MD; Edouard Dupis; Eugene P. Kennedy, MD, FACS; Mario Mautino, PhD | Clinical study; Clinical trial; Immune suppression; Solid tumors |
| P332 | CheckMate 9TM: Phase 3 study of nivolumab + cisplatin + radiotherapy in cisplatin-eligible patients with intermediate- or high-risk locally advanced squamous cell carcinoma of the head & neck | Maura L. Gillison, MD, PhD; Vincent Gregoire, MD, PhD; Makoto Tahara; Quynh Thu Le, MD; Wilfried Budach; Mark Lynch, PhD; Justin Kopit; Vijayvel Jayaprakash, MBBS, PhD; Peng Sun; Robert L. Ferris, MD, PhD | Chemotherapy; Clinical trial; Radiotherapy; Solid tumors; Targeted therapy |
| P333 | CheckMate 9TM: Phase 3 study of nivolumab + radiotherapy (RT) vs cetuximab + RT in cisplatin-ineligible patients with intermediate-/high-risk locally advanced squamous cell carcinoma of the head/neck | robert haddad, MD; Kevin Harrington, MD; Lisa Licitra, MD; Peter Brossart; Dennis Soulières; Loren K. Mell, MD; Laurence Toms; Justin Kopit; Mark Lynch, PhD; Vijayvel Jayaprakash, MBBS, PhD; Ezra Cohen, MD | Clinical trial; Radiotherapy; Solid tumors; Targeted therapy |
| P334 | AI-designed dual peptide vaccine plus novel combination adjuvant showed markedly induction of antigen-specific CTLs with disease stabilization in last line patients with GI cancers. | Masao Nakajima, MD; Shoichi Hazama; Koji Tamada, MD PhD; Keiko Udaka; Yasunari Kouki; Toshinari Uematsu; Hideki Arima; Shun Doi, PhD; Hiroto Matsui; Sinsuke Kanekiyo; Yoshitaro Shindo; Yukio Tokumitsu; Shinobu Tomochika; Shin Yoshida; Michihisa Iida; Nobuaki Suzuki; Shigeru Takeda; Shigeru Yamamoto; Shigefumi Yoshino; Tomio Ueno; Hiroaki Nagano | Clinical trial; Costimulation; Immune adjuvant; Immune suppression; Regulatory T cell (Treg cell); T cell; Vaccine |
| P335 | A phase 1 study of ALX148: CD47 blockade in combination with anticancer antibodies to bridge innate and adaptive immune responses for advanced malignancy | Nehal Lakhani, MD, PhD; Patricia LoRusso, DO; Laura Q. Chow, MD; Yung-Jue Bang, MD PhD; Philip Fanning; Yonggang Zhao, PhD, MBA; Jaume Pons; Hong Wan; Sophia S. Randolph, MD, PhD; Wells Messersmith, MD | Antigen presenting cells; Checkpoint blockade; Clinical trial; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P336 | An international, single-arm, phase 2 study of INCMGA00012 in patients with advanced squamous carcinoma of the anal canal (SCAC) who have progressed following platinum-based chemotherapy (NCT03597295) | Sheela Rao; May Cho; Anne Demols; Talal Kayyal; Hiral Parekh; Gerard Kennealey, MD; Chuan Tian; Melissa Catlett; Marwan Fakih, MD | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P337 | Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist with or without anti-PD1antibodies in patients with advanced solid tumors | Lucie Heinzerling; Juergen Krauss; Carsten Weishaupt; Patrick Terheyden; Benjamin Weide, MD; Ralf Gutzmer; Peter Mohr; Juergen C. Becker, MD, PhD; Felix Kiecker; Angelika Daehling; Fatma Doener, PhD; Regina Heidenreich; Sarah-Katharina Kays; Ute Klinkhardt, MD; Birgit Scheel; Oliver Schönborn-Kellenberger; Tobias Seibel, II; Tanja Strack; Ulrike Gnad-Vogt, MD; | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR; Tumor microenvironment |
| P338 | Phase II neoadjuvant and immunologic study using the anti B7-H3 antibody, Enoblituzumab, in patients with localized prostate cancer | Eugene Shenderov, MD, PhD; Karim Boudadi, MD; Angelo M. Demarzo, MD, PhD; Mohamad E. Allaf, MD; Onur Ertunc, MD; Igor Vidal, MD; Carolyn Chapman, AAS; Hao Wang; Jim Vasselli, MD; Jon M. Wigginton, MD; Jan Davidson-Moncada, MD, PhD; Rehab Abdallah, MB BCh; Tanya O'Neal, BS, MS; Christian Pavlovich, MD; Trinity J. Bivalacqua, MD PhD; Ashley Ross, MD; Charles G. Drake, MD, PhD; Drew M. Pardoll, MD, PhD; Emmanuel S. Antonarakis, MD; | Antibody; Checkpoint blockade; Clinical trial; Tumor microenvironment |
| P339 | HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer | Kristen R. Spencer, DO, MPH; Daniella E. Portal, BS; Christopher R. Heery, MD; Lynne M. Bauman, MS; Howard Hochster, MD; Elizabeth Poplin, MD; Usha Malhotra, MD; Richard B. Alexander, MD; David A. August, MD; Timothy Kennedy, MD; Miral Grandhi, MD; Russell C. Langan, MD; Edmund C. Lattime, PhD; Dirk F. Moore, PhD; Michael P. Kane, RPh, BCOP; Liesel Dudek, RN, OCN, CCRP; Sarah Nabeel; Darren Carpizo, MD, PhD | Checkpoint blockade; Chemotherapy; Clinical trial; Immune adjuvant; Solid tumors; Surgery; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P340 | Pharmacokinetic and pharmacodynamic characterization of ALX148, a CD47 blocker, in patients with advanced malignancy and non-Hodgkin lymphoma | Feng Jin, PhD; Nehal Lakhani, MD, PhD; Patricia LoRusso, DO; Laura Q. Chow, MD; Wells Messersmith, MD; Sangetha Bollini; Laura Doyle; Steven Kauder, PhD; Philip Fanning; Jaume Pons; Sophia S. Randolph, MD, PhD; Hong Wan | Antigen presenting cells; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P341 | Phase 1 study of CA-170, a first-in-class, orally available, small molecule immune checkpoint inhibitor (ICI) dually targeting VISTA and PD-L1, in patients with advanced solid tumors or lymphomas | Yung-Lue Bang, MD; Jeffrey A. Sosman, MD; Adil Daud, MBBS MD; Funda Meric-Bernstam, MD; Javier Garcia-Corbacho; Manish R. Patel, MD; James J. Lee, MD, PhD; Kyu-Pyo Kim; Joshua Brody, MD; Sun Young Rha; Marta Gil Martin; Santiago Ponce Aix, MD; Erika P. Hamilton, MD; Radhakrishnan Ramchandren, MD; Myung-Ju Ahn; James Spicer, MD, PhD; Simon Pacey; Gerald S. Falchook, MD; Hongwei Wang, MD, PhD; Guangxin Xu; Lisa Adams, BS; Anna W. Ma, MS; Robert Ghararvi; David Tuck; John D. Powderly, II, MD, CPI | Checkpoint blockade; Clinical study; Clinical trial |
| P342 | Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC | Scott Cowan, MD; Charalambos Solomides, MD; Craig D. Hooper, PhD; Larry Harshyne, PhD; Grace Lu-Yao, PhD; Hushan Yang, PhD; Linda Phan, BS; Dawn Poller, BS; Sung Whang, DNP, CRNP; Benjamin Leiby, PhD; Marie Werner-Wasik, MD; Bo Lu, MD; Jennifer Johnson, MD; Rita Axelrod, MD; Argiris Athanassios, MD PhD; Natathiel Evans, MD; Ralph G. Zinner, MD | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune adjuvant; Immune monitoring; Solid tumors; Surgery; Tumor evasion; Tumor microenvironment |
| P343 | Nivolumab plus weekly carboplatin and paclitaxel as induction therapy in resectable locally advanced head and neck cancer | David Cognetti, MD; Joseph Curry, MD; Adam Luginbuhl, MD; Richard Goldman, MD; Charalambos Solomides, MD; Madalina Tuluc, MD; Stacey Mardekian, MD; Craig D. Hooper, PhD; Larry Harshyne, PhD; Grace Lu-Yao, PhD; Hushan Yang, PhD; Linda Phan, BS; Dawn Poller, BS; Benjamin Leiby, PhD; Voichita Bar-Ad, MD; Jennifer Johnson, MD; Rita Axelrod, MD; Argiris Athanassios, MD PhD; Ralph G. Zinner, MD | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune adjuvant; Immune monitoring; Solid tumors; Surgery; Tumor microenvironment |
| P344 | Spherical Nucleic Acid (SNA) TLR9 agonists induce long-term tumor-specific immune responses in synergy with PD-1 checkpoint inhibition | Bart R. Anderson, PhD; SubbaRao Nallagatla, PhD; Richard Kang, PhD; Ekambar R. Kandimalla, PhD | Checkpoint blockade; Immune adjuvant; Solid tumors; TLR |
| P345 | Depletion of plasma arginine with pegzilarginase enhances the anti-tumor activity of immune checkpoint inhibitors | Mark D. Badeaux, PhD; Giulia Agnello, PhD; Danlee Enzler, BS; Leslie Priddy, B.S; Jason F. Wiggins, BS; Christopher Daige; Scott W. Rowlinson, PhD; | Checkpoint blockade; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P346 | A phase 1b/2 study of the safety and efficacy of HBI-8000-nivolumab combination in melanoma (MEL), renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) | Nikhil I. Khushalani, MD; Zeynep Eroglu, MD; Andrew S. Brohl, MD; Thai H. Ho, MD, PhD; Heather Yeckes-Rodin, MD; Michael R. Kurman, MD; Reid P. Bissonnette; Mireille Gillings, PhD; Gloria Lee, MD, PhD; | Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Tumor evasion; Tumor microenvironment |
| P347 | Targeting phosphatidylserine enhances the anti-tumor response to radiation therapy and immune checkpoint blockade in a preclinical melanoma model | Sadna Budhu, PhD; Rachel A. Giese, MD; Aditi Gupta, BA; Sara Schad, BS; Olivier De Henau, MD; Roberta Zappasodi, PhD; Luis F. Campesato, PhD; Christopher A. Barker, MD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD | Checkpoint blockade; Radiotherapy |
| P348 | Survival and immune modulation in homologous recombination deficient murine ovarian tumors using the PARP inhibitor, rucaparib and immune agonist, NKTR-214 | Deborah Charych, PhD; Liliane Robillard, Ph.D.; Andrew Simmons, PhD; Thomas C. Harding, Ph.D.; Minh Nguyen; Rachel Dusek, PhD; | Biomarkers; Chemokine; Cytokine; Gene expression; Immune monitoring; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P349 | Spatial distribution analysis reveals increased PD1 expression on cytotoxic T cells leading to tumor regression upon combined MEK and HDAC inhibition in spontaneous PDAC mouse model | Phyllis F. Cheung, PhD; Jens T. Siveke; Anna Bazarna; Christian Neander; Konstantinos Savvatakis; Sven-Thorsten Liffers; Marija Trajkovic-Arsic; Aayush Gupta; Alexander Herner | Coinhibition; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P350 | First-line nivolumab plus ipilimumab is associated with lower costs per responder versus sunitinib among patients with advanced renal cell carcinoma | Toni K. Choueiri; Keith A. Betts, PhD; Shuo Yang, PhD; Ella X. Du, MESc; Sumati Rao, PhD; Saby George, MD, FACP | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P351 | ADU-S100 (MIW815) synergizes with checkpoint inhibition to elicit an anti-tumor CD8+ T cell response to control distal tumors | Kelsey Sivick Gauthier, PhD; Anthony L. Desbien, PhD; Gabrielle Reiner; Leticia Corrales; Weiwen Deng; Laura H. Glickman, PhD; Natalie H. Surh; Brian Francica; David Kanne; Justin J. Leong, PhD; Ken Metchette; Lianxing Zheng; Charles Cho; Yan Feng; Jeffrey M. McKenna; Steve Bender, PhD; Chudi Ndubaku; Meredith L. Leong; Thomas W. Dubensky, Jr.; Andrea van Elsas; Sarah McWhirter; | Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P352 | Blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase A (TrkA) improves the anti-tumor efficacy of immune checkpoint blockade | Colm R. Duffy, B.A.; Stephen Mok; James P. Allison, PhD; | Checkpoint blockade; Chemokine; Cytokine; Immune suppression; Monocyte/Macrophage; Myeloid cells; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P353 | Strategic combination of multiple immune-oncology agents to engage, expand, and enable immune responses against tumors | Kellsye Fabian, PhD; Michelle Padget; Anthony Malamas; Rika Fujii; John Lee, MD; Jeffrey Schlom, PhD; James W. Hodge, PhD, MBA | Checkpoint blockade; Chemotherapy; Immune adjuvant; Solid tumors; Vaccine |
| P354 | Co-clinical trials of MEK inhibitor, anti PD-L1 and anti CTLA-4 combination treatment in Non-Small Cell Lung Cancer | Pierre-Olivier Gaudreau; David H. Peng, Ph.D.; Bertha Leticia Rodriguez; Jared J. Fradette; Laura A. Gibson; Samrat Kundu, Ph.D.; Limo Chen, PhD; Jennifer A. Wargo, MD, MMSc; Don L. Gibbons, MD, PhD; | Checkpoint blockade; Clinical study; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P355 | Nivolumab plus ipilimumab is associated with lower number needed to treat compared with sunitinib for preventing death in advanced renal cell carcinoma | Saby George, MD, FACP; Keith A. Betts, PhD; Shuo Yang, PhD; Ella X. Du, MESc; Jennifer Johansen, PharmD, BCPS; Sumati Rao, PhD; Toni K. Choueiri; | Checkpoint blockade; Clinical study; Clinical trial; Targeted therapy |
| P356 | CXCR4 antagonism converts the cold tumor into hot tumor by enhancing the infiltration of antigen-specific CD8 T-cells in the TME leading to increased anti-tumor effects of anti-OX40 | Pankaj Gaur, PhD; Vivek Verma; Rahul Nandre, PhD; Ella Sorani, PhD; Abi Vainstein-Haras, MD; Galia Oberkovitz; Amnon Peled, PhD; Seema Gupta, PhD; Samir N. Khleif, MD; Stephen M. Shaw, PhD; Osnat Bohana-Kashtan; | Costimulation; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P357 | Entinostat increases the frequency of tumor-specific effector T-cells and their functionality is enhanced by anti-OX40 leading to durable anti-tumor effects | Rahul Nandre, PhD; Vivek Verma; Pankaj Gaur, PhD; Hua Wang; Peter Ordentlich, PhD; Lei Wang, PhD; Seema Gupta, PhD; Samir N. Khleif, MD; Samir N. Khleif, MD; | Costimulation; Immune monitoring; T cell; Tumor microenvironment; Vaccine |
| P358 | ROR-gamma agonist induces long-lived Th17 cells in the TME leading to increased anti-tumor effects of agonist anti-OX40 | Pankaj Gaur, PhD; Vivek Verma; Rahul Nandre, PhD; Laura L. Carter, PhD; Xiao Hu, PhD; Xikui Liu, PhD; Seema Gupta, PhD; Samir N. Khleif, MD | Costimulation; Immune monitoring; Tumor microenvironment; Vaccine |
| P359 | Immune cell responses and dose scheduling optimization of radiation and anti-PD-L1 treatment combination using a joint experimental and systems modeling approach | Yuri Kosinsky, PhD; Simon J. Dovedi, PhD; Kirill Peskov, PhD; Veronika Voronova, MSc; Lulu Chu, PhD; Donald R. Stanski, MD; Gabriel Helmlinger, PhD; | Checkpoint blockade; Immune suppression; Radiotherapy; T cell; Tumor microenvironment |
| P360 | Enhanced anti-tumor efficacy of mesothelin-targeted immunotoxin LMB-100 combined with anti-PD-1 antibody | Qun Jiang, PhD; Daniel Rathkey; Jingli Zhang; Ira H. Pastan, MD; Raffit Hassan, MD | Checkpoint blockade; T cell; Targeted therapy |
| P361 | Phase 1/2 study of mogamulizumab (anti-CCR4), to deplete regulatory T-cells, in combination with PD-1 checkpoint inhibitor nivolumab in subjects with locally advanced or metastatic solid tumors | David Hong, MD; Olivier Rixe, MD, PhD; Vi K. Chiu, MD, PhD; Patrick Forde, MD; Tomislav Dragovich, MD; Yanyan Lou, MD; Asha Nayak, MD; Rom Leidner, MD; James Atkins, MD; Agron Collaku, PhD; Floyd E. Fox, PhD; Margaret A. Marshall, MD; Anthony J. Olszanski, MD, RPh; | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy |
| P362 | TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 “do not eat” signal, enhances the anti-tumor effect of radiation and targeted therapy in ovarian cancer models | Lisa Johnson, PhD; Lei LC. Cui, PhD, BS; Hui Chen, BS; April Lewtak, MSc; Sean Oh; Carole Galligan, PhD; Simone Helke; Julia Berchadsky, PhD; Bob Uger, BS, PhD | Checkpoint blockade; Monocyte/Macrophage; Radiotherapy; Solid tumors |
| P363 | Pegzilarginase in combination with agonist anti-OX40 therapy enhances T cell priming and effector function leading to improved tumor regression and survival | Melissa J. Kasiewicz, BS; Annah S. Rolig, Ph. D; Elizabeth R. Sturgill, PhD; Mark D. Badeaux, PhD; Scott W. Rowlinson, PhD; William L. Redmond, PhD | Checkpoint blockade; Coinhibition; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P364 | Systemic anti-tumor immunity and immune memory formation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214 | Saul Kivimae, PhD; Marlene Hennessy, BS; Rhoneil Pena; Yolanda Kirksey, MSc; Wildaliz Nieves, PhD; Phi Quach, BS PhD; Janet Cetz, BS; Zhongxu Ren, PhD; Haiying Cai, BS; BoLiang Deng, PhD; Wen Zhang, PhD; Fiore Cattaruzza; Christie Fanton, PhD; Neel K. Anand, PhD; Werner Rubas, PhD; Stephen K. Doberstein, PhD; Loui Madakamutil; Jonathan Zalevsky, PhD | Antigen presenting cells; Costimulation; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR |
| P365 | Triple checkpoint blockade targeting PD-1, TIM-3, and LAG3 improves T cell reinvigoration and antitumor efficacy over single and double combinations | Johanna K. Kaufmann, PhD; Geeta Sharma; Srimoyee Ghosh, PhD; Sujatha Kumar, PhD; Kevin G. Coleman, PhD; Sridhar Ramaswamy, MD; David Jenkins, PhD | Checkpoint blockade; Coinhibition |
| P366 | Blockade of the PD-1/PD-L1 pathway with the Anti-PD-1 mAb, MGA012, enhances the biological activity of the B7-H3 x CD3 bispecific DART® molecule, MGD009 | Liqin Liu, PhD; Yinhua Yang; Ralph F. Alderson, PhD; Jonathan Li, PhD; Qihong Xu; Daorong Liu; Robert Burns; Vatana Long; Syd Johnson, PhD; Ezio Bonvini; Paul Moore, PhD; | Antibody; Checkpoint blockade; T cell; Tumor antigens |
| P367 | Synergistic anti-tumor effects of TLR4 agonist G100 and anti-OX40 antibody | Hailing Lu, MD, PhD; Alec Betancur; Howard JR. Lee; Jan H. Ter Meulen, MD, PhD | Antigen presenting cells; Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P368 | Combination of a dipeptidyl peptidase inhibitor BXCL701 and biased CD122 agonist NKTR-214 with anti-PD1 provides functional immunological memory through inflammatory cell death. | John MacDougall, PhD; Snigdha Gupta, PhD; Veena Agarwal; Luca Rastelli; Annie An; wenqing yang, PhD; Henry Li; Deborah Charych, PhD; Jonathan Zalevsky, PhD; Vincent O'Neill; | Checkpoint blockade; Inflammation; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P369 | Pegilodecakin, a pegylated human IL-10 (AM0010), enhances the cytotoxicity of CAR-T cells In Vitro | Scott McCauley, BA; Rakesh Verma, PhD; Martin Oft, MD; | Adoptive immunotherapy; CAR T cells; Cytokine; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P370 | Forced expression of OX40L and inhibition of IDO within the murine glioblastoma microenvironment creates a potent anti-tumor immune response. | Teresa Nguyen, BS; Yisel A. Rivera-Molina, PhD; Francisco Puerta-Martinez, PhD; Debora Kim; Xuejun Fan, BS; Frederick Lang, MD; Hong Jiang, PhD; Candelaria Gomez-Manzano, MD; Juan Fueyo | Costimulation; Immune suppression; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P371 | Reprogramming the immune phenotype of Rb-deficient tumor cells using BET inhibition | Brian M. Olson, PhD; Christina J. Hong; Riyue Bao, PhD; Gregory B. Lesinski, PhD, MPH; Akash Patnaik, MD, PhD | Biomarkers; Checkpoint blockade; Immune suppression; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P372 | BETAMUNE, a replication competent type 5 adenovirus carrying a TGF-Beta trap, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model | Christopher Larson, MD PhD; Corey A. Carter, MD; Bryan Oronsky, MD PhD; Tony Reid, MD PhD; | Antibody; Antigen presenting cells; Checkpoint blockade; Gene expression; Immune suppression; Monocyte/Macrophage; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| P373 | Synergistic efficacy of duvelisib with checkpoint or co-stimulatory antibodies in a B cell lymphoma model: Advantages of dual inhibition of PI3K-delta and PI3K-gamma | Jonathan A. Pachter, PhD; David Weaver, PhD; | Checkpoint blockade; Costimulation; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor microenvironment |
| P374 | Sex-based heterogeneity of response to immunotherapy in non small cell lung cancer | Fabio Conforti, MD; Laura Pala; Vincenzo Bagnardi; Giuseppe Viale; Tommaso De Pas, MD; Elisabetta Pennacchioli; Emilia Cocorocchio; Pier Francesco F. Ferrucci, MD; Richard Gelber; Aron Goldhirsch; | Checkpoint blockade; Chemotherapy |
| P375 | Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/ONC0055, a 4-1BB / PD-L1 bispecific compound for tumor localized activation of the immune system | Marina Pavlidou, PhD; Janet K. Peper; Lucia Pattarini; Christian Barthels; Eva-Maria Hansbauer; Rachida Bel Aiba; Milan Blanusa; Alix Scholer-Dahirel; Maximilien Grandclaudon; Celine Grand; Jamila Elhmouzi-Younes; Matthieu Rivière; Véronique Blanc, PhD; Christine Rothe; Shane Olwill; | Antibody; Antigen presenting cells; Checkpoint blockade; Coinhibition; Costimulation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P376 | Targeting vasoactive intestinal peptide signaling to enhance immunotherapy against solid tumors | Sruthi Ravindranathan, PhD; Rebecca A. Pankove, MS; Yiwen Li, MS; Shuhua Wang, MD; Edmund K. Waller, MD, PhD, FACP; Mohammad Y. Zaidi, MD, MS; Gregory B. Lesinski, PhD, MPH; | Coinhibition; Solid tumors |
| P377 | Combination immunotherapy anti-PD-1 anti-body (Ab) with CBT-101 (c-MET inhibitor) demonstrates enhanced activity in tumors not dependent on c-MET | Mamatha Reddy; Gavin Choy, PharmD; Sarath Kanekal, PhD; Sanjeev Redkar, PhD; | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; Immune contexture; Immune suppression; T cell; Targeted therapy; Tumor microenvironment |
| P378 | NKTR-214 (CD122-biased agonist) and NKTR-262 (TLR7/8 agonist) combination treatment pairs local innate immune activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity | Annah S. Rolig, Ph. D; Daniel C. Rose, BS; Saul Kivimäe; Deborah Charych, PhD; Werner Rubas, PhD; Jonathan Zalevsky, PhD; William L. Redmond, PhD | Monocyte/Macrophage; Radiotherapy; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P379 | Nanobodies® as a platform for multispecific targeting of immunomodulatory receptors. | Anandi Sawant, Ph.D.; Douglas Linn, PhD | Biomarkers; Checkpoint blockade; Gene expression; Tumor infiltrating lymphocytes (TILs) |
| P380 | Treatment-free survival (TFS), with and without immunomodulatory medications (IMMs), as a novel outcome applied to immuno-oncology (IO) agents in advanced melanoma | Samantha Sawh; Meredith Regan, PhD; Lillian Werner; Ahmad A. Tarhini, MD, PhD; Sumati Rao, PhD; Komal Gupte-Singh, PhD; Corey Ritchings, PharmD; Michael B. Atkins, MD; David F. McDermott, MD | Checkpoint blockade; Clinical study; Solid tumors |
| P381 | Schweinfurthin natural products promote immune-dependent regression of murine melanoma and improve anti-PD-1-based immunotherapy to achieve durable complete responses and protective immunity | Kathleen Kokolus, MS, PhD; Jeremy S. Haley, MS; Emily J. Koubek; Raghavendra Gowda, PhD; Saketh S. Dinavahi, PhD; Arati Sharma, PhD; David F. Claxton, MD; Klaus F. Helm, MD; Joseph J. Drabick, MD; Gavin P. Robertson, PhD; Jeffrey D. Neighbors, PhD; Raymond J. Hohl, MD; Todd D. Schell, PhD | Checkpoint blockade; Myeloid cells; Metabolism; T cell; Tumor microenvironment |
| P382 | CD28-negative memory tumor infiltrating lymphocytes (TILs) maintain an activated cytotoxic phenotype | Lillian Seu, PhD; Bijal Kakrecha, BS; Paul Fischer, MSc; Malinda Aitken; Alice Tang; Steven Nadler, PhD; Laurence Menard, PhD; | Checkpoint blockade; Costimulation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P383 | Combination therapy with M7824 (MSB0011359C) and NHS-muIL12 enhances antitumor efficacy in preclinical cancer models | Chunxiao Xu, PhD; Bo Marelli; Jin Qi; Guozhong Qin; Huakui Yu; Molly H. Jenkins; Kin-Ming Lo; Joern-Peter Halle; Yan Lan, MD | Checkpoint blockade; Cytokine; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P384 | M7824 (MSB0011359C) is an effective combination partner with standard-of-care therapies in tumor models | Yan Lan, MD; Rinat Zaynagetdinov, M.D., PhD; Kenneth W. Hance; Chia Lin Chu, PhD; Chunxiao Xu, PhD; Bo Marelli; Jin Qi; Guozhong Qin; Huakui Yu; Giorgio Kradjian; Yanping Zhang; Molly H. Jenkins; Joern-Peter Halle; Kin-Ming Lo | Checkpoint blockade; Chemotherapy; Radiotherapy; Targeted therapy |
| P385 | Preliminary biomarker analysis of sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor | Vanessa Tassell; James Christensen; Peter Olson; Igor Rybkin, MD, PhD; Ticiana A. Leal, MD; Alexander I. Spira, MD, PhD, FACP; Collin Blakely, MD; Manish R. Patel, DO; Leora Horn, MD; Kai He, MD, PhD; David Berz, MD; Ryan Ramaekers, MD; Alison Savage; Timothy Larson; Donald Richards; Tammy Roque; Anthony Pham; Massarelli Erminia; James Uyeki; Abhinav B. Chandra, MD, FACP; Robert Jotte; Wangjian Zhong, MD; David Hong, MD; Joshua M. Lang, MD MS; Jennifer Schehr; Ticiana A. Leal, MD; Julio Fernandez Banet; Adam Pavlicek; Kai He, MD, PhD; | Biomarkers; Checkpoint blockade; Immune suppression; T cell; Targeted therapy |
| P386 | CTX-471, a novel agonistic antibody targeting CD137, enhances the anti-tumor activity of tumor antigen-targeted antibodies and immune checkpoint inhibitors when used in combination | Ugur Eskiocak, PhD; Wilson Guzman, BS; Robert Tighe, BS | Antibody; Checkpoint blockade; Coinhibition; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor evasion |
| P387 | A multicenter, phase II study in patients with first line NSCLC, or recurrent PD-X refractory NSCLC or with recurrent HNSCC receiving Eftilagimod Alpha in combination with Pembrolizumab (TACTI-002) | Christian Mueller, MSc; Frederic Triebel, MD, PhD; Chrystelle Brignone, PhD; Tatsiana Skrahina; Martin Forster; | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Targeted therapy |
| P388 | Combination of the Wee1 inhibitor adavosertib (AZD1775) with anti-PD-L1 shows activity in pre-clinical studies | Viia Valge-Archer, PhD; Matthew King, PhD; Chrysiis Michaloglou, PhD; Jennifer Hare; Anisha Solanki, PhD; Susan Critchlow, PhD; | Checkpoint blockade; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P389 | Digital spatial profiling on uveal melanoma tissue treated with combined radiofrequency ablation and ipilimumab | Trieu My T. Van, PhD; Lisette EA. Rozeman, MD; Sarah Warren, PhD; Joseph M. Beechem, PhD; John Haanen, MD PhD; Christian Blank, MD PhD; | Antibody; Biomarkers; Carcinogenesis; Checkpoint blockade; Clinical study; Clinical trial; Proteomics; Radiotherapy; Tumor microenvironment |
| P390 | Vasoactive Intestinal Peptide Antagonist Synergizing with PD1 Antibody Inhibits the Tumor Growth of Breast Cancer. | Shuhua Wang, MD; Sruthi Ravindranathan, PhD; Yiwen Li, MS; Rebecca A. Pankove, MS; Parvin Forghani; Edmund K. Waller, MD, PhD, FACP; Shuhua Wang, MD; | Antibody; Antigen presenting cells; Checkpoint blockade; Costimulation; Dendritic cell; Immune suppression; Inflammation; MDSC; Solid tumors; T cell; Tumor microenvironment |
| P391 | A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with advanced melanoma | Matthew Taylor, MD; Nicholas J. Vogelzang, MD; Allen L. Cohn; Daniel E. Stepan; Robert C. Shumaker, Ph.D.,; Corina E. Dutcus; Matthew Guo; Emmett Schmidt, MD PhD; Drew Rasco; | Angiogenesis; Antibody; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| P392 | A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with non-small cell lung cancer | Marcia S. Brose, MD PhD; Nicholas J. Vogelzang, MD; Christopher Di Simone; Sharad K. Jain, MD; Donald Richards; Carlos A. Encarnacion; Drew Rasco; Robert C. Shumaker, Ph.D.,; Corina E. Dutcus; Daniel E. Stepan; Matthew Guo; Emmett Schmidt, MD PhD; Matthew Taylor, MD; | Angiogenesis; Antibody; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| P393 | A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with urothelial cancer | Nicholas J. Vogelzang, MD; Carlos A. Encarnacion; Allen L. Cohn; Christopher Di Simone; Drew Rasco; Donald Richards; Matthew Taylor, MD; Corina E. Dutcus; Daniel E. Stepan; Robert C. Shumaker, Ph.D.,; Matthew Guo; Emmett Schmidt, MD PhD; James W. Mier, MD; | Angiogenesis; Antibody; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| P394 | CX3CR1+CD8+ T cells is responsible to the clinical benefit of chemoimmunotherapy in metastatic melanoma patients after disease progression on PD-1 blockade | Yiyi Yan, MD PhD; Roxana Dronca, MD; Svetomir N. Markovic, MD, PhD; Haidong Dong, MD, PhD | Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Immune monitoring; T cell |
| P395 | PD-1 blockade synergies with RetroNectin-activated cytokine-induced killer cells in pretreated metastatic renal cell cancer | Lingdi Zhao; Yonghao Yang; Tiepeng Li; Yong Zhang; Wei Li; Lu Han; Hongwei Lin; Quanli Gao | Adoptive immunotherapy; Checkpoint blockade |
| P396 | Phase I trial of interferon-gamma (IFN-g) combined with nivolumab (nivo) in patients with advanced solid tumors | Matthew Zibelman, MD; Alexander W. Macfarlane; Kimberly Costello; Thomas McGowan; John P. O'Neill, BA; Rutika Kokate; Igor Astsaturov; Matthew Zibelman, MD; Matthew Zibelman, MD; Hossein Borghaei, MS, DO; Christina Chu, MD; Crystal Denlinger; Efrat Dotan, MD; Daniel Geynisman; Angela Jain, MD; Lainie Martin, MD; Elias Obeid, MD, MPH; Joseph Treat, MD; Namrata Vijayvergia, MD; Rohit Walia; Jennifer S. Winn, MD, MS; Jeffery A. Nieves, PharmD; Amy Grahn, MS; Jeffrey W. Sherman, MD, FACP; Karthik Devarajan; Karen Ruth; R K. Alpaugh, PhD; Essel D. Al-Saleem; Edna Cukierman, PhD; Kerry S. Campbell, PhD; Elizabeth R. Plimack, MD MS; | Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Solid tumors |
| P397 | Ectopic Tim-3 expression on T regulatory cells leads to lymphoproliferation and T cell activation. | Hridesh Banerjee; Héctor M. Nieves-Rosado; Lawrence P. Kane, Ph.D. | Autoimmunity; B cell; Biomarkers; CAR T cells; Checkpoint blockade; Chemokine; Clinical trial; Coinhibition; Costimulation; Cytokine; Epidemiology; Gene expression; Immune adjuvant; Immune monitoring; Immune suppression; Immune tolerance; Immune toxicity; Inflammation; Metabolism; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P398 | Activation of the T Cell costimulatory protein CD137 using multivalent bicyclic peptides | Kristen Hurov; Punit Upadhyaya; Jessica Kublin; Xueyuan Zhou; Julia Kristensson; Rachid Lani; Gemma Mudd; Katerine van Rietschoten; W. Frank An; Johanna Lahdenranta; Liuhong Chen; Gavin Bennett; Kevin McDonnell; Nicholas Keen; Peter U. Park, PhD; | Antibody; Costimulation; Cytokine; NK/NK T cell; T cell |
| P399 | Induction of tumor-specific immune responses and modulation of the tumor micro-environment by TLR9 agonist lefitolimod in murine syngeneic tumor models | Kerstin Kapp, PhD; Barbara Volz; Detlef Oswald; Burghardt Wittig, MD, PhD; Manuel Schmidt, MSc | Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment |
| P400 | Tumor-localizing NKp30/ICOSL vIgD fusion proteins direct effective dual CD28/ICOS T cell costimulation to B7-H6+ tumor cells in vitro and tumors in vivo | Steven D. Levin, PhD; Lawrence Evans, BS; Erika Rickel; Katherine E. Lewis, PhD; Daniel Demonte; Martin Wolfson, BS; Stacey R. Dillon, PhD; Ryan Swanson, BS; Kristine M. Swiderek, PhD; Stanford L. Peng, MD, PhD; | Antigen presenting cells; Costimulation; Immune contexture; Inflammation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P401 | Blockade of T cell immunoreceptor with Ig and ITIM domains (TIGIT) leads to increased proliferation of bone marrow T cells from patients with acute myeloid leukemia (AML) | Yoko Kosaka, PhD; Adam Lamble, MD; Fei Huang, PhD; Evan F. Lind, PhD | Checkpoint blockade; Immune contexture; Immune suppression; Leukemia/Lymphoma; Myeloid cells; T cell; Tumor evasion; Tumor microenvironment |
| P402 | DuoBody-CD40x41BB conditionally enhances immune activation by crosslinking of CD40- and 4-1BB positive cells | Alexander Muik, PhD; Friederike Gieseke; Isil Altintas, PhD; Saskia Burm; Mustafa Diken; Christian Grunwitz; Sebastian Kreiter; David Satijn, PhD; Danita Schuurhuis; Ozlem Tureci; Ugur Sahin; Esther Breij, PhD | Antibody; Antigen presenting cells; Costimulation; T cell; Tumor infiltrating lymphocytes (TILs) |
| P403 | Preliminary results from a first-in-human phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 | Rachel E. Sanborn, MD; Michael S. Gordon, MD; Mark O'Hara, MD; Nina Bhardwaj, MD, PhD; Yi He, PhD; Tracey Rawls; Tibor Keler, PhD; Michael Yellin, MD | Antibody; Antigen presenting cells; Clinical trial; Dendritic cell; Immune monitoring |
| P404 | The discovery and characterization of PTZ-522 (ASP1951), a fully-human, high affinity agonistic anti-GITR tetravalent monospecific monoclonal antibody | Cynthia Seidel-Dugan, PhD; Sonja Kleffel; Heather Brodkin; Sandra Abbott; Daniel Hicklin; Nels Nielson; Christopher Nirschl; Rebekah O'Donnell; Andreas Salmeron; Philipp Steiner, PhD; Christopher Thomas; William Winston; Cynthia Seidel-Dugan, PhD | Antibody; Costimulation; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P405 | Agonistic IgM antibodies targeting immunostimulatory TNFRSF family members GITR and OX40 enhance immune responses beyond that of IgGs | Angus M. Sinclair, PhD; Dalya Rosner, PhD; Beatrice Wang; Tasnim Kothambawala; Ling Wang; Susan Calhoun; Avneesh Salini; Sachi Rahman; RAMESH BALIGA, PhD; Bruce Keyt | Antibody; Costimulation; Cytokine; Regulatory T cell (Treg cell); T cell; T cell lineages; Targeted therapy |
| P406 | ALPN-202, a combined PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 T cell costimulator, elicits potent intratumoral T cell immunity superior to and differentiated from PD-L1 inhibitor monotherapy | Ryan Swanson, BS; Mark Maurer, BS; Chris Navas, BS; Chelsea J. Gudgeon, BS; Katherine E. Lewis, PhD; Martin Wolfson, BS; Sherri Mudri, BS; Kayla N. Susmilch, MS; Joe Kuijper; Stacey R. Dillon, PhD; Steven D. Levin, PhD; Kristine M. Swiderek, PhD; Stanford L. Peng, MD, PhD | Antigen presenting cells; Checkpoint blockade; Coinhibition; Costimulation; Dendritic cell; Gene expression; Inflammation; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs) |
| P407 | CTX-471, a novel agonistic antibody targeting CD137, eradicates very large tumors in vivo by selectively reprogramming the tumor microenvironment without causing hepatic toxicity | Ugur Eskiocak, PhD; Wilson Guzman, BS; Nora Zizlsperger, PhD; Benjamin Wolf; Christine Cummings; Thomas Daly; Puru Nanjappa, M.Sc; Lauren Milling; Xianzhe Wang; Lucy Liu; Samantha Ottinger; Jason Lajoie; Michael Schmidt; Robert Tighe, BS; | Antibody; Biomarkers; Costimulation; Immune toxicity; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P408 | Preclinical identification of the pharmacologically active dose range of the tumor targeted 4-1BB agonist MP0310 based on tumor regression, receptor occupancy and CD8 T lymphocyte expansion | Elmar Vom Baur, PhD, MBA, MEng; Ivana Tosevski, PhD; Laurent Juglair, MSc; Alexander Link, PhD; Guy Lemaillet; Heïdi Poulet; Christian Reichen, PhD; Patricia Schildknecht, MSc; Joanna Taylor, MSc; Alexander Titz, MSc; Waleed Ali; Doris Schaible; Mirela Matzner; Christof Zitt, PhD; Jörg Herbst, PhD, DABT; Keith Dawson, PhD; Julia Hepp, PhD; Dan Snell, PhD; Michael T. Stumpp, PhD; Victor Levitsky, MD PhD; Hong Ji, MD, PhD; Ivana Tosevski, PhD | Biomarkers; Clinical study; Clinical trial; Costimulation; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P409 | Pharmacodynamic activity of MEDI1873, a Glucocorticoid-Induced tumor necrosis factor family-related protein (GITR) agonist molecule, administered intravenously to patients with advanced solid tumors | Nicholas M. Durham, PhD; Nathan Standifer, PhD; Jennifer Cann, PhD; Christopher A. Morehouse, MD; Li Yan; Kristina Kovacina; Xu Liu; Jia Li; Yuling Wu; Katie Streicher, PhD; Paolo Vicini; Ayesh Perera; Rakesh Kumar, PhD; Raid Aljumaily, MD; Aung Naing, MD, FACP; Ashish Chintakuntlawar, MBBS, PhD; Naiyer A. Rizvi, MD; Helen Ross, MD; Michael S. Gordon, MD; Jeffrey Infante; Crystal Denlinger; Ani Balmanoukian, MD; | Clinical trial; Costimulation; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| P410 | MV-626, a potent and selective inhibitor of ENPP1 enhances STING activation and augments T-cell mediated anti-tumor activity in vivo | Jason R. Baird, PhD; Gregory N. Dietsch, PhD, DABT; Vincent Florio, PhD; Michael Gallatin, PhD; Clayton D. Knox, MD; Joshua Odingo, PhD; Marka R. Crittenden, MD, PhD; Michael J. Gough, PhD | Cytokine; Immune adjuvant; Radiotherapy; Tumor microenvironment |
| P411 | An IL15/IL15Rα heterodimeric Fc-fusion engineered for reduced potency demonstrates an optimal balance of in vivo activity and exposure | Matthew J. Bernett, PhD; Rajat Varma, PhD; Christine Bonzon, PhD; Liz Bogaert, PhD; Rumana Rashid, PhD; Ke Liu, PhD; Irene Leung, PhD; Suzanne Schubbert, PhD; Sung-Hyung Lee, PhD; Daniel C. Kirouac, PhD; Fei Hua, PhD; Nicole Rodriguez, PhD; Yoon Kim, PhD; Kendra N. Avery, PhD; Connie Ardila; Nargess Hassanzadeh-Kiabi, PhD; Umesh Muchhal, PhD; Seung Chu, PhD; Gregory L. Moore, PhD; John R. Desjarlais, PhD | Cytokine; NK/NK T cell; Solid tumors; T cell |
| P412 | Tumor cell-intrinsic defects in STING pathway signaling | Blake Flood, BS; Leticia Corrales; Thomas F. Gajewski, MD, PhD | Cytokine; Gene expression; Tumor microenvironment |
| P413 | The FAP-IL2v immunocytokine is a versatile combination partner for cancer immunotherapy | Valeria Nicolini; Inja Waldhauer; Anne Freimoser-Grundschober; Federica Cavallo; Sara Colombetti; Marina Bacac; Gonzalo Acuna; Jehad Charo, PhD; Stefan Evers, PhD; Volker Teichgraeber, MD; Pablo Umana, PhD; Christian Klein, Dr rer nat; Christian Klein, Dr rer nat; Christian Klein, Dr rer nat; | Antibody; Checkpoint blockade; Cytokine; T cell; Targeted therapy; Tumor stroma |
| P414 | Efficacy of anti-PD-L1/IL-15 fusion protein in multiple tumor models | Stella Martomo, PhD; Dan Lu, MA; Zhanna Polonskaya; Xenia Luna; Kevin McCracken; Jeegar Patel | Antibody; Checkpoint blockade; Cytokine; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs) |
| P415 | Preclinical characterization of IL-2 Superkines engineered with biased CD8+ T cell stimulating properties | Fahar Merchant, PhD; Shafique Fidai; Aaron M. Ring | Antibody; Cytokine; Immune suppression; Immune toxicity; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P416 | Short-course IL-15 given as a continuous infusion leads to massive expansion of NK cells: Implications for combination therapy with anti-tumor antibodies | Milos Miljkovic, MD, MSc; Sigrid Dubois, PhD; Thomas A. Fleisher, MD; Jennifer H. Albert, RN; Thomas A. Waldmann, MD; Kevin C. Conlon, MD; | Antibody; Clinical study; Clinical trial; Cytokine; NK/NK T cell; Solid tumors; T cell |
| P417 | SYTX80-013-A: an engineered IL-2 for the treatment of solid tumors with superior pre-clinical efficacy and safety evidence | Marcos E. Milla, PhD; Jerod L. Ptacin, PhD; Carolina E. Caffaro; Hans R. Aerni, PhD; Lina Ma; Kristine M. San Jose; Michael J. Pena; Robert W. Herman; Yelena Pavlova; David B. Chen; Laura K. Shawver; Lilia K. Koriazova; Ingrid B. Joseph | Cytokine; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| P418 | Pre-clinical investigation of NKTR-255, a polymer-conjugated human IL-15 with a potent NK cell dependent anti-tumor efficacy | Takahiro Miyazaki, MS; Murali K. Addepalli, PhD; Arunasree Lanka, PhD; Amol Murkar, MSc; Ravikumar Nutakki; Palakshi Obalapur, PhD; Peiwen Kuo, PhD; Phi Quach, BS PhD; Mekhala Maiti, PhD; Laurie VanderVeen, PhD; Ping Zhang, MS PhD; Loui Madakamutil; Jonathan Zalevsky, PhD | Cytokine; Immune monitoring; NK/NK T cell |
| P419 | NKTR-214 in combination with radiation produces a potent in situ vaccine in the syngeneic B78 melanoma model. | Alexander Pieper, B.S.; Alexander L. Rakhmilevich, MD, PhD; Jacob Slowinski, Mr.; Amy K. Erbe, PhD; Jacquelyn A. Hank, PhD; Zachary S. Morris, MD, PhD; Deborah Charych, PhD; Paul M. Sondel, MD, PhD | Cytokine; NK/NK T cell; Solid tumors; T cell; Vaccine |
| P420 | Outpatient staccato pulse intravenous Interleukin-2 in metastatic melanoma | Walter S. Quan, Jr., MD; Leah I. Gutierrez, RN BSN; Erin Johnson; Francine M. Quan, RN MSN OCN | Adoptive immunotherapy; Cytokine |
| P421 | Combination of Pegilodecakin (AM0010) with Docetaxel improves immune cell-mediated anti-tumor response in mouse 4T1 tumor model | Navneet Ratti, BS, MBA; Rakesh Verma, PhD; Martin Oft, MD | Chemotherapy; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P422 | A polymer-associated human IL-15 (NKTR-255) has optimized biological activity and unique mechanisms of action on CD8 T Cells and NK Cells | Tanya O. Robinson, PhD; Shweta M. Hegde; Sarai C. Rivas, BS; Takahiro Miyazaki, MS; Kimberly S. Schluns, PhD | Cytokine; NK/NK T cell; T cell |
| P423 | Safety, pharmacokinetics and pharmacodynamic effects of ALKS 4230 in patients with advanced solid tumors from the ongoing dose escalation portion of a first in human (FIH) study | Ulka Vaishampayan, MD; Vamsidhar Velcheti, MD FACP; David F. McDermott, MD; Mayer N. Fishman, MD, PhD; Chris J. Hoimes, MD; Daniel C. Cho, MD; Lei Sun, Ph.D; Juan C. Alvarez, PhD; Heather C. Losey, PhD; Rose Marino, MD; Emily L. Putiri, PhD; Sean Rossi; Lisa Von Moltke, MD; William J. Slichenmyer, MD; Marc S. Ernstoff, MD | Biomarkers; Clinical study; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P424 | NKTR-214, an engineered IL-2, selectively depletes intratumoral Tregs and expands immunotherapy-induced effector T cell responses | Meenu Sharma, PhD; Hiep Khong, PhD; Faisal Fa'ak, MD; Brent C. Chesson; Barbara M. Pazdrak; Laura Maria S Kahn; Louise Janssen, MSc; Uddalak Bharadwaj; Binisha Karki; Zhilan Xiao, MD; Yared Hailemichael, PhD; Manisha Singh, PhD; Christina Vianden, MSc; David Tweardy; Salah Eddine Bentebibel; Cara Haymaker, PhD; Chantale Bernatchez; Adi Diab, MD; Ute Hoch, PhD; Jonathan Zalevsky, PhD; Willem W. Overwijk, PhD; | Checkpoint blockade; Cytokine; Regulatory T cell (Treg cell); Vaccine |
| P425 | Pharmacokinetics and pharmacodynamic effects of ALKS 4230, an investigational immunotherapeutic agent, in cynomolgus monkeys after intravenous and subcutaneous administration | Lei Sun, Ph.D; Jared Lopes, PhD; Heather L. Flick, MS; Erin A. Murphy, MS; Heather C. Losey, PhD | Biomarkers; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell |
| P426 | Chaos-based fractal radiomic features of nodule vasculature predicts response to immunotherapy on non-contrast lung CT | Mehdi Alilou, PHD; Marjan Firouznia, PHD; Pradnya Patil; Kaustav Bera, MBBS; Robert Gilkeson; Prabhakar Rajiah; Vamsidhar Velcheti, MD FACP; Anant Madabhushi, PhD; | Bioinformatics; Biomarkers; Checkpoint blockade; Solid tumors |
| P427 | Novel immune competent murine glioblastoma models derived from Nestin-CreERT2 QuakingL/L; P53L/L; PTENL/L mice | Chao-Hsien Chen, MD; Renee Chin, MS; Genevieve P. Hartley, PhD; Takashi Shingu, PhD; David Hong, MD; Jian Hu, PhD; Michael A. Curran, PhD; | Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Regulatory T cell (Treg cell); T cell; Tumor microenvironment |
| P428 | Spatially-resolved, high-plex digital profiling enables characterization of complex immune biology of the colorectal cancer microenvironment | Sarah E. Church; Chris Merritt, PhD; Andrew M. White, BSc; Douglas Hinerfeld, PhD; Dan Zollinger; Giang Ong, MS; Kristi Barker, MS; Sarah Warren, PhD; Joseph M. Beechem, PhD | Biomarkers; Gene expression; Immune contexture; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P429 | Integrative spatially-resolved, high-plex digital profiling enables characterization of complex immune biology in the tumor microenvironment of mesothelioma | Carmen Ballesteros Merino, PhD; Moritz Widmaier, PhD; Sarah E. Church; Thomas Herz, PhD; Alexei Budco, MSC; Dasa Medrikova, PhD; Ivan Kanchev, PhD; Andrew M. White, BSc; Douglas Hinerfeld, PhD; Shawn M. Jensen, PhD; John R. Handy, MD; Rachel E. Sanborn, MD; Carlo B. Bifulco, MD; Sarah Warren, PhD; Joseph M. Beechem, PhD; Bernard A. Fox, PhD | Bioinformatics; Biomarkers; Immune contexture; Immune monitoring; Immune suppression; Monocyte/Macrophage; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P430 | Radiomic texture features from MR perfusion images predicts pseudoprogression from true progression in glioblastoma patients: A multi-institutional study | Nabil A. Elshafeey; Aikaterini Kotrotsou; Srishti Abrol; Islam Hassan; Ahmed Hassan; Kamel El Salek, MD; Fanny E. Moron; Meng Law; Pascal O. Zinn; Rivka Colen, MD; | Bioinformatics; Biomarkers; Clinical study; Solid tumors |
| P431 | Radiomic Analysis differentiates between True Progression and Pseudo-progression in Glioblastoma patients: A large scale multi-institutional study | Srishti Abrol; Aikaterini Kotrotsou; Nabil A. Elshafeey; Islam Hassan; Ahmed Hassan; Tagwa Idris, MD; Kamel El Salek, MD; Ahmed Elakkad, MD; Kristin Alfaro-Munoz; Shiao-Pei Weathers; Fanny E. Moron; John F. deGroot; Meng Law; Rivka Colen, MD | Bioinformatics; Biomarkers; Solid tumors |
| P432 | High tumor mutation burden (Hypermutation) in gliomas exhibit a unique predictive radiomic signature | Islam Hassan; Aikaterini Kotrotsou; Carlos Kamiya Matsuoka; Kristin Alfaro-Munoz; Nabil A. Elshafeey; Nancy Elshafeey; Pascal O. Zinn; John F. deGroot; Rivka Colen, MD; | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P433 | Advances in multiplex fluorescence immunohistochemistry: 9 color imaging; whole slide multispectral | Carla Coltharp, PhD; Yi Zheng, PhD; Rachel Schaefer; Ryan Dilworth, PhD; Linying Liu; Chichung Wang; Kristin Roman, MS; Clifford C. Hoyt, MS; Peter Miller, MS; | Biomarkers; Immune suppression; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma |
| P434 | Mathematical modeling of CAR T cell therapy outcomes to develop design specifications for CAR T cell engineering | Amritava Das, PhD; Rachel R. Grosser, undergraduate; Ambar C. Velazquez Albino, BS Student; Krishanu -. Saha; Christian M. Capitini, MD; Amritava Das, PhD; | Adoptive immunotherapy; CAR T cells; T cell; T cell lineages |
| P435 | Image-based analysis of the myeloid cell landscape in the 3D co-culture with tumor cells | Gera Goverse, PhD; Kuan Yan, PhD; Lars Geulen; Paul Vink, BS; Leo Price; Lidia Daszkiewicz, PhD | Antigen presenting cells; Checkpoint blockade; Dendritic cell; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor infiltrating lymphocytes (TILs); TLR; Tumor evasion; Tumor microenvironment |
| P436 | Image analysis simulations of needle biopsy tumor specimens to investigate CD8+ TIL heterogeneity | Thomas Herz, PhD; Victor Matvienko; Tobias Wiestler, PhD; Rene Korn, PhD; Keith E. Steele, DVM, PhD | Bioinformatics; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P437 | In vivo synergistic effect of checkpoint blockade and radiation therapy against chordomas in a humanized mouse model | Wataru Ishida, MD; Kyle L. McCormick, B.A.; Aayushi Mahajan, M.S.; Eric M. Feldstein, B.S.; Michael Lim, MD; Jeffrey N. Bruce; Peter Canoll, MD PhD; Sheng-fu L. Lo, M.D.; | Antibody; Checkpoint blockade; Cytokine; Immune tolerance; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P438 | Effect of CD3 affinity and normal tissue expression on the biodistribution and tumor targeting of MUC16xCD3 bispecific antibodies in MUC16 and CD3 humanized mice | Marcus P. Kelly, PhD; Alison Crawford, PhD; Jason T. Giurleo, PhD; Richard Tavaré, PhD; Sosina Makonnen; Carlos Hickey; Makenzie Danton; Cody Arnold; Lauric Haber; Eric Smith, PhD; Dangshe Ma; William Olson, PhD; Gavin Thurston, PhD; Jessica R. Kirshner, PhD | Antibody; Targeted therapy; Tumor antigens |
| P439 | A novel high-throughput, high-content real-time imaging platform to assess immunogenic cell killing activity of immunotherapeutic agents using patient-derived tumor samples. | Melanie Mediavilla-Varela, PhD; Melba Marie Page, Ph.D.; Jenny Kreahling, PhD; Soner Altiok, MD, PhD | Biomarkers; Immune monitoring; Immunoscore; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma |
| P440 | Open-source digital image analysis of whole-slide multiplex immunohistochemistry | Nikhil Lonberg, HSDG; Carmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Bernard A. Fox, PhD; | Bioinformatics; Biomarkers; Solid tumors; Tumor microenvironment; Tumor stroma |
| P442 | Automated quantification of whole-slide multispectral immunofluorescence images to identify spatial expression patterns in the lung cancer microenvironment | Lorenz Rognoni, PhD; Vinay Pawar, PhD; Tze Heng Tan, MSc, PhD, Dipl.Ing.; Felix Segerer, PhD; Philip Wortmann, PhD; Sara Batelli, PhD; Pierre Bonneau; Andrew Fisher, PhD; Gayathri Mohankumar, MS; David Chain, PhD; Michael Surace, PhD; Keith E. Steele, DVM, PhD; Jaime Rodriguez-Canales, MD | Immune contexture; Inflammation; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P443 | Haplotype human immune system (HIS) modeling and co-engraftment of PDX: ImmunoGraft® platform for evaluation of pharmacodynamics of Immuno Oncology therapeutics | Bhavana Verma, PhD; Maria Mancini, PhD; Angela M. Davies, MD; David Sidransky, MD; Amy Wesa, PhD; Neal Goodwin, PhD | Checkpoint blockade; Myeloid cells; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| P444 | Autologous human immune system (HIS) ImmunoGraft®: Mobilized peripheral blood (MPB) derived CD34 engraftment and lineage development | Bhavana Verma, PhD; Georgia Z. Chen, PhD; Edmund K. Waller, MD, PhD, FACP; Neal Goodwin, PhD; Angela M. Davies, MD; Amy Wesa, PhD; Nabil F. Saba, MD | Myeloid cells; Stem cell/cancer-initiating cell; T cell; T cell lineages |
| P445 | Human CD33+ myeloid cells support metastatic colonization in a humanized mouse model of melanoma | Jan Martinek, PhD; Chun I. Yu, PhD; Te-Chia Wu; Kyung In. Kim; Elaheh Ahmadzadeh, PhD; Rick Maser; Florentina Marches; Patrick Metang; Pierre Authie; Hannah Brookes; Joshy George, Ph.D.; Jacques Banchereau; A. Karolina Palucka, MD, PhD | Myeloid cells; Tumor evasion; Tumor microenvironment |
| P446 | Using monocytes to instill brain tumors with TILs | Meenakshi Shanmugasundaram; Anna Zal; Shouhao Zhou; Amy B. Heimberger, MD; Tomasz Zal, PhD; Felix Nwajei, PhD | Adoptive immunotherapy; Chemokine; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P447 | A case of checkpoint inhibitor-induced celiac disease | Dana Alsaadi; Neil J. Shah, MD; Aline Charabaty, MD; Michael Atkins, MD; | Autoimmunity; Checkpoint blockade; Immune toxicity; Inflammation |
| P448 | Blockade of EphB4-ephrin-B2 interaction remodels the tumor immune microenvironment in head and neck cancers | Sana Karam, MD, PhD; Shilpa Bhatia | Monocyte/Macrophage; Regulatory T cell (Treg cell); Targeted therapy; Tumor microenvironment |
| P449 | Improving PDAC outcomes through targeting immune populations and fibrosis by EphB4-ephrinB2 or Treg inhibition combined with radiation | Sana Karam, MD, PhD | Radiotherapy; Regulatory T cell (Treg cell); Targeted therapy; Tumor microenvironment |
| P450 | The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models | Luis A. Carvajal, PhD; Narayana Narasimhan, PhD; Jian-Guo Ren, PhD; Solimar Santiago, M.S; Manoj Samant, PhD; David Sutton, PhD; Vincent Guerlavais, PhD; D. Allen Annis, PhD; Manuel Aivado, MD/PhD; | Checkpoint blockade; Coinhibition; Immune suppression; Immune tolerance; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P451 | Gal9/Tim-3 expression level is higher in patient with failed chemotherapy in AML | Justin P. Kline, MDPAOLA DAMA, PhD; Hongtao Liu, MD, PhD; | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; Immune toxicity; Leukemia/Lymphoma; Targeted therapy |
| P452 | Cisplatin treatment induces anti-tumor immune response in NSCLC by activation of the innate immune response pathway | CARMINIA M. DELLA CORTE, MD; Triparna Sen, PhD; Lixia Diao; Kavya Ramkumar; Carl M. Gay; Pan Tong; You-Hong Fan; Robert J. Cardnell; Don Gibbons, MD; John V. Heymach; Jing Wang; Lauren A. Byers, MD | Bioinformatics; Biomarkers; Chemotherapy; Gene expression; Proteomics |
| P453 | Enhancing the anti-tumor immunity elicited by alpha radiation-based brachytherapy using immunoadjuvants and blockade of suppressor cells | Vered Domankevich-Bachar, DR; Adi Cohen; Margalit Efrati; Michael Schmidt; Hans Georg Rammensee; Itzhak Kelson; Yona Keisari | Immune adjuvant; MDSC; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; TLR; Tumor microenvironment; Vaccine |
| P454 | Elucidating the functional role of type-1 interferon signaling following a medium-dose intermittent cyclophosphamide schedule in preclinical breast cancer models | Kshama Doshi, PhD; Cameron Vergato; Darren Roblyer, PhD; David J. Waxman, PhD | Chemokine; Chemotherapy; Cytokine; Gene expression; Solid tumors |
| P455 | Inducible T cell Co-stimulator (ICOS) is upregulated on lymphocytes following radiation of tumors and ICOS agonism in combination with radiation results in enhanced tumor control | Michael J. Gough, PhD; Shelly Bambina; Monica Gostissa, PhD; Christopher Harvey, PhD; David J. Friedman, PhD; Marka R. Crittenden, MD, PhD | Biomarkers; Checkpoint blockade; Costimulation; Radiotherapy; T cell; Tumor microenvironment |
| P456 | Pressure-enabled delivery of CAR-T cells into the porcine pancreas results in highly-targeted pancreatic delivery with minimal systemic exposure and no pancreatitis or severe systemic cytokine release | John C. Hardaway, MD, PhD; James E. Chomas, PhD; David Jaroch, PhD; Prajna Guha, PhD; N. Joseph Espat, MD, FACS; Steven C. Katz, MD; Aravind Arepally, MD | CAR T cells; Solid tumors; T cell; Targeted therapy |
| P457 | TP53 gene therapy emanating from the investigational agent SGT-53 is capable of augmenting cancer immunotherapy in multiple murine syngeneic tumor models | Joe B. Harford, PhD; Sang-Soo Kim, PhD; Kathleen F. Pirollo, PhD; Antonina Rait, PhD; Manish Moghe; Esther H. Chang, PhD | Checkpoint blockade; Gene expression; Immune tolerance; Immune toxicity; MDSC; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P458 | Contribution of an immune system to RACPP mediated drug delivery | Dina V. Hingorani, PhD; Maria F. Camargo; Matthew K. Doan, B.S.; Joesph Aguilera; Stephen R. Adams; Sunil J. Advani; | Monocyte/Macrophage; Radiotherapy; Solid tumors; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P459 | Detection of tumor-specific antibodies and their binding regions in mice cured from B78 melanoma | Anna Hoefges, MS; Amy K. Erbe, PhD; Drew Melby; Alexander L. Rakhmilevich, MD, PhD; Jacquelyn A. Hank, PhD; Claire Baniel, BS, BA; Clinton M. Heinze, BS; Irene M. Ong, PhD; Sean Mcilwain, PhD; Hanying Li, PhD; Richard Pinapati, PhD; Bradley H. Garcia, II, PhD; Jigar Patel, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD | Adoptive immunotherapy; Antibody; B cell; Bioinformatics; Biomarkers; Checkpoint blockade; Immune monitoring; Neoantigens; Pediatric tumors; Proteomics; Radiotherapy; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P460 | Chemotherapy induced immunogenic cell death and response to STING agonist in high-grade serous ovarian cancer | Madhuri Koti, DVM, MVSc, PhD; Sarah Nersesian, MSc; Nichole Peterson, MSc; Julie-Ann Francis; | Chemokine; Chemotherapy; Cytokine; Gene expression; Immune adjuvant; Inflammation; Tumor microenvironment |
| P462 | Fractionated radiation with PD-1 blockade promotes anti-tumor activity in mouse head and neck cancer | Go Inokuchi, MD, PhD; Elizabeth McMichael, PhD; Masahiro Kikuchi, MD, PhD; David A. Clump, MD PhD; Robert Ferris | Checkpoint blockade; Radiotherapy; Tumor infiltrating lymphocytes (TILs) |
| P463 | HfO2 nanoparticles exposed to radiotherapy generate abscopal effect through activation of CD8+ T cells. | Audrey Darmon, BS; Ping Zhang, MD, PhD; Sébastien Paris, PhD | Immune monitoring; Monocyte/Macrophage; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P464 | Molecular targeted radiotherapy (MTRT) enhances the efficacy of immunotherapy increasing complete response rates of both local and distant disease in a “cold” tumor models | Ravi Patel, MD, PhD; Reinier Hernandez, PhD; Peter M. Carlson; Ryan Brown; Abigail Jaquish; Luke Zangl; Raghava N. Sriramaneni, PhD; Joseph Grudzinski, PhD; Bryan Bednarz, PhD; Jamey Weichert, PhD; Paul M. Sondel, MD, PhD; Zachary S. Morris, MD, PhD; | Checkpoint blockade; Cytokine; Radiotherapy; Targeted therapy |
| P465 | Comparison of peripheral immune response during chemoradiotherapy (CRT) with and without PD-1 blockade in patients with head and neck squamous cell carcinoma (HNSCC) | Juan L. Callejas-Valera, PhD; Daniel Vermeer; Christopher T. Lucido; Caitlin Williamson; Marisela Killian; William C. Spanos, MD; Paola Vermeer, PhD; Steven F. Powell, MD; | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; MDSC; Radiotherapy; T cell |
| P466 | TGF beta blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies. | Maria E. Rodriguez-Ruiz, MD, PhD; Inmaculada Rodriguez; Lina Mayorga; Tania Labiano; benigno Barbes; inaki etxeberria; Mariano Ponz-Sarvise; arantza Azpilicueta; elisabeth Bolanos; Miguel F.Sanmamed; Pedro Berraondo; Felipe Manuel Alfonso Calvo; Mary Helen Barcelos-Hoff; Jose Luis Perez-Gracia; Ignacio Melero, MD, PhD; | Antibody; Immune suppression; Radiotherapy |
| P467 | Augmenting immunity with IAP antagonists in PDAC | Kevin Roehle, PhD; Michael Dougan, MD, PhD; Stephanie K. Dougan, PhD | Checkpoint blockade; Dendritic cell; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs) |
| P468 | Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod | Mariya Rozenblit, MD; Wouter R. Hendrickx, PhD; Adriana Heguy; Luis Chiriboga; Cynthia Loomis; Karina Ray; Farbod Darvishian, MD; Mikala Egeblad, PhD; Davide Bedognetti, MD, PhD; Sylvia Adams, MD; | Chemokine; Cytokine; Gene expression; Granulocyte; Inflammation; Monocyte/Macrophage; NK/NK T cell; T cell; TLR; Tumor microenvironment |
| P469 | TCR repertoire correlates of response in tumor-bearing mice treated with radiotherapy and CTLA-4 blockade | Nils-Petter Rudqvist, PhD; Claire Lhuillier, PhD; Erik Wennerberg, PhD; Jennifer S. Sims, PhD; Sandra Demaria, MD; | Bioinformatics; Checkpoint blockade; Neoantigens; Radiotherapy; Surgery; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P470 | Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer | Triparna Sen, PhD; Triparna Sen, PhD; Bertha Leticia Rodriguez; Limo Chen, PhD; Naoto Morikawa; Junya Fujimoto; Lixia Diao; Youhong Fan; Jing Wang; Bonnie S. Glisson; Ignacio Wistuba, MD; Julien Sage; John V. Heymach; Don Gibbons, MD; Lauren A. Byers, MD | Checkpoint blockade; Coinhibition; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P471 | Mertk is a therapeutic target in combination with radiation to promote adaptive immune tumor responses | Garth Tormoen, MD, PhD; Jason R. Baird, PhD; Gwen F. Kramer, BS; Shelly Bambina; Marka R. Crittenden, MD, PhD; Michael J. Gough, PhD | Monocyte/Macrophage; Radiotherapy; Solid tumors |
| P472 | Immunogenic tumor antigen is required in antitumor effect of cisplatin monotherapy and its combination with anti-PD-L1 | Daiko Wakita, PhD; Toshiki Iwai, BS; Masamichi Sugimoto, PhD; Osamu Kondoh | Checkpoint blockade; Chemotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P473 | Enhancing abscopal responses to radiation therapy by manipulating autophagy | Takahiro Yamazaki, PhD; Marissa Rybstein; Aitziber Buqué, PhD; Ai Sato; Lorenzo Galluzzi, PhD; | Checkpoint blockade; Immune adjuvant; Metabolism; Radiotherapy; Solid tumors; Systems biology |
| P474 | Antibody targeting of WNT signaling modulator dickkopf1 (DKK1) enhances innate anti-tumor immunity and complements anti-PD-1 therapy | Mike Haas; Heidi Heather; Franziska Schürpf-Huber; Lane Newman; Walter Newman, PhD; Mike Kagey; Min Yang, Ph.D.; | Antibody; Checkpoint blockade; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P475 | Avadomide in combination with nivolumab results in increased activated and memory T-cells and enhances CD8+ tumor infiltration in hepatocellular carcinoma patients | Patrick Hagner, PhD; Fadi Towfic, PhD; Alfredo Romano, MD; Julien Edeline, MD; Carlos Gomez-Martin, MD, PhD; Antoine Hollebecque, MD; Robin Kate Kelley, MD; Armando Santoro, MD, PhD; Michael Pourdehnad, MD; Anita Gandhi, PhD | Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Leukemia/Lymphoma; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P476 | EWS-FLI1 expression level modulates T-cell mediated tumor apoptosis in Ewing sarcoma. | Claire M. Julian; Ariel N. Klinghoffer; Hether M. Bernard, MD; Linda M. McAllister-Lucas; Kelly M. Bailey, MD, PhD | Solid tumors; T cell; Tumor microenvironment |
| P477 | HMBD-002-V4: A novel anti-VISTA antibody that uniquely binds murine and human VISTA and potently inhibits tumor growth by remodeling the immunosuppressive tumor microenvironment | Jerome D. Boyd-Kirkup, PhD; Dipti Thakkar, PhD; Vicente Sancenon, PhD; Siyu Guan, PhD; Konrad Paszkiewicz, PhD; Piers Ingram, PhD | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; Myeloid cells; MDSC; Systems biology; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P478 | Platelets as immune suppressors in anti-cancer immune responses | Ana Micaela M. Carnaz Simões; Morten O. Holström, PhD; Mads H. Andersen, PhD; Per Thor Straten, PhD; | Immune suppression; Immune tolerance; T cell; Tumor evasion |
| P479 | NG-641: an oncolytic T-SIGn virus targeting cancer-associated fibroblasts in the stromal microenvironment of human carcinomas | Matthieu Besneux; Brian R. Champion, PhD; Nalini Marino; Marilena Patsalidou; Gianfranco di Genova; Sam Illingworth; Stefania Fedele; Lorna Slater; Darren Plumb; Katy West; Joshua Freedman, BS; Len Seymour; Kerry S. Fisher, MD PhD; Alice C. Brown, PhD | Chemokine; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P480 | Transcriptomic characterization of tumor vs. peripheral blood NK cells in head and neck cancer patients | Fernando Concha-Benavente, MD, PhD; Robert Ferris | Immune suppression; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P481 | The epigenetic underpinnings of regulatory T cell fragility in the tumor microenvironment | Becky Dadey, BS; Abigail E. Overacre-Delgoffe, PhD; Ting Wang; Zhe Sun; Rong Zhang, MS; Wei Chen; Natalie Rittenhouse; Amanda Poholek; Tracy Tabib; Robert Lafyatis; Creg Workman, PhD; Dario A. Vignali, PhD; | Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P482 | Humanization and characterization of novel, best in class isoform-specific anti-TGFβ monoclonal antibodies | Matteo Brioschi; Pamela Cheou; Jacques Van Snick, PhD; Catherine Uyttenhove, PhD; George Coukos, MD, PhD; Gerd Ritter; Steven M. Dunn, PhD | Antibody; Cytokine; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P483 | Iron and HLA-G: Neglected immunosuppressive molecules in the human microenvironment | Xian P. Jiang; Robert Elliott; | NK/NK T cell; Tumor microenvironment |
| P484 | Pharmacokinetics, pharmacodynamics, and safety of FLX475, an orally-available, potent, and selective small-molecule antagonist of CCR4, in healthy volunteers | Primary Author - Sjoerd van Marle, M.D.; Ewoud-Jan van Hoogdalem, Ph.D., R.Ph.; Daniel Johnson; Abood Okal, PhD; Paul D. Kassner, PhD; David J. Wustrow, PhD; William Y. Ho, MD, PhD; Steven A. Smith; | Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor microenvironment |
| P485 | Testing of two bispecific SNIPER™ antibodies targeting mouse tumor-infiltrating Tregs | Anna Hoefges, MS; Bonnie Hammer; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Jacquelyn A. Hank, PhD; Bryan Glaser, Ph.D.; Lucas Bailey, PhD; Roland Green, PhD; Paul M. Sondel, MD, PhD | Antibody; Immune adjuvant; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P486 | Antisense oligonucleotides targeting CD39 and PD-L1 modulate the immunosuppressive tumor microenvironment and have potent anti-tumor activity | Frank Jaschinski, PhD; Tamara Thelemann; Frank Jaschinski, PhD; Richard Klar, PhD; Monika Schell; Lisa Hinterwimmer; Sven Michel; Melanie Buchi; Abhishek S. Kashyap; Alfred Zippelius, MD | Immune suppression; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P487 | The role of MultiOmyx in illustrating the pancreatic tumor microenvironment | Juncker-Jensen Juncker-Jensen, PhD; Juncker-Jensen Juncker-Jensen, PhD; Juncker-Jensen Juncker-Jensen, PhD; Jun Fang; Judy Kuo; Mate Nagy; Qingyan Au; Eric Leones; Flora Sahafi; RaghavKrishna Padmanabhan; Nicholas Hoe; Josette William, PhD, MD; | Antibody; Biomarkers; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment; Tumor stroma |
| P488 | Targeting hIDO1 with 3rd generation antisense oligonucleotides for modulation of the tumor microenvironment | Richard Klar, PhD; Sandra Kallert, PhD; Tamara Thelemann; Sven Michel; Monika Schell; Lisa Hinterwimmer; Alfred Zippelius, MD; Frank Jaschinski, PhD | Immune suppression; Myeloid cells; MDSC; Metabolism; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P489 | Prognostic significance of tumor-associated macrophage content in head and neck squamous cell carcinoma: A meta-analysis | Ayan T. Kumar, BS; Alexander Knops, BA; Brian P. Swendseid, MD; Ubaldo Martinez-Outschoom, MD; Larry Harshyne, PhD; Nancy Philp, PhD; Ulrich Rodeck, MD PhD; Christopher M. Snyder; Adam Luginbuhl, MD; David Cognetti, MD; Jennifer Johnson, MD; Joseph Curry, MD; Joseph Curry, MD; | Autoimmunity; Immune adjuvant; Immune monitoring; Immune suppression; Monocyte/Macrophage; Myeloid cells; Targeted therapy; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P490 | Characterization of the tumor immune microenvironment in treatment-naïve EGFR-mutant NSCLC uncovers a suppressed immune phenotype | Xiuning Le; Alexandre Reuben; Marcelo V. Negrao, MD; Won-Chul Lee, PhD; Edwin Parra; Carmen Behrens, MD; Humam Kadara, PhD; Ignacio Wistuba, MD; Jianjun Zhang, MD, PhD; John V. Heymach; | Immune suppression; Tumor microenvironment |
| P491 | The DNA methyltransferase inhibitor, guadecitabine, has beneficial immunomodulatory effects on myeloid derived suppressor cells, and augments adoptive immunotherapy for solid tumors | Andrea Luker, Ph.D. candidate; Harry D. Bear, M.D., Ph.D.; Andrea Luker, Ph.D. candidate; Daniel H. Conrad, Ph.D.; Laura Graham; | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Immune suppression; Myeloid cells; MDSC; Solid tumors; Tumor microenvironment |
| P492 | Myeloid-derived suppressor cells (MDSC) assessment using a fully automated sequential chromogenic multiplex assay | Anna Martirosyan, Dr; Assil Benchaaben; Aurélie Collignon, MS; Emilie Bonzom, Trainee; Matthieu Duval, Apprentice; Emmanuel Prestat, PhD; Christophe Haond; Jacques Fieschi, PhD | Biomarkers; Immune contexture; Immune monitoring; Immune suppression; Myeloid cells; MDSC; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P493 | B cells in glioblastoma are associated with diminished survival | Ileana S. Mauldin, PhD; Jasmin Jo, MD; Nolan A. Wages, PhD; Samuel J. Young, BS; Loren D. Erickson, PhD; Maria-Beatriz S. Lopes, MD, PhD; Craig L. Slingluff, Jr., MD; Camilo E. Fadul, MD, FAAN | B cell; Biomarkers; Immune suppression; Tumor infiltrating lymphocytes (TILs) |
| P494 | Targeting the CCR2/MCP-1 chemokine axis for cancer therapy | Payal Mittal; Tatiana Akimova; Craig Leach; Jose Clemente; Matthew Sender; Liqing Wang; Joseph Marino; Yao Chen; Peiling Chen; Brandon Turunen; Wayne W. Hancock, MD, PhD; | Immune monitoring; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P495 | Pegfilgrastim, but not Plinabulin, generates a blood myeloid cell (BMC) repertoire with a predominant immunosuppressive phenotype | Douglas W. Blayney, MD; Stephan Ogenstad; Yuankai Shi; Lihua Du; Lan Huang; Ramon Mohanlal, MD, PhD, MBA; | Clinical study; Clinical trial; Granulocyte; Immune contexture; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; T cell; Tumor microenvironment |
| P496 | Innate and adaptive immune responses to metastatic colorectal cancer differ by sex and correlate with survival | Anita L. Ray, PhD; Robert A. Nofchissey, BS; Sarah F. Adams, MD; William T. Berry; Katherine T. Morris, MD, FACS; | Cytokine; Immune contexture; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P497 | Study of anti-HER2 CAR T cells in the immunosuppressive ependymoma tumor microenvironment | Anandani Nellan, MD; Marissa Kane; Andrea Griesinger; Andrew Donson; Vladimir Amani; Nicholas Foreman; Davis Witt; Jean Mulcahy Levy | CAR T cells; Pediatric tumors; Solid tumors; Tumor microenvironment |
| P498 | Characterization of the tumor microenvironment in a spontaneous mouse model of cholangiocarinoma: a robust model for evaluating therapeutic interventions for treating the disease | Luis I. Ruffolo, MD; Katherine M. Jackson, MD; Joseph D. Murphy, M.Sc; Nathania Figueroa, MD; Brian A. Belt, JD; David C. Linehan, MD; Peter A. Prieto, MD, MPH; | Checkpoint blockade; Granulocyte; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor stroma |
| P499 | Correlation of immune escape mediated defects in the HLA class I antigen-presenting machinery with the immune cell infiltration and prognosis in oral squamous cell carcinoma | Barbara Seliger, MD, PhD; Claudia Wickenhauser, MD, PhD | Antigen presenting cells; Tumor evasion; Tumor microenvironment |
| P500 | Novel bispecific antibody preferentially and efficiently depletes tumor-associated immunosuppressive myeloid cells and enhances therapeutic responses to PD-L1 blockade in immune-excluded tumor model | Seng-Lai Tan, PhD; Sangeetha Palakurthi, PhD; Jacqueline Lee | Antibody; Chemokine; Cytokine; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P501 | Multiplex immunofluorescence evaluation of immune cell relationships within PDAC resection tissues using tailored analysis of multi-spectral image component data | Alison Bigley, CSci, FIBMS; Lorcan Sherry, PhD; Mark Anderson, BSc; Mariana Beltran; Dawn B. Lyster, MSc; Mike Millar; | Biomarkers; Immune contexture; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P502 | Novel approach of modulating immune cell metabolism in the tumor microenvironment to enhance efficacy of immunotherapy | Frank Boriello, MD/PhD; HongBum Lee; Vincent O'Neil; Ted Kim, PhD; James Lederer, PhD; Sanghee Yoo, PhD; | Immune suppression; MDSC; Metabolism; Regulatory T cell (Treg cell); Tumor microenvironment |
| P503 | Characterization of the immune desert in metastatic non-small cell lung cancer (NSCLC) and the use of cell proliferation to predict clinical response to immune checkpoint inhibitors (ICIs) | Jason Zhu, MD; Matthew K. Labriola, MD; Daniele Marin, MD; Shannon J. McCall, MD; Edwin Yau, MD, PhD; Grace K. Dy; Sarabjot Pabla, MSc, PhD, BS; Sean T. Glenn, PhD; Carl D. Morrison, MD, DVM; Daniel J. George, MD; Tian Zhang, MD; Jeffrey M. Clarke, MD | Biomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment |
| P504 | Nutritional measures to boost immunosurveillance of breast cancer by NK cells | Lorenzo Galluzzi, PhD; Aitziber Buqué, PhD; Maria Perez-Lanzon, M.Sc (Master of Science); Guido Kroemer, MD, PhD; Takahiro Yamazaki, PhD; | Checkpoint blockade; Gene expression; Immune suppression; Metabolism; NK/NK T cell; Solid tumors; Tumor evasion |
| P505 | The gut microbiome of metastatic melanoma patients initiating systemic therapy is influenced by host factors including diet, probiotic and antibiotic use | Vancheswaran Gopalakrishnan, MPH, PhD; Christine N. Spencer, PhD; Jennifer L. McQuade, MD; Miles Andrews, MD, PhD; Beth Helmink, MD PhD; Alexandria P. Cogdill, MEng; Md AW. Khan; Elizabeth Sirmans; Lauren E. Haydu, MS, BChe, MIPH; Eliza Posada; Elizabeth Burton; Isabella C. Glitza, MD, PhD; Rodabe N. Amaria, MD; Sapna Patel, MD; Adi Diab, MD; Michael K. Wong, MD PhD FRCPC; Hussein A. Tawbi, MD, PhD; Wen-Jen Hwu, MD, PhD; Michael Davies, MD, PhD; Patrick Hwu, MD; Robert Jenq, MD; Kelly Nelson, MD; Carrie Daniel-MacDougall, MPH, PhD; Lorenzo Cohen; Jennifer A. Wargo, MD, MMSc; | Checkpoint blockade; Epidemiology; Microbiome |
| P506 | Subcutaneous and intramuscular fat indices predict survival in advanced stage cancer patients treated with immunotherapy | Dylan J. Martini, BA; Julie M. Shabto, BA; Yuan Liu, PhD; Milton Williams; Amir I. Khan; Colleen Lewis; Hannah Collins; Mehmet Akce; Haydn T. Kissick; Bradley C. Carthon, MD, PhD; Walid L. Shaib, MD; Olatunji B. Alese, MD; Conor Steuer, MD; Christina Wu, MD; David H. Lawson, MD; Ragini R. Kudchadkar, MD; Bassel El-rayes, MD; Suresh S. Ramalingam, MD; Taofeek K. Owonikoko, MD, PhD; R. Donald Harvey, PharmD; Viraj A. Master, MD, PhD; Mehmet A. Bilen, MD; | Biomarkers; Checkpoint blockade; Metabolism; Solid tumors; Tumor microenvironment |
| P507 | Body mass index as a predictor of survival in advanced stage cancer patients treated with immunotherapy | Julie M. Shabto, BA; Dylan J. Martini, BA; Yuan Liu, PhD; Milton Williams; Amir I. Khan; Colleen Lewis; Hannah Collins; Mehmet Akce; Haydn T. Kissick; Bradley C. Carthon, MD, PhD; Walid L. Shaib, MD; Olatunji B. Alese, MD; Conor Steuer, MD; Christina Wu, MD; David H. Lawson, MD; Ragini R. Kudchadkar, MD; Bassel El-rayes, MD; Suresh S. Ramalingam, MD; Viraj A. Master, MD, PhD; Taofeek K. Owonikoko, MD, PhD; R. Donald Harvey, PharmD; Mehmet A. Bilen, MD | Biomarkers; Checkpoint blockade; Clinical trial; Metabolism; Solid tumors; Tumor microenvironment |
| P508 | Obesity promotes PD-1 mediated T cell dysfunction and tumor pro-gression but superior anti-tumor effects upon checkpoint blockade | Ziming Wang, MS; Jesus I. Luna, Ph.D.; Cordelia Dunai, MS; Lam T. Khuat; Catherine T. Le, BS; Ethan G. Aguilar; Annie Mirsoian; Christine M. Minnar, PhD; Kevin M. Stoffel, MS; Ian Sturgill; Steven Grossenbacher; Robert Canter, MD, MAS, FACS; Arta Monjazeb, MD, PhD; William J. Murphy, PhD; Ziming Wang, MS | Checkpoint blockade; Metabolism |
| P509 | Tumor spheroid model to dissect the interplay between myeloid cells and cancer cells | Elaheh Ahmadzadeh, PhD; Jan Martinek, PhD; Florentina Marches; Chun I. Yu, PhD; A. Karolina Palucka, MD, PhD | Dendritic cell; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| P510 | Monoclonal antibodies targeting the MerTK receptor de-repress the innate immune response | Diego Alvarado, Ph.D.; Mike Murphy; Laura Vitale, BS; Thomas O'Neill, BA; Andrew Proffitt; Jay Lillquist; Gwenda Ligon; Craig Polson; Anna Wasiuk; Jeffrey Weidlick, BS; Jenifer Widger, BA; Laura Mills-Chen; Andrea Crocker, BS; Colleen Patterson; Russell Hammond; Li-Zhen He, MD; Joel Goldstein, PhD; Lawrence Thomas, PhD; Henry Marsh, BS PhD; Tibor Keler, PhD; Richard Gedrich | Antibody; Antigen presenting cells; Carcinogenesis; Checkpoint blockade; Chemokine; Cytokine; Dendritic cell; Immune suppression; Inflammation; Monocyte/Macrophage |
| P511 | Co-expression of a chimeric NKG2D receptor with membrane bound IL-15 enhances natural killer cell function and long-term persistence in vitro and in vivo | Luxuan Buren; James Trager, PhD; | CAR T cells; NK/NK T cell; Targeted therapy |
| P512 | AO-176, a next generation CD47 antibody, induces immunogenic cell death | Ben J. Capoccia, PhD; Michael J. Donio; Ronald R. Hiebsch; Alun J. Carter; Robyn J. Puro; Benjamin J. Capoccia; W. Casey Wilson; Daniel S. Pereira; Pamela T. Manning; Robert W. Karr; | Antibody; Checkpoint blockade; Immune toxicity; Monocyte/Macrophage |
| P513 | Targeting adenosinergic immunometabolic suppression with engineered natural killer cells for immunotherapy of CD73+ solid tumors | Andrea Chambers, MS; Kyle B. Lupo; Jiao Wang, PhD; Sandro Matosevic, PhD; | Adoptive immunotherapy; Cytokine; Metabolism; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| P514 | High efficiency electroporation of primary human NK cells | Jian Chen, PhD; Xiaofeng Xia, PhD; | Adoptive immunotherapy; NK/NK T cell |
| P515 | Novel class of small molecule direct STING agonists as potential cancer immunotherapy | Monika Dobrzanska; Stefan Chmielewski, PhD; Magdalena Zawadzka; Adam Radzimierski; Karolina Gluza; Katarzyna Wojcik-Jaszczynska; Maciej Kujawa; Grzegorz Topolnicki; Grzegorz Cwiertnia; Aleksandra Poczkaj; Izabela Dolata; Jolanta Mazurek; Magdalena Mroczkowska; Agnieszka Gibas; Tushar Mahajan; Marcin Les; Wojciech Schonemann; Sylwia Sudol; Kinga Michalik; Magdalena Sieprawska-Lupa; Katarzyna Banaszak; Charles-Henry Fabritius; Karolina Wiatrowska; Agnieszka Adamus; Krzysztof Brzozka | Antigen presenting cells; Cytokine; Dendritic cell; Inflammation; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P516 | SIRPα blockade increases the activity of multiple myeloid lineage cells, enhances dendritic cell cross-presentation, and aids in remodeling the tumor microenvironment | Brian Francica; Brandy Chavez; Erik Voets, Ph.D.; Andrea van Elsas; Hans van Eenennaam, PhD; Meredith L. Leong | Antibody; Antigen presenting cells; Checkpoint blockade; Myeloid cells; Solid tumors |
| P517 | Pan-allele anti-SIRPα antibodies that block the SIRPα–CD47 innate immune checkpoint | Erik Voets, Ph.D.; Paul Vink, BS; David Lutje Hulsik; Marc Paradé; Sanne Spijkers; Inge Reinieren-Beeren; Joost Rens; Wout Janssen, BS; Brian Francica; Meredith L. Leong; Andrea van Elsas; Hans van Eenennaam, PhD; | Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Granulocyte; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| P518 | Non-canonical cross-presenting dendritic cells mediate anti-tumor immunity | Ellen Duong, Sc.B.; Stefani Spranger, PhD; | Antigen presenting cells; Dendritic cell; Myeloid cells; Tumor microenvironment |
| P519 | Agonist redirected checkpoint platform (ARC), engineering bi-functional fusion proteins (SIRP -Fc-CD40L), for cancer immunotherapy | George J. Fromm, Jr., PhD; Suresh de Silva, Ph.D.; Taylor H. Schreiber, MD, PhD; | Antigen presenting cells; Checkpoint blockade; Costimulation; Cytokine; Dendritic cell; Immune suppression; Monocyte/Macrophage; T cell; Tumor antigens |
| P520 | Natural killer (NK) cells orchestrate the antitumor activities of Listeria monocytogenes (Lm)-based immunotherapy | Rachelle Kosoff, PhD; Lauren K. Pettit, MS; Nithya Thambi, MS; Kimberly Ramos, BS; Jeff Jones; Skye Kuseryk; Robert G. Petit, PhD; Michael F. Princiotta, MS, PhD; Kim Jaffe, PhD; SANDY HAYES, PhD | Dendritic cell; Gene expression; NK/NK T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P521 | T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects | Daniel Hirschhorn-Cymerman, PhD; Jacob Ricca; Billel Gasmi, MD; Olivier De Henau, MD; Levi M. Mangarin, BS; Sadna Budhu, PhD; Yanyun Li, PhD MD; Czrina Cortez, BS; Cailian Liu, MD; Roberta Zappasodi, PhD; Sean Houghton; Allison Betof; Katherine S. Panageas, PhD; Mario Lacuoture, MD; Tracvis Hollmann, MD PhD; Jean Albrengues, PhD; Mikala Egeblad, PhD; Taha Merghoub, PhD; Jedd D. Wolchok, MD, PhD; | Checkpoint blockade; Costimulation; Immune toxicity; Inflammation; Solid tumors; T cell |
| P522 | Immune-profiling reveals DNAM-1 downregulation in tumor-infiltrating lymphocytes of renal cell carcinoma patients | Veronika Kremer, MSc; Christina Seitz, MSc; Ann-Helen Scherman Plogell, MD; Eugenia Colon, MD, PhD; Evren Alici, MD, PhD; Andreas Lundqvist, PhD | Immune contexture; Immune suppression; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P523 | Engineering responsive multi-functional natural killer cells derived from induced pluripotent stem cells capable of overcoming immunometabolic suppression for immunotherapy of solid tumors | Kyle B. Lupo; Andrea M. Chambers; Jiao Wang, PhD; Sandro Matosevic, PhD; | Immune suppression; NK/NK T cell; Stem cell/cancer-initiating cell; Targeted therapy; Tumor microenvironment |
| P524 | Preclinical characterization of BMS-986299, a first-in-class NLRP3 innate agonist with potent antitumor activity, alone and in combination with checkpoint blockade | Michael Wichroski, Ph.D; Huilin Qi; Jie Fang; Adam Bata; Ramola Sane; Anwar Murtaza, PhD; Ashvinikumar Gavai, PhD; Ragini Vuppugalla; Frederic Reu; Dana Banas; Julie Carman, PhD; Damien Bertheloot; Dennis Dean; Luigi Franchi; Shomir Ghosh; Gary Glick; Jonathan D. Graves; Ana Kitanovic, PhD; Eicke Latz; Xiaokang Lu, BS; Edward Olhava; William Roush; Brian Sanchez; Andrea Stutz; David Winkler, PhD; John Hunt, PhD; Miguel A. Sanjuan, PhD; James Burke | Checkpoint blockade; Cytokine; Dendritic cell; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors |
| P525 | Preclinical characterization of BMS-986301, a differentiated STING agonist with robust antitumor activity as monotherapy or in combination with anti‒PD-1 | Gary Schieven, Ph.D.; Jennifer Brown; Jesse Swanson, BS; Caitlyn Stromko; Ching-Ping Ho, BS; Rosemary Zhang; Bifang Li-Wang; Hongchen Qiu; Huadong Sun; Brian Fink, PhD; Anwar Murtaza, PhD; John Hunt, PhD | Antibody; Checkpoint blockade; Inflammation; NK/NK T cell; T cell; Tumor microenvironment |
| P526 | The potential role of fibroblast activation protein as a natural killer cell immune checkpoint in pancreatic cancer | Louis M. Weiner, MD; Shangzi Wang, PhD; Allison O'Connell, MD/PhD Candidate; | Checkpoint blockade; Coinhibition; NK/NK T cell; Solid tumors; Tumor microenvironment; Tumor stroma |
| P527 | Imprime PGG, a novel cancer immunotherapeutic, engages the complement system to prime innate immune effector functions | Xiaohong Qiu, BS; Ben Harrison, MS; Adria B. Jonas, MS; Anissa S. Chan, PhD; Nadine Ottoson, BS; Keith Gorden, BS; | Checkpoint blockade; Chemokine; Cytokine; Granulocyte; Immune monitoring |
| P528 | Tumor-derived alpha fetoprotein suppression of mitochondrial metabolism via PGC1-α and SREBP-1 expression and activity in human dendritic cells | Patricia M. Santos, PhD; Ashley Menk, BS; Jian Shi, MD; Allan Tsung, MD; Greg M. Delgoffe, PhD; Lisa H. Butterfield, PhD | Antigen presenting cells; Dendritic cell; Immune suppression; Myeloid cells; Metabolism; Tumor antigens |
| P529 | Efficacy and safety profile of AU7R-104, a small molecule targeting CD47/SIRPα pathway | Pottayil Sasikumar, PhD; Chennakrishnareddy Gundala; Wesley Balasubramanian, PhD; Sudarshan Naremaddepalli, PhD; Archana Bhumireddy, MSc; Sandeep Patil, PhD; Amit Dhudashiya; Vijaysai Rayavarapu, MSc; Dodheri Samiulla, PhD; Sanjeev Giri, PhD; Rajesh Eswarappa, Ph.D., DABT., ERT; Kiran Aithal, PhD; Girish Daginakatte, PhD; Murali Ramachandra, PhD | Checkpoint blockade; Monocyte/Macrophage |
| P530 | Novel bispecific antibody targeting NKp30 receptor enhances NK-mediated killing activity against multiple myeloma cells and overcomes CD16A deficiency | Jennifer Watkins-Yoon; Jamie L. Schafer, PhD; Sara Haserlat; Sri Vadde; Xin Kai; Allison Nelson; Lucy Liu; Nora Zizlsperger, PhD; Amanda Oliphant; Michael Schmidt; Robert Tighe, BS; MONIA DRAGHI, PhD | Antibody; Leukemia/Lymphoma; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor evasion; Tumor microenvironment |
| P531 | Redirecting immunometabolic suppression by targeting purinergic signaling enhances immunotherapy of solid tumors with CAR-NK cells | Sandro Matosevic, PhD; Jiao Wang, PhD; Kyle B. Lupo; Andrea M. Chambers; | Antibody; Cytokine; Immune monitoring; Immune suppression; Metabolism; NK/NK T cell; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P532 | Preclinical characterization of a first-in-class ILT4 antagonist, MK-4830 | Luis A. Zuniga, Ph.D.; Barbara Joyce-Shaikh, B.S.; Douglas C. Wilson; Holly Cherwinski; Yi Chen; Grein Jeff; Eric Muise, MS; Wendy Blumenschein, BA; Xiaoyan Du; Edward Hsieh; Sripriya Dhandapani; Gulesi Ayanoglu; Maribel Beaumont; Shuli Zhang; Michael Rosenzweig, DVM, PhD; Robert Kastelein, PhD; Robert N. Stein, MD PhD; Dennis Underwood, PhD; Milan Blanusa; Rachel Altura, MD; Daniel J. Cua | Antibody; Antigen presenting cells; Checkpoint blockade; Clinical trial; Granulocyte; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC |
| P533 | Gastrointestinal symptoms observed after chimeric antigen receptor T–cell therapy | Hamzah Abu-Sbeih, M.D.; Tenglong Tang, MD; Jason R. Westin, MD; David Richards, MD; Sattva S. Neelapu, MD; Yinghong Wang, MD, PhD; | Adoptive immunotherapy; CAR T cells; Immune tolerance; Immune toxicity |
| P534 | Timely endoscopic and histological evaluation is critical to provide appropriate management for immune checkpoint inhibitor induced colitis | Hamzah Abu-Sbeih, M.D.; Faisal S. Ali; Wenyi Luo, MD; Wei Qiao, PhD; Gottumukkala S. Raju, MD; Yinghong Wang, MD, PhD; | Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity; Inflammation; T cell |
| P535 | Upper gastrointestinal symptoms and associated endoscopic and histologic features in patients receiving immune checkpoint inhibitors | Hamzah Abu-Sbeih, M.D.; Tenglong Tang, MD; Wenyi Luo, MD; Wei Qiao, PhD; David Richards, MD; Yinghong Wang, MD, PhD; | Autoimmunity; Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity; T cell |
| P536 | The fate of immune–mediated diarrhea after the resumption of immune checkpoint inhibitor treatment | Hamzah Abu-Sbeih, M.D.; Faisal S. Ali; Jianjun Gao, MD PhD; Yinghong Wang, MD, PhD; | Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity; T cell |
| P537 | Immune checkpoint inhibitor–induced colitis as a predictor of survival in metastatic melanoma | Hamzah Abu-Sbeih, M.D.; Faisal S. Ali; Wei Qiao, PhD; Yang Lu, MD; Sapna Patel, MD; Adi Diab, MD; Yinghong Wang, MD, PhD; | Checkpoint blockade; Clinical study; Immune suppression; Immune tolerance; Immune toxicity; T cell |
| P538 | Precision medicine in immune checkpoint inhibitor–induced diarrhea and colitis treatment: the advent of organ targeted vedolizumab therapy | Hamzah Abu-Sbeih, M.D.; Faisal S. Ali; Dana Alsaadi; Joseph Jennings, MD; Wenyi Luo, MD; Zimu Gong, MD; David Richards, MD; Aline Charabaty, MD; Yinghong Wang, MD, PhD; | Autoimmunity; Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity |
| P539 | Development of cutaneous squamous cell carcinoma in patients receiving anti PD-1/PD-L1 therapy | Amanda Herrmann, MD PhD; Priyadharsini Nagarajan, MD PhD; Vivek Subbiah, MD; Kelly Nelson, MD; Alexander J. Lazar, MD, PhD; Courtney Hudgens, MS; Khalida Wani, PhD; Michael T. Tetzlaff, MD PhD; Jennifer A. Wargo, MD, MMSc; Anisha B. Patel, MD; Anisha B. Patel, MD; | Clinical study; Immune toxicity |
| P540 | Safety of cancer patients with preexisting autoimmune diseases presenting in the emergency center following immune checkpoint blockade | Mohsin Shah, MD; Mazen N. Jizzini, MD; Imad El. Majzoub, MD; Aiham Qdaisat, MD; Cielito C. Reyes, DrPH; Sai-Ching J. Yeung, MD, PhD; | Autoimmunity; Checkpoint blockade; Immune toxicity |
| P541 | The immunosuppressive tumor microenvironment (TME) in Epstein-Barr virus (EBV)-positive and EBV-negative gastric cancers: implications for immunotherapy | Sepideh Besharati, MD; Tracee L. McMiller, MS; Mark Yarchoan; Qingfeng Zhu, PhD; Elizabeth L. Engle, MSc; Janis M. Taube, MD, MSC; Alan Berger; Robert A. Anders, MD, PhD; Suzanne L. Topalian, MD | Biomarkers; Checkpoint blockade; Coinhibition; Cytokine; Gene expression; Immune suppression; Monocyte/Macrophage; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P542 | Exposure to anti-PD-1 causes Functional Differences in Tumor-Infiltrating Lymphocytes in Solid Tumors | Caitlin Creasy, MS; Cara Haymaker, PhD; Marie-Andrée Forget, Ph.D.; Gopal Singh, PhD; Coya Tapia, MD, PhD; Jeane M. Painter, PhD; Funda Meric-Bernstam, MD; Chantale Bernatchez; Aung Naing, MD, FACP | Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P543 | Neoantigen heterogeneity as contributing factor for non-responders to neoantigen specific T-cell therapy in patients with metastatic gastrointestinal malignancies | Eric M. Groh, MD; Jared Gartner, MS; Todd D. Prickett, PhD; Yong Li, MS; Steven A. Rosenberg, MD, PhD; Paul F. Robbins, PhD | Adoptive immunotherapy; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P544 | Interferon-γ regulates the expression of PD-L1 and NKG2D ligand families in nasopharyngeal carcinoma | Lingling Guo; Yu Chen, MD, PhD; Lingling Guo; Chuanben Chen; | Biomarkers; Immune tolerance; NK/NK T cell; Tumor evasion; Tumor microenvironment |
| P545 | The tumor inflammasome functions as a rheostat for regulating the efficacy of anti-PD-1 antibody immunotherapy by driving the recruitment of myeloid-derived suppressor cells | Bala Thievanthiran, Ph.D.; Kathy Evans, B.S.; Nicholas DeVito, M.D.; Christine Xiao, BS; Yubin Kang, M.D.; David Hsu, M.D., Ph.D.; Alisha H. Holtzhausen, PhD; Brent A. Hanks, MD, PhD; | Checkpoint blockade; Chemokine; Granulocyte; Immune suppression; Myeloid cells; MDSC; Solid tumors; TLR; Tumor evasion; Tumor microenvironment |
| P546 | Targeted hypoxia reduction restores T cell infiltration and sensitivity to immunotherapy in prostate cancer | Priyamvada Jayaprakash, PhD; Midan Ai, PhD; Arthur Liu; Pratha Budhani, BS, MS; Todd Bartkowiak; Jie Sheng; Casey Ager, BS; Courtney Nicholas, PhD; Ashvin Jaiswal; Yanqiu Sun; Krishna Shah; Sadhana Balasubramanyam; Nan Li; Guocan Wang, PhD; Jing Ning; Anna Zal; Tomasz Zal, PhD; Michael A. Curran, PhD | Checkpoint blockade; Immune suppression; Myeloid cells; MDSC; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P547 | Adoptive cell therapy and intratumoral nanoplexed poly I:C as an effective immunotherapy in interferon-signaling deficient melanoma | Anusha Kalbasi, MD; Kevin Hakimi, B.S.; Sarah Kremer; Christine Nguyen, B.S.; Davis Y. Torrejon, MD; Giulia Parisi; Pedro P. Lopez-Casas, PhD; Marisol Quintero, PhD, MBA; Antoni Ribas, MD, PhD | Adoptive immunotherapy; T cell; TLR; Tumor evasion |
| P548 | Association between corticosteroid use at time of immune checkpoint inhibitor (CPI) therapy initiation and CNS disease control/survival in patients with brain metastases (BM) | William J. Kelly, MD; Neil J. Shah; Michael T. Serzan, MD; Barbara T. Ma; Matthew Blackburn; Sebastian Ochoa; Alice R. Knoedler; Jeevan M. Puthiamadathil; Ariana Santopietro; Subha Madhavan; Anas Belouali; Shruti Rao; Kellie Gardner, NP; Suthee Rapisuwon, MD; Stephen Liu, MD; Deepa Subramaniam; Michael B. Atkins, MD; Geoffrey T. Gibney, MD; | Checkpoint blockade; Solid tumors |
| P549 | Cell proliferation defines an additional mechanism of immune escape in non-small cell lung cancer | Carl D. Morrison, MD, DVM; Sarabjot Pabla, MSc, PhD, BS; Mary Nesline, MS; Jeffrey Conroy, BS; Sean T. Glenn, PhD; Antonios Papanicolau-Sengos, MD; Paul DePietro, PhD; Jacob Hagen; Blake Burgher, BS, RN; Vincent Giamo, BS, MS; Jonathan Andreas, MS; Felicia L. Lenzo; Maochun Qin, MD, MS; Yirong Wang, M.S.; Devin Dressman, PhD; Konstantin Dragnev, MD; Laura J. Tafe; Tian Zhang, MD; Jeffrey M. Clarke, MD; Matthew Zibelman, MD; Luis de la Cruz-Merino; Alexander C. MacKinnon; Robin Jacob; Oliver Binns; Neel Shah; Mark Gardner; Grace K. Dy | Biomarkers; Solid tumors; Tumor microenvironment |
| P550 | Defeating checkpoint resistance: Highly specific inhibition of latent TGFβ1 activation renders resistant solid tumors vulnerable to PD-1 blockade | Thomas Schürpf; Constance J. Martin, PhD; Christopher Littlefield, MSc; Christopher Chapron, M.S.; Stefan Wawersik, PhD; Ashish Kalra, Ph.D.; Kevin Dagbay, PhD; Allison Simpson, BS; Francis Danehy, B.S.; Christopher Boston; Anastasia Nikiforov, MS; Susan Lin, BS; Justin Jackson, BS; Pichai Raman, PhD; Elizabeth Rainbolt, B.S.; Laurie Comfort, BS; David Harris; Madelyn Cecil-Taylor; Lorne Celentano; Danielle Meadows; gregory J. carven, PhD; Alan Buckler, Ph.D; Allan Capili, PhD; Abhishek Datta, PhD | Antibody; Checkpoint blockade; Immune suppression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P551 | Suppression of immune response by tumor cell-induced XIAP-NFκB signaling and targeting strategies to overcome immunotherapy resistance in breast cancer | Michael A. Morse; Scott J. Sauer, PhD; Myron Evans; Mohamed M. Ibrahim, MD; Xuhui Bao, MD; Pranalee Patel; Gayathri Devi, MSc., PhD; Gayathri Devi, MSc., PhD | Immune suppression; Tumor evasion |
| P552 | Analysis of TIL from human carcinoma combined with tissue imaging and in vitro models uncovers tumor-inflicted T cell deviations related to immune escape and strategies of intervention | Elfriede Noessner, PhD; Petra U. Prinz; Ilias Masouris; Anna Mendler; | Adoptive immunotherapy; Costimulation; Immune contexture; Monocyte/Macrophage; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| P553 | Targeting mechanisms of immune suppression via CXCR2 inhibition to enhance checkpoint blockade | Elaine Pinheiro, PhD; Sarah Javaid, PhD; Ruban Mangadu; Marlene Hinton; Yun Wang; Sonia Feau; Amanda A. Watkins, PhD; Andrey Loboda, PhD; Xue Liang; Dario Gutierrez; Rebecca Ruck; Michael Rosenzweig, DVM, PhD; Vincent Giranda, MD, PhD; | Chemokine; Immune suppression; Myeloid cells; MDSC; Tumor infiltrating lymphocytes (TILs) |
| P554 | Role of immune escape for resistance to cancer (immuno) therapy and its strategies targeting these mechanisms | Barbara Seliger, MD, PhD; Juergen Bukur, PhD MD | Cytokine; Targeted therapy |
| P555 | A role for mutant p53 in mediating T cell immune evasion in pancreatic adenocarcinoma and other solid tumors | Deborah A. Silverman, BS; Supporting Author - Emily Ashkin; Simone Punt, PhD; Minying Zhang; Leila Williams, MSc; Anil Korkut; Jason Roszik, PhD; Anirban Maitra, MBBS; Patrick Hwu, MD; | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Gene expression; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P556 | STAT3-related cytokines drive IR-specific immune suppression of effector, memory and naïve, peripheral blood CD8+ T cells in cancer patients | Ashwin Somasundaram, MD; Dario A. Vignali, PhD; Anthony R. Cillo, PhD; James Herman; John M. Kirkwood, MD; Robert L. Ferris, MD, PhD; Tullia C. Bruno, PhD | Antibody; Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Immune monitoring; Immune suppression; Immune tolerance; T cell; T cell lineages; Tumor evasion; Tumor microenvironment |
| P557 | Overcoming genetically-based resistance mechanisms to PD-1 blockade | Davis Y. Torrejon, MD; Gabriel Abril-Rodriguez, MS; Jennifer Tsoi; Ameya Champhekar; Giulia Parisi; Gardenia Cheung-Lau; Tom Wohlwender; Mykola Onyshchenko; Beata Berent-maoz; Catherine S. Grasso; Begoña Comin-Anduix, PhD; Siwen Hu-Lieskovan, MD, PhD; Antoni Ribas, MD, PhD; | Antigen presenting cells; Biomarkers; Checkpoint blockade; NK/NK T cell; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); TLR; Tumor evasion; Tumor microenvironment |
| P558 | Secondary resistance to immunotherapy associated with β-catenin pathway activation or genetic loss of phosphatase and tensin homolog (PTEN) in metastatic melanoma | Jonathan A. Trujillo, MD, PhD; Jason J. Luke, MD, FACP; Stefani Spranger, PhD; Yuanyuan Zha, PhD; Karen Matijevich, RN, BSN; Thomas F. Gajewski, MD, PhD; | Checkpoint blockade; Immune monitoring; Solid tumors; Tumor evasion; Tumor microenvironment; Vaccine |
| P559 | Co-expression of TNF receptor 1 and 2 on human BRAF V600E+ melanomas is required for TNF-induced resistance to MAPK pathway inhibitors | Lazar Vujanovic, PhD; Cindy Sander, BS; Jian Shi, MD; John M. Kirkwood, MD; Lisa H. Butterfield, PhD | Chemotherapy; Cytokine; Immune contexture; Immune monitoring; Inflammation; Solid tumors; Tumor evasion; Tumor microenvironment |
| P560 | Resistance of CD44+ subpopulation to CTL though high production a protease inhibitor in colorectal cancer | Tomonori Yaguchi, MD, PhD; Tsubasa Miyauchi; Kenji Morii, MS; Yutaka Kawakami, MD PhD | Immune suppression; Tumor microenvironment |
| P561 | A new mechanism of ADCC resistance | David Zahavi, MS, BS; Dalal Aldeghaither; Louis M. Weiner, MD; Joseph Murray, MD, PhD; Elana Fertig; Garrett Graham; Yong-Wei Zhang; Allison O'Connell, MD/PhD Candidate; Junfeng Ma; Sandra Jablonski, PhD; | Antibody; NK/NK T cell; Targeted therapy; Tumor evasion |
| P562 | Delayed immune-related events after discontinuation of immunotherapy – DIRE syndrome? | Marcus A. Couey, MD, DDS; Bryan R. Bell, MD, DDS, FACS; Ashish Patel, MD; Marka R. Crittenden, MD, PhD; Brendan D. Curti, MD; Rom Leidner, MD; | Autoimmunity; Checkpoint blockade; Costimulation; Immune toxicity; Inflammation; Surgery |
| P563 | Characterizing immune-mediated adverse events of anti-PD-1 and anti-CTLA-4 monotherapies and combinations using a quantitative model based meta-analysis | Boris Shulgin, PhD; Yuri Kosinsky, PhD; Andrey Omelchenko, PhD; Lulu Chu, PhD; Ganesh Mugundu, PhD; Garrett J. DeYulia, Jr., PhD; Rodrigo Pimentel, MD; Kirill Peskov, PhD; Gabriel Helmlinger, PhD; | Checkpoint blockade; Clinical trial; Immune toxicity; Solid tumors |
| P564 | Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis | Daniel H. Johnson, MD; Cara Haymaker, PhD; Khalida Wani, PhD; Wai Chin Foo, MD; Salah Eddine Bentebibel; Yinghong Wang, MD, PhD; Jonathan L. Curry, MD; Adi Diab, MD; Jennifer A. Wargo, MD, MMSc; Alexandre Reuben; Elizabeth Burton; | Autoimmunity; Checkpoint blockade; Cytokine; Gene expression; Immune toxicity; Inflammation; Tumor microenvironment |
| P565 | Characterization of lymphoid cells in synovial fluid from cancer patients with immunotherapy-associated arthritis | Sang Kim, MD, PhD; Roza Nurieva, PhD; Jean H. Tayar, MD; Huifang Lu, MD, PhD; Jennifer Wang, MD; Don Gibbons, MD; Guillermo Garcia-Manero, MD; Maria Suarez-Almazor, MD, PhD; Patrick Hwu, MD; Adi Diab, MD; | Autoimmunity; Checkpoint blockade; Inflammation; T cell |
| P566 | Hypoalbuminemia as a predictor factor for immune related adverse events (irAEs) in advanced melanoma patients treated with immune checkpoint inhibitors (ICIs) | Steven Blum, MD; Jeffrey Ishizuka, M.D.,D.Phil; Taha M. Qazi, MD; Rawad Elias, MD; Kruti B. Vora, BA; Alex B. Ruan; Anita Giobbie-Hurder, MS; Shilpa Grover, MD, MPH; Rizwan Haq, MD, PhD; Meredith Davis; Maria E. Gargano, PA-C; Elizabeth Buchbinder, MD; Patrick A. Ott, MD, PhD; F. Stephen Hodi, Jr., MD; E E. Rahma, MD; | Checkpoint blockade; Immune toxicity |
| P567 | A meta-analysis of immune checkpoint inhibitors tumor type and dose-toxicity correlation | E E. Rahma, MD; Joshua E. Reuss, MD; Ghazaleh GR. Shoja E Razavi, MD; Rawad Elias, MD; Anita Giobbie-Hurder, MS; Samir N. Khleif, MD; | Checkpoint blockade; Immune toxicity |
| P568 | Pembrolizumab induced multiple immune related adverse events including myasthenia gravis, hepatitis and thyroiditis in a patient with thymoma | Kyunghoon Rhee, MD; Taeyeong ko, MD; Sangmin Chang, MD; Ji Hyun Rhee, MD; Lee Chun Park, MD; Young Kwang Chae, MD; | Autoimmunity; Checkpoint blockade; Immune toxicity |
| P569 | Novel Pharmacobiotic approach to enhance the tamoxifen efficacy using bacterial extracellular vesicles as the immunotherapy in breast cancer | Jeongshin An, MD,Ph.D; Yeun-yeoul Yang; Won-Hee Lee; Jinho Yang; Jong-kyu Kim; HyunGoo Kim; Se Hyun Paek; Jun Woo Lee; Joohyun Woo; Jong Bin Kim; Hyungju Kwon; Woosung Lim; Nam Sun Paik; Yoon-Keun Kim; Byung-In Moon; | Tumor microenvironment |
| P570 | Commensal bacteria Bifidobacterium stimulates an anti-tumor response via cross-reactivity. | Catherine A. Bessell, BA; Ariel Y. Isser; Jonathan Havel, PhD; Sangyun Lee, PhD; Ruhong Zhou, PhD; Timothy A. Chan, MD, PhD; Jonathan P. Schneck, MD, PhD; David Bell, PhD | Adoptive immunotherapy; Microbiome; Neoantigens; T cell |
| P571 | Targeted sequencing of 16s rRNA Gene to understand the diversity and composition of the gut microbiome | Jianping Zheng; Karen L. Clyde, PhD; Fiona Hyland; Janice Au-Young, PhD; Rajesh K. Gottimukkala, MS; Asha Kamat, PhD; | Bioinformatics; Biomarkers; Checkpoint blockade; Microbiome |
| P572 | Variation of the gut microbiome of complete responders to immune checkpoint blockade and healthy individuals – implications for clinical trial design | Beth Helmink, MD PhD; Vancheswaran Gopalakrishnan, MPH, PhD; Abdul Wadud Khan, MD; Pierre-Olivier Gaudreau; Elizabeth Sirmans; Elizabeth Burton; Vanessa B. Jensen, DVM; Adrienne F. Duran, B.A.S.; Linsey Martin; Angela L. Harris; Miles Andrews, MD, PhD; Jennifer L. McQuade, MD; Alexandria P. Cogdill, MEng; Christine N. Spencer, PhD; Reetakshi Arora; Nadim Ajami, PhD; Joseph Petrosino, PhD; Jamal A. Mohamed; Sapna Patel, MD; Michael K. Wong, MD PhD FRCPC; Rodabe N. Amaria, MD; Jeffrey E. Gershenwald, MD; Patrick Hwu, MD; Wen-Jen Hwu, MD, PhD; Michael Davies, MD, PhD; Isabella C. Glitza, MD, PhD; Hussein A. Tawbi, MD, PhD; George Marnellos; Jaclyn Sceneay; Jennifer Wortman; Lata Jayaraman; David Cook; Theresa LaVallee; Robert Jenq, MD; Timothy Heffernan, PhD; Jennifer A. Wargo, MD, MMSc; | Clinical trial; Microbiome; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P573 | Antibiotic use and clinical outcomes of PD-1 antagonists in advanced non-small cell lung cancers | Amit Kulkarni, MD; Manish R. Patel, DO; Ying Wang, MD, Ph.D.; Todd Defor, MS | Checkpoint blockade; Clinical study; Microbiome; Solid tumors |
| P574 | A rationally-designed consortium of human gut commensals induces CD8 T cells and modulates host anti-cancer immunity | Takeshi Tanoue; Satoru Morita; Koji Atarashi; Wataru Suda; Damian Plichta; Seiko Narushima; Ashwin Skelly; Atsushi Shiota; Jason Norman; Vanni Bucci; Yutaka Kawakami, MD PhD; Masahira Hattori; Ramnik Xavier; Bernat Olle; Bruce L. Roberts, PhD; Kenya Honda, MD, PhD | Checkpoint blockade; Microbiome; T cell; Tumor infiltrating lymphocytes (TILs) |
| P575 | Classification of the human gut microbiome using a validated 16S rRNA next generation sequencing method | Janet Doolittle-Hall; Melissa Howard; Jennifer K. Sims; Scott Yourstone; Jason Powers; Patrick Hurban, PhD; Victor J. Weigman, Jr. | Microbiome |
| P576 | Evaluating the importance of inhibiting HDAC6 in metastatic breast cancer to enhance the efficacy of immunotherapy | Debarati Banik, PhD; Erica Palmer, BS; Melissa Beaty, MS; Satish R. Noonepalle, PhD; Maria MG. Hernendez, BS; Prathima Vembu, MS; Alejandro Villagra, PhD | Checkpoint blockade; Chemokine; Cytokine; Monocyte/Macrophage; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P577 | Activation of GSK3-beta in the melanoma tumor microenvironment renders dendritic cells refractory to immune suppression and induces T cell activation and oncolysis | Marta Lopez Gonzalez, Msc.; Rieneke van de Ven, PhD; Anita Stam; Wen Dong; Victor W. van Beusechem; Tanja D. de Gruijl, PhD | Antigen presenting cells; Dendritic cell; Immune contexture; Immune suppression; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| P578 | Application of multiplexed immunofluorescence and multispectral imaging to investigate TGFβ pathway activation of immune cell populations in human lung cancer | Carmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Bernard A. Fox, PhD; Sebastian Marwitz; Sebastian Marwitz; | Biomarkers; Carcinogenesis; Immune contexture; Inflammation; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P579 | The leukocyte chemoattractant chemerin modulates PTEN and PD-L1 expression and activity via CMKLR1 in human tumors | Russell Pachynski, MD; Keith R. Rennier, PhD; Gurpal Virdi, BS; Woo Jae Shin, BA; | Antibody; Biomarkers; Checkpoint blockade; Chemokine; Gene expression; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| P580 | Genomic portraits of immune escape mechanism in cold tumours | Venkateswar R. Addala, PhD - Research Student; Futoshi Kawamata; Stephen H. Kazakoff, PhD; Pamela Mukhopadhyay; Catherine Bond; Katia Nones; Felicity Newell; Jennifer Borowsky; Scott Wood; Conrad Leonard; Qinying Xu; Matthew E Burge; Akinobu Taketomi; Toshiya Kamiyama; Barbara Leggett, MD FRACP; John Pearson; Vicki Whitehall; Ann-Marie Patch; Nic Waddell; | Antigen presenting cells; Bioinformatics; Immune suppression; Monocyte/Macrophage; Neoantigens; T cell; Tumor evasion; Tumor microenvironment |
| P581 | Whole-genome sequencing and multi-omic analysis of immuno-oncology biomarkers using formalin-fixed, paraffin-embedded samples | Shannon T. Bailey, PhD; Wanfeng Yu, PhD; Jim Lund, PhD; Richard T. Williams; Jeffrey R. Gulcher | Bioinformatics; Biomarkers; Gene expression; Solid tumors; Systems biology |
| P582 | Implications of ARID1A deficiency on tumor microenvironment and immune landscape in non-small cell lung cancer (NSCLC) | Young Kwang Chae, MD; Pedro Viveiros, MD; Bhoomika Sukhadia, MD; Lee Chun Park, MD; Muhammad Mubbashir Sheikh, MBBS / MD; Jeffrey Chuang; | Biomarkers; Checkpoint blockade; Gene expression; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P583 | Single cell transcriptional immune landscape of human papilloma virus positive and negative head and neck squamous cell carcinoma | Anthony R. Cillo, PhD; Tullia C. Bruno, PhD; Tracy Tabib; Zengbiao Qi; Ting Wang; Umamaheswar Duvvuri; Ryan Soose, MD; Wei Chen; Robert Lafyatis; Robert Ferris; Dario A. Vignali, PhD | Bioinformatics; Gene expression; Solid tumors; Systems biology; Tumor microenvironment |
| P584 | High DNA repair activity is associated with immune exclusion in pediatric kidney cancers | Emily Higgs, BA; Ami V. Desai, MD; Riyue Bao, PhD; Thomas F. Gajewski, MD, PhD; | Bioinformatics; Gene expression; Immune suppression; Pediatric tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P585 | Structured literature review and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in endometrial and ovarian cancers | Maria Lorenzi; Mayur Amonkar, PhD; Jacky Zhang; Shivani Mehta; Kai-Li Liaw | Epidemiology; Solid tumors; Targeted therapy |
| P586 | Frameshift indel selectively correlates with immunotherapy outcome for advanced NSCLC | Wungki Park, MD; Lee Chun Park, MD; Vaia Florou, MD; Diana Saravia, MD; Sangmin Chang, MD; Si Wang, M.D.; Lauren Chiec; Ashkon Rahbari; Pedro Viveiros, MD; Bhoomika Sukhadia, MD; Muhammad Mubbashir Sheikh, MBBS / MD; Nisha Mohindra; Victoria Villaflor, MD; Gilberto Lopes, MD, MBA; Young Kwang Chae, MD; | Antigen presenting cells; Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Neoantigens; Solid tumors |
| P587 | Conditional activation of immune-related pathways and prognostic significance: a pan cancer analysis | Jessica Roelands; Michele Ceccarelli; Darawan Rinchai, PhD; Sara Pai, MD, PhD; Francesco M. Marincola, MD; Lance D. Miller, MS, PhD; Peter Kuppen; Davide Bedognetti, MD, PhD; Wouter R. Hendrickx, PhD | Bioinformatics; Gene expression; Immune contexture; Immune suppression; Immune tolerance; Neoantigens; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P588 | Deep learning of the immune synapse | John-William Sidhom, MSE; Drew M. Pardoll, MD, PhD; Alexander Baras; | Antigen presenting cells; Biomarkers; Immune monitoring; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P589 | Endogenous oncogene mutation-specific T cell responses in patients with clinical response to PD-1 blockade | Kellie N. Smith, PhD; Nicolas J. Llosa, MD; Valsamo Anagnostou, MD PhD; Hok Yee N. Chan, MS; Jiajia Zhang, MD, MPH; Haidan N. Guo, BS, BA; Tricia Cottrell, MD, PhD; Jarushka Naidoo, MD; Kristen Marrone, MD; Janis M. Taube, MD, MSC; Victor E. Velculescu, MD, PhD; Julie R. Brahmer, MD; Patrick Forde, MD; Drew M. Pardoll, MD, PhD; Franck Housseau, PhD | Neoantigens; Solid tumors; T cell; Tumor antigens |
| P590 | Evaluation of whole exome sequencing for quantitative immune cell type deconvolution in tumor for clinical application in oncology | Alex So, PhD; Joyee Yao, BA; Aaron Wise, PhD; Kevin Wu; Kristina Kruglyak, PhD; Sven Biike; Traci Pawlowski, PhD; Shile Zhang, PhD | B cell; Biomarkers; Checkpoint blockade; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P591 | Somatic alterations in PD-L1 predict response to platinum-based chemotherapy in patients with advanced prostate cancer | Panagiotis J. Vlachostergios, MD, PhD; Aileen Lee; Charlene Thomas; Priyanka Patel; Amy L. Hackett; Naureen Rashid; Ana M. Molina, MD; David M. Nanus, MD; Himisha Beltran, MD; Scott T. Tagawa, MD, MS; Panagiotis J. Vlachostergios, MD, PhD | Bioinformatics; Biomarkers; Chemotherapy; Clinical study; Gene expression; Solid tumors |
| P592 | Clonality of tumor infiltrating and peri-tumoral lymphocytes in colorectal cancers with high-microsatellite instability | Pamela M. Ward, PhD; Mihaela Campan, PhD; Katherine A. Scribner, DO; Ashley S. Hagiya, MD; Cristina Costales, MD; Michael Bask, BS; Tiffany I. Long, BS; Afsaneh Barzi, MD; Jonas Pettersson, PhD; Louis Dubeau, MD PhD | Immune contexture; Immunoscore; Solid tumors; T cell; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P593 | Robust TMB values calculated from tumor-only material show correlation and precision with paired results | Victor J. Weigman, Jr.; Natalie Mola, MS | Bioinformatics; Clinical trial; Tumor antigens; Tumor evasion |
| P594 | Dynamic analysis and visualization of the interactions between tumor and the immune cell infiltration by integrating TCGA genomic- and transcriptional- data | Mingchao Xie, PhD; Bolan Linghu; Pei Zhang, PhD; Zhongwu Lai, PhD; Jonathan Dry; Benjamin Sidders | Bioinformatics; Biomarkers; Gene expression; Immune contexture; Solid tumors; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P595 | Smoking and KRAS mutation status in lung adenocarcinomas are associated with distinct favorable immune cell contexture in the tumor microenvironment | Yuanquan Yang, MD, PhD; Qiang Hu, MD, PhD; Song Liu; Maya Khalil, MD; Grace K. Dy; | Bioinformatics; Immune contexture; Tumor microenvironment |
| P596 | Immune gene expression characterization of genomic subsets of metastatic non-squamous non-small cell lung cancer | Edwin Yau, MD, PhD; Sarabjot Pabla, MSc, PhD, BS; Sean T. Glenn, PhD; Antonios Papanicolau-Sengos, MD; Jason Zhu, MD; Matthew K. Labriola, MD; Tian Zhang, MD; Jeffrey M. Clarke, MD; Carl D. Morrison, MD, DVM; Grace K. Dy; Edwin Yau, MD, PhD; Edwin Yau, MD, PhD; | Biomarkers; Checkpoint blockade; Gene expression; Immune contexture; Targeted therapy |
| P597 | Reovirus infection of prostate cancer induces upregulation of the negative regulators PD-L1 and BTLA | Nicola E. Annels, PhD; Guy R. Simpson; Hardev S. Pandha, PhD, FRCP, FRACP, FR; Mehreen Arif; Kevin Harrington, MD; Alan Melcher; Richard Vile, PhD | Checkpoint blockade; Dendritic cell; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P598 | Discovery and preclinical development of E7766, a novel STING agonist for cancer immunotherapy with a superior profile over a leading reference compound | Xingfeng Bao, Ph.D; Kuan-Chun Huang, Ph.D.; Atsushi Endo; Dinesh Chandra, PhD; Jiayi Wu; Dae-Shik Kim; Diana Albu; Karen Tendyke; Kara Loiacono; Thomas A. Noland, Jr, PhD; Christy Ingersoll; David Verbel, MPH; Rongrong Jiang; Donna Kolber-Simonds; Chi Zhang; Muzaffar Akram, MSc., MA; Minghong Hao; HyeongWook Choi; Vaishali Dixit; Janna Hutz, PhD; John Wang; Frank Fang | Antigen presenting cells; Genetic polymorphism; T cell; Tumor microenvironment |
| P599 | OncoVEXmGM-CSF in combination with checkpoint inhibition leads to tumor-specific systemic immunity and increased tumor antigen response in a murine syngeneic melanoma model | Keegan Cooke, BS; Juan Estrada; Petia Mitchell; Jinghui Zhan; Jing Qing; Jude Canon; Pedro J. Beltran | Checkpoint blockade; Neoantigens; T cell; Tumor antigens |
| P600 | IL12/IL15 and PD-L1 blocker co-expressing oncolytic herpes virus VG161 significantly alters tumor microenvironment and eliminates prostate tumors in animal models | Zahid Delwar, PhD; Neetu Saxena, PhD; Erica Lee, PhD; Morgan E. Roberts, PhD; Luke Bu, M.Sc.; Guoyu Liu, MD; Yanal Murad, PhD; Jun Ding, PhD; Dmitry Chouljenko, PhD; Igor Moskalev; Syam Somasekharan, PhD; Ronghua Zhao, MD; Paul Rennie, PhD; William Jia, PhD | Adoptive immunotherapy; Checkpoint blockade; Cytokine; Gene expression; Immune monitoring; Regulatory T cell (Treg cell); Stem cell/cancer-initiating cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P601 | STING signaling can enhance melanoma antigenicity | Rana Falahat, PhD; Adam W. Mailloux, PhD; Patricio Perez-Villarroel; Genyuan Zhu, PhD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; James J. Mulé, PhD; | Adoptive immunotherapy; Cytokine; Immune adjuvant; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor evasion; Tumor microenvironment |
| P602 | Generation and characterization of a CTLA-4 antibody with improved FcgammaR-dependent Treg deletion for tumor microenvironment-targeted oncolytic virotherapy of cancer | Bjorn Frendeus, PhD; Monika Semmrich, PHD; Monika Semmrich, PHD; Jean-Baptiste jb. Marchand, pHD; Petra Holmkvist; Linda Mårtensson; Ulla-Carin Tornberg; Ingrid Teige; Andres McAllister; Eric Quemeneur, PharmD, PhD; Bjorn Frendeus, PhD; Nathalie Silvestre | Checkpoint blockade; Coinhibition; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P603 | Novel treatment strategy for peritoneal carcinomatosis: adoptive cell transfer of tumor-specific lymphocytes after dual therapy with oncolytic virus and PD-1 blockade | Esther Giehl, MD; David Bartlett, MD; Zong Sheng Guo, PhD; Mathilde Feist, MD; | Adoptive immunotherapy; Checkpoint blockade; T cell |
| P604 | DNA-based delivery of immunomodulatory antibodies is effective both in muscle and tumor despite distinct pharmacokinetics | Liesl Jacobs, MPharm; Elien De Smidt; Nick Geukens; Paul Declerck; Kevin Hollevoet, PhD | Antibody; Checkpoint blockade; Targeted therapy |
| P605 | Localized treatment with oncolytic adenovirus Delta-24-RGDOX elicits efficacious abscopal immunity against disseminated melanomas | Hong Jiang, PhD; Dong Ho Shin; Caroline Carrillo, BS; Verlene Henry, BS; Teresa Nguyen, BS; Yisel A. Rivera-Molina, PhD; Frederick Lang, MD; Candelaria Gomez-Manzano, MD; Juan Fueyo | Costimulation; Gene expression; Immune contexture; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P606 | IFN gamma-independent upregulation of PD-L1 in oHSV-1 infected tumour cells | Erica Lee, PhD; Jun Ding, PhD; Sheng Yu; Yanal Murad, PhD; Dmitry Chouljenko, PhD; Guoyu Liu, MSc, MD; Zahid Delwar, PhD; Luke Bu, M.Sc.; Will Liu, PhD; Ronghua Zhao, MD; William Jia, PhD | Checkpoint blockade; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P607 | The TLR4 agonist G100 enhances the efficacy of adoptive T-cell therapy | Jardin Leleux, PhD; Tina C. Albershardt, PhD; Peter Berglund, PhD; Jan H. Ter Meulen, MD, PhD | Adoptive immunotherapy; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P608 | ProTriTAC: a protease-activatable T cell engager platform that links half-life extension to functional masking and expands therapeutic window to enable targeting of broadly expressed tumor antigens | S. Jack Lin, PhD; Maria Rosalyn Dayao; Kendrick J. Kim; Sony S. Rocha; Kathryn Kwant, PhD; Timothy Yu; Thomas Evans; Stephen Yu; Michael Cremin; Wade Aaron, BS; Maria Gamez-Guerrero; Evan Callihan; Golzar Hemmati; Kevin J. Wright, PhD; Yinghua Xiao, Master Degree; Manasi Barath; Che-Leung Law, PhD; Bryan Lemon, PhD; Richard Austin, PhD; Holger Wesche, PhD | Antibody; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Tumor stroma |
| P609 | First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells | Boris Minev, MD; Elliot Lander, MD; John F. Feller, MD; Mark Berman, MD; Stuart May, MD; Bernadette Greenwood; Ivelina Minev, MSc; Duong Nguyen, PhD; Antonio F. Santidrian; Dobrin Draganov, PhD; Mehmet O. Kilinc, PhD; Santosh Kesari, MD, PhD; Edward McClay, MD; Gabriel Carabulea, MD; Aladar Szalay, PhD; | Clinical trial; Cytokine; Immune monitoring; Leukemia/Lymphoma; MDSC; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| P610 | Transcriptome analysis of CT26 tumors treated with HSV-1 oncolytic virus expressing multiple immune factors | Yanal Murad, PhD; Jun Ding, PhD; Erica Lee, PhD; Dmitry Chouljenko, PhD; Luke Bu, M.Sc.; Guoyu Liu, MSc, MD; Zahid Delwar, PhD; Will Liu, PhD; Ronghua Zhao, MD; William Jia, PhD | Tumor microenvironment |
| P611 | Single shot intravenous oncolytic vesicular stomatitis virus therapy promotes intratumoral CD8+ T-cell infiltration and enhances therapeutic response to checkpoint blockade | Shruthi Naik, PhD; Kah Whye Peng, PhD; Stephen J. Russell, MD, PhD | Biomarkers; Checkpoint blockade; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P612 | Overcoming oncolytic poliovirus-mediated adaptive immune resistance by combining with anti-PD1/-PDL1 therapy in cancer. | Smita Nair, PhD; Eda Holl, PhD, RAC; Michael Brown, PhD; Victoria Frazier; David Boczkowski, BS, MSc; Vidyalakshmi Chandramohan, PhD; Darell D. Bigner, MD, PhD; Shelley Hwang; Matthias Gromeier, MD; | Checkpoint blockade; Immune adjuvant; Inflammation; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P613 | Non-oncolytic viral infection reduces tumor burden and promotes anti-tumor immunity in synergy with checkpoint blockade | Jenna Newman; Charles B. Chesson, PhD; Andrew Zloza | Checkpoint blockade; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P614 | Nano-Pulse Stimulation™ of murine melanoma and mammary carcinoma is a physical modality that eliminates the treated tumor by regulated cell death and induces innate and adaptive immune responses | Richard Nuccitelli, MS, PhD; Amanda McDaniel, BA; Bruce Freimark, PhD; Joel Benjamin, PhD; Jessica Sood, BS; Darrin Uecker, MS; | Biomarkers; Gene expression; Immune monitoring; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P615 | Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment | Eric Quemeneur, PharmD, PhD; Jean-Baptiste jb. Marchand, pHD | Immune contexture; Immune suppression; Regulatory T cell (Treg cell); Tumor microenvironment |
| P616 | Fueling antitumor immunity using oncolytic viruses encoding metabolic modulators | Dayana B. Rivadeneira, PhD; Kristin DePeaux; Nicole E. Scharping, BS; Padmavathi Sampath, PhD; Saumendra Sarkar, PhD; Stephen H. Thorne, PhD; Greg M. Delgoffe, PhD | Metabolism; T cell; Tumor infiltrating lymphocytes (TILs) |
| P617 | A cell-based platform to protect and enhance oncolytic virus therapies | Antonio F. Santidrian; Dobrin Draganov, PhD; Duong Nguyen, PhD; Okyay Kilinc; Ivelina Minev, MSc; Boris Minev, MD; Aladar Szalay, PhD; | Immune suppression; NK/NK T cell; Solid tumors; T cell; Tumor evasion; Vaccine |
| P618 | Selective delivery of exosome-mediated STING agonist to antigen presenting cells results in significantly improved potency and reduced toxicity | Su Chul Jang, PhD; Raymond J. Moniz; Christine Sia; Joyoti Dey, Ph.D., M.P.H; Rane Harrison; NIKKI ROSS, PhD; Ke Xu; Kevin Dooley; Nuruddeen Lewis; Christine McCoy; Agata Villiger-Oberbek; Scott Estes; Jorge Sanchez-Salazar; Kyriakos Economides; Sriram Sathyanarayanan | Antigen presenting cells; Cytokine; Dendritic cell; Gene expression; Immune toxicity; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR |
| P619 | Image-guided intratumoral delivery of immunotherapeutics: interventional radiology perspective | Rahul A. Sheth, MD; Ravi Murthy, MD; Funda Meric-Bernstam, MD; David Hong, MD; Sapna Patel, MD; Alda Tam; | Clinical study; Immune adjuvant; Solid tumors; Targeted therapy |
| P620 | Enhanced efficacy and combinability of low dose toca 511 and 5-FC with metronomic chemotherapy in preclinical models | Sophie Viaud; Derek Ostertag; | Chemotherapy; Targeted therapy |
| P621 | Local immunotherapy with a mixture of mRNAs encoding pro-inflammatory cytokines promotes potent anti-tumor immunity and tumor eradication across multiple preclinical tumor models. | Timothy Wagenaar; Christian Hotz; Friederike Gieseke; Hui Cao; Jan Diekmann; Mustafa Diken; Christian Grunwitz; Andrew Hebert; Karl Hsu; Marie Bernardo; Katalin Kariko, PhD; Sebastian Kreiter; Andreas N. Kuhn; Mikhail Levit; Natalia Malkova; Serena Masciari, MD, MSc; Jack Pollard; Hui Qu; Abderaouf Selmi; Julia Schlereth; Fangxian Sun; Bodo Tillmann; Tatiana Tolstykh; Lena Wicke; Sonja Witzel; Qunyan Yu; Yu-An Zhang; Gang Zheng; Gary Nabel; Joanne Lager; Ugur Sahin, MD; Dmitri Wiederschain | Checkpoint blockade; Cytokine; Inflammation; Tumor microenvironment; Vaccine |
| P622 | Phase 1/2 evaluation of intratumoral INT230-6 for the treatment of solid tumors | Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, M.S., M.A, M.B.A.; Ian B. Walters, MD; Diana Hanna, MD; Jacob Thomas, MD; Lillian Siu, MD; Anthony El-Khoueiry, MD | Antigen presenting cells; Chemotherapy; Clinical trial; Dendritic cell; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P623 | The oncolytic peptide LTX-315 promotes natural killer cell recruitment and reduces lung metastatic burden in combination with local radiation therapy | Erik Wennerberg, PhD; Takahiro Yamazaki, PhD; Baldur Sveinbjornsson, PhD; Oystein Rekdal, PhD; Lorenzo Galluzzi, PhD; Sandra Demaria, MD; | Antigen presenting cells; Dendritic cell; NK/NK T cell; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P624 | Development of a STING agonist-producing synthetic Biotic™ medicine to activate innate and adaptive immunity and drive antitumor immune responses | Kip A. West, PhD; DANIEL LEVENTHAL, PHD; Ning W. Li, PhD; Christopher Plescia, MS; Starsha Kolodziej, BS; Rudy Christmas, BS; Carey Gallant, BS; Michael James, BS; Adam Fisher, PhD; Anna Sokolovska, PhD; Paul W. Miller, PhD; Jose M. Lora, PhD; Kip A. West, PhD; | Antigen presenting cells; T cell; Tumor microenvironment |
| P625 | Outcomes with first-line PD-1/PD-L1 inhibition in advanced urothelial cancer (UC): A single institution experience | Arjun V. Balar, MD; Miles Hsu, BS; Yuhe Xia; Andrea Troxel, PhD; Daniela Delbeau, RN; Kaitlyn Francese, RN; Dayna Leis, RN; Deneuve Shepherd; | Checkpoint blockade; Clinical study |
| P626 | Overcoming target-driven fratricide for CAR-T cell therapy | Eytan Breman, MSc; Benjamin Demoulin; Sophie AGAUGUE, PhD; Sebastien Mauen, PhD; Alexandre E. Michaux, PhD; Lorraine P. Springuel; Fanny Huberty; Céline Jacques-Hespel; Celine Marchand, Laboratory Technician; Jérôme Marijsse; Peter DeWaele; David E. Gilham, PhD; Valérie Steenwinckel, PhD | CAR T cells; Cytokine; Solid tumors; T cell; Targeted therapy |
| P627 | From staining to analysis: fully automated workflow for multiplexed immuno-profiling in FFPE tumor samples using UltiMapper™ reagent kits | Amanda J. Bares, PhD; Michael Murphy; Heike Boisvert, PhD; Katir K. Patel, PhD; Bonnie Phillips, PhD; Sean R. Downing, PhD; Mael Manesse, PhD | Antibody; Biomarkers; Immune contexture; Tumor microenvironment |
| P628 | High dimensional immune cell profiling with data-independent acquisition mass spectrometry | Jakob Vowinckel, PhD; Tobias Treiber; Nicholas Dupuis, PhD; Kristina Beeler; Claudia Escher | Bioinformatics; Biomarkers; Monocyte/Macrophage; NK/NK T cell; Proteomics; T cell; T cell lineages |
| P629 | Addressing immunotherapy educational needs: esults from an educational program on immunotherapy for cancer patients and caregivers | Maria B. Gonzalo; Liliana Zigo, BA; Claire Saxton, MBA; Heather Hollen, BS, MS; Julie S. Olson, PhD; Kevin Stein, PhD, FAPOS; | Adoptive immunotherapy; Immune toxicity |
| P630 | Patient-reported toxicities in lung cancer patients receiving immune checkpoint blockade | Heather Jim, PhD; Sandra S. Shaw, BS, MBA; Sarah Eisel, PhD; Aasha I. Hoogland, PhD; David LeDuc, CFRE; Adam P. Dicker, MD, PhD; | Immune toxicity; Solid tumors |
| P631 | A novel CD137/PD-L1 bispecific antibody modulates the tumour microenvironment by activating CD8⁺ T cells and results in tumour growth inhibition | Matthew A. Lakins, PhD; Jose Munoz-Olaya; Daniel Jones; Raffaella Giambalvo; Clinton M. Hall; Anne Knudsen; Neus Masque Soler, Dr; Sarka Pechouckova; Emma Goodman, BSc; Cristian Gradinaru; Alexander Koers, PhD; Sylwia Marshall; Mateusz Wydro, PhD; Francisca Wollerton; Sarah Batey; Dan Gliddon; Jacqueline F. Doody, PhD; Michael Davies; Michelle Morrow, PhD; Mihriban Tuna, PhD; Neil Brewis, PhD | Antibody; Checkpoint blockade; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P632 | A multi-omics approach to understanding the tumor microenvironment | Deepali Malhotra, PhD; Gordon Moody; Michael Surace, PhD; Jaime Rodriguez-Canales, MD; Ronald Herbst, PhD; John B. Mumm, PhD; | Antigen presenting cells; Dendritic cell; Immune contexture; Myeloid cells; MDSC; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P633 | Generation of a modular landing pad cell line for T cell receptor exchange and screening | ETHAN PATTERSON; Stacey Ward, Ph.D.; jason Gustin | CAR T cells; Gene expression; T cell |
| P634 | Precision genome editing in macrophage and CD8+ human primary T cells for immuno-therapeutics applications | Laura Daley; ETHAN PATTERSON; | CAR T cells; Gene expression; Monocyte/Macrophage; T cell; T cell lineages; Targeted therapy |
| P635 | Effectiveness and tolerance of immune checkpoint blockade in a real-world lung cancer patient population | Daniel F. Pease, MD; Michael Shyne; Shilvi Joshi; Allison Lee; Manish R. Patel, DO | Autoimmunity; Checkpoint blockade; Immune toxicity; Solid tumors |
| P636 | Evaluating the occurrence of early tumor progression (ETP) in patients with gastric cancer treated with nivolumab versus placebo | Yan Feng; Paul Nghiem, MD, PhD; Paul Nghiem, MD, PhD; Ricardo Zwirtes, MD; Dan Reshef; Greg Plautz; Narikazu Boku; Li-Tzong Chen; Yoon-Koo Kang; Akintunde Bello, PhD; Amit Roy; Jennifer Sheng; | Checkpoint blockade; Clinical study; Solid tumors |
| P637 | Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin® molecule for tumor-restricted immune activation | Nicolo Rigamonti, PhD; Anja Schlegel; Sophie Barsin, MS; Jonas Schwestermann; Jennifer Krieg; Susanne Mangold; Maria Paladino; Valérie Calabro, PhD; Victor Levitsky, MD PhD; Simon E. Plyte, PhD; Michael T. Stumpp, PhD; Clara Metz, PhD | Antigen presenting cells; B cell; Costimulation; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P638 | Comparison of immunoprofiling from whole tumor versus pathologist-selected regions of interest in tissues: a study using multiplex immunofluorescence and multispectral analysis on lung cancer | Michael Surace, PhD; Matthew Gates; Clifford C. Hoyt, MS; Jennifer Cann, PhD; Jaime Rodriguez-Canales, MD; | Immunoscore; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P639 | Tumor-associated B cells promote melanoma cell dedifferentiation and invasiveness | Anastasia Samarkina, MSc; Rajasekharan Somasundaram, PhD; Meenhard Herlyn, DVM PhD; | Angiogenesis; B cell; Inflammation; Stem cell/cancer-initiating cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P640 | hMENA is a key regulator of tumor cell-cancer associated fibroblasts dialogue via Gas6/Axl paracrine axis | sheila spada, PhD; Roberta Melchionna; Francesca Di Modugno, PhD; Mariangela Panetta; Anna Di Carlo; - Anna Maria Mileo; Isabella Sperduti; Barbara Antoniani; Rita Teresa Lawlor; Lorenzo Piemonti; Maria Grazia Diodoro; Daniel D'Andrea, Ph.D.; Paolo Visca; Michele Milella; Gian Luca Grazi; Francesco Facciolo; Emily Chen; Aldo Scarpa; Paola Nistico', MD; | Tumor microenvironment; Tumor stroma |
| P641 | Development of automated protocols for OPAL, SMIFT and ESIFT 4-color lymphocyte kits | Joe A.Vargas; Julio S. Masabanda, PhD; David A. Tacha, PhD | Antibody; Antigen presenting cells; B cell; Biomarkers; Immune monitoring; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P643 | Oncology Nursing Society’s patient immunotherapy wallet cards improve communication and immune-related adverse event management | Kathleen Wiley, RN, MSN, AOCNS; Michele Galioto, RN, MSN; Kathleen Wiley, RN, MSN, AOCNS; Nicole Lininger; PhD ANP-BC, PhD APRN; | CAR T cells; Checkpoint blockade; Immune toxicity |
| P644 | Checkpoint inhibitor therapy in solid organ and allogeneic stem cell transplantation: data mining of The Truven Health Marketscan Research Database | Noha Abdel-Wahab, MD, PhD; Ala Abudayyeh; Xiudong Lei; Gheath Alatrash, DO, PhD; Hui Zhao; Sharon H. Giordano; Houssein Safa, MD; Daniel H. Johnson, MD; Van A. Trinh, DPharm; Maen Abdelrahim, MD, PhD; Ahmed O. Gaber, MD; Maria Suarez-Almazor, MD, PhD; Adi Diab, MD; | Checkpoint blockade; Epidemiology; Immune toxicity |
| P645 | Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury | Hamzah Abu-Sbeih, M.D.; Tenglong Tang, MD; Yinghong Wang, MD, PhD; | Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity |
| P646 | Discovery and characterization of therapeutic human monoclonal antibodies against 17 immuno-oncology targets using microfluidics and molecular genomics | Adam Adler, PhD; Rena Mizrahi, PhD; Carter R. Keller, MBA; David Johnson, PhD | Antibody; B cell; Checkpoint blockade; Coinhibition; Costimulation |
| P647 | DuoBody-PD-L1x4-1BB combines checkpoint blockade and 4-1BB co-stimulation to promote antigen-specific T-cell stimulation and proliferation | Isil Altintas, PhD; Alexander Muik, PhD; Isil Altintas, PhD; Friederike Gieseke; Theodora Salcedo; Saskia Burm; Mustafa Diken, PhD; Christian Grunwitz; Sebastian Kreiter, MD; David Satijn, PhD; Danita Schuurhuis; Ozlem Tureci; Esther Breij, PhD; Ugur Sahin, MD | Antibody; Coinhibition; Costimulation; Cytokine; Tumor infiltrating lymphocytes (TILs) |
| P648 | Different exhausted t-cell subsets exhibit different degrees of dysfunction in follicular lymphoma | Theodora Anagnostou, MD; Zhi Zhang Yang, MD; Hyo Jin Kim, PhD; Jose C. Villasboas, MD; Tammy L. . Price-Troska; Shahrzad Jalali, PhD; Anne J. Novak, PhD; Stephen M. Ansell, MD, PhD; | Checkpoint blockade; T cell; Tumor microenvironment |
| P649 | Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding | Lawrence P. Andrews, PhD; Ashwin Somasundaram, MD; Jessica Moskovitz, MD; Andrea L. Szymczak; Chang Liu, PhD; Anthony R. Cillo, PhD; Brenda F. Kurland; Huang Lin; Kelly D. Moynihan, PhD; Darrell J. Irvine, PhD; Robert L. Ferris, MD, PhD; Tullia C. Bruno, PhD; Creg Workman, PhD; Dario A. Vignali, PhD | Checkpoint blockade; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P650 | Selective CD47 immune checkpoint targeting on tumor cells modulates the tumor microenvironment to enhance macrophage tumoricidal function | Vanessa Buatois, PhD; Xavier Chauchet, PhD; Laura Cons; Laurence Chatel; Limin Shang, PhD; Marie H. Kosco-Vilbois; Krzysztof Masternak, PhD; Nicolas Fischer, PhD; Walter G. Ferlin, PhD | Antibody; Checkpoint blockade; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| P651 | First-in-human study of FAZ053, an anti-PD-L1 mAb, alone and in combination with spartalizumab, an anti-PD-1 mAb, in patients with advanced malignancies | Filip Janku, MD, PhD; David SP. Tan; Juan Martin-Liberal; Shunji Takahashi; Ravit Geva, MD; Ayca Gucalp; Xueying Chen; Kulandayan Subramanian; Jennifer Mataraza; Jennifer Wheler; Philippe Bedard, MD | Antibody; Checkpoint blockade; Clinical trial; Solid tumors |
| P652 | Cytokine-mediated induction of PD-L1 expression on tumor and immune cells | Shuming Chen, PhD; George A. Crabill, MS; Theresa S. Pritchard, MS; Tracee L. McMiller, MS; Drew M. Pardoll, MD, PhD; Fan Pan; Suzanne L. Topalian, MD | Checkpoint blockade; Cytokine; Immune suppression; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment |
| P653 | Discovery of a novel TIGIT therapeutic antibody with strong efficacy in tumor xenografts as monotherapy | Feifei Cui, PhD; Lei Fang; Zhengyi Wang; Taylor B. Guo; Jingwu Zang | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
| P654 | T-cell profiling in cancer tissue with multiplexed IHC using UltiMapper™ I/O assays | Sean R. Downing, PhD; Alexis Wong, PhD; Amy Zhang, M.S.; Max Rubinstein; Laura Sciarra, PhD; Chakib Boussahmain, Mr., B.S; Bonnie Phillips, PhD; Katir K. Patel, PhD; Stephanie Hennek, PhD | Antibody; Biomarkers; Immune contexture; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P656 | ATOR-1017, a tumor directed Fcγ-receptor cross linking dependent 4-1BB agonistic antibody | Karin Enell Smith, PhD; Anna Rosén; Karin Barchan; Ida Aberg; Doreen Werchau, BS; Mia Thagesson; Anna Dahlman; Niina Veitonmaki; Christina Furebring, PhD; Peter Ellmark, PhD | Antibody; Costimulation; Leukemia/Lymphoma; NK/NK T cell; Solid tumors; T cell |
| P657 | Agonist redirected checkpoint platform (ARC), engineering bi-functional fusion proteins (PD1-Fc-OX40L), for cancer immunotherapy | George J. Fromm, Jr., PhD; Suresh de Silva, Ph.D.; Taylor H. Schreiber, MD, PhD; | Checkpoint blockade; Costimulation; Cytokine; Immune suppression; T cell; Tumor antigens |
| P658 | Agonist redirected checkpoint platform (ARC), engineering bi-functional fusion proteins (TIM3-Fc-OX40L and TIM3-Fc-CD40L), for cancer immunotherapy | George J. Fromm, Jr., PhD; Suresh de Silva, Ph.D.; Taylor H. Schreiber, MD, PhD; | Antigen presenting cells; Checkpoint blockade; Costimulation; Cytokine; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P659 | AGEN2373 is a conditionally-active agonist antibody targeting the co-stimulatory receptor CD137 for the treatment of human malignancies | Claire H. Galand, PhD; David Savitsky, PhD; Vignesh Venkatraman; Min Lim; Rebecca Ward, MSc; Nicholas S. Wilson; Christina Riordan; Matthew Costa; Randi B. Gombos, PhD; Benjamin Morin, PhD; Dhan Chand, PhD | Antibody; Costimulation; NK/NK T cell; T cell; Tumor microenvironment |
| P660 | A novel bispecific agent targeting PD-L1 and IL-15/IL-15Ralpha promotes potent anti-tumor efficacy in multiple models of human solid carcinomas | Karin M. Knudson, PhD; Kristin C. Hicks, PhD; Yohei Ozawa, MD, PhD; Jeffrey Schlom, PhD; John Lee, MD; Shahrooz Rabizadeh, PhD; Patrick Soon-Shiong, MD, FRCS, FACS; Sofia Gameiro, PharmD, PhD | Checkpoint blockade; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P661 | Quantitative cell-based reporter gene bioassays to advance individual or combination cancer immunotherapy | Jamison J. Grailer, PhD; Jun Wang; Julia Gilden, PhD; Pete Stecha; Denise Garvin; Michael Beck; Jim Hartnett; Frank Fan, PhD; Mei Cong, PhD; Zhi-jie J. Cheng, PhD | Antibody; Checkpoint blockade; Coinhibition; Costimulation; T cell |
| P662 | A phase 1a/b study investigating novel anti-PD-L1 antibody (LY3300054): interim safety and clinical activity in patients with advanced cancers. | Antoine Hollebecque, MD; Hyun Cheol Chung, MD, PhD; Marcus O. Butler, MD; Antoine Italiano, MD; Chia-Chi Lin, MD, PhD; Jean-Pascal Machiels, MD, PhD; Wu-Chou Su, MD; Marc Peeters, MD, PhD; Leijun Hu, PhD; Anna M. Szpurka, PhD; Danni Yu, PhD; Anindya Chatterjee, PhD; Burkhard Vangerow, MD; Shivani Nanda, MS; Yumin Zhao, PhD; Mythili Koneru, MD; Yung-Jue Bang, MD PhD; Antoine Hollebecque, MD; Antoine Hollebecque, MD | Antibody; Biomarkers; Clinical study; Solid tumors; Targeted therapy |
| P663 | Successful monitoring of checkpoint inhibitors by flow cytometry | Laila-Aicha Hanafi; Valerie Hebert; Delphine Labit; Jean-Francpos Poulin, PhD, MBA; Vicky Sgouroudis, PhD; Philippe Pouliot, PhD | Checkpoint blockade; Immune monitoring; Immune suppression; T cell |
| P664 | Simultaneous checkpoint - checkpoint or checkpoint - costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation | Michael Hedvat, PhD; Gregory L. Moore, PhD; Matthew J. Bernett, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Alex Nisthal, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD | Antibody; Checkpoint blockade; Coinhibition; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P665 | Anti-tumor synergy evaluation of an AZD4635/ anti-PD-L1 combination therapy using a quantitative systems model | Veronika Voronova, MSc; Lulu Chu, PhD; Yuri Kosinsky, PhD; Alexandra Borodovsky, PhD; Richard Woessner, PhD; Kris Sachsenmeier, PhD; Ganesh Mugundu, PhD; Melinda S. Merchant, MD, PhD; Wenlin Shao, PhD; Kirill Peskov, PhD; Gabriel Helmlinger, PhD; | Antigen presenting cells; Checkpoint blockade; T cell; Tumor microenvironment |
| P666 | Antitumor efficacy of anti-TIGIT antagonist antibody EOS884448 is mediated by a dual mechanism of action involving restoration of T cell effector functions and preferential depletion of Tregs. | Chaterine Hoofd; Julia Cuende, PhD; Virginie Rabolli, PhD; Julie Preillon, MSc; Noemie Wald, PhD; Lucile Garnero; Florence Lambolez, PhD; Marjorie Mercier; Shruthi Prasad, PhD; Florence Nyawame; Sofie Denies, PhD; Margreet Brouwer, MSc; Erica Houthuys, PhD; Veronique Bodo, PhD; Xavier Leroy, PhD; Scott Chappel; Michel Detheux, PhD; Gregory Driessens, PhD; Chaterine Hoofd; Olivier de Henau; | Antibody; Checkpoint blockade; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P667 | EOS100850, an insurmountable and non-brain penetrant A2A receptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and shows best-in class characteristics. | Erica Houthuys, PhD; Stefano Crosignani, PhD; Reece Marillier, PhD; Theo Deregnaucourt, MSc; Margreet Brouwer, MSc; Romain Pirson, MSc; Joao Marchante, MSc; Annelise Hermant, MSc; Florence Nyawouame, MSc; Julie Preillon, MSc; Kim Frederix, PhD; Anne-Catherine Michaux, MSc; Jakub Swiercz, PhD; Gregory Driessens, PhD; Noemie Wald, PhD; Chiara Martinoli, PhD; Veronique Bodo, PhD; Michel Detheux, PhD; Xavier Leroy, PhD | Checkpoint blockade; Immune suppression; T cell; Tumor evasion; Tumor microenvironment |
| P668 | Selection of optimized drug candidates, dosing regimen, pharmacodynamic endpoints, tumor types, and biomarkers for translating inhibition of the adenosine pathway into effective anti-tumor activity | Juan C. Jaen, PhD; Jay P. Powers, PhD; Ulrike Schindler, PhD; Steve W. Young, PhD; Matthew J. Walters, PhD; Joanne BL. Tan, PhD; Lisa Seitz, MSc | Checkpoint blockade; Clinical trial; Immune suppression; Immune tolerance; T cell; Tumor microenvironment |
| P669 | First-in-human Phase 1 study of INCMGA00012 in patients with advanced solid tumors: Interim results of the cohort expansion phase | Janice J. Mehnert, MD; Anthony Joshua, MD; Nehal Lakhani, MD, PhD; Udai Banerji; Drew Rasco; Iwona Lugowska; Monika Tomaszewska-Kiecana; Elena Garralda; Deanna Kornacki, PhD; Bradley J. Sumrow; Mark Cornfeld, MD, MPH; Chuan Tian; John D. Powderly, II, MD, CPI | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P671 | Discovery of a novel anti-LAG3 antagonist antibody | Wenqing Jiang, PhD; Lei Fang; Zhengyi Wang; Taylor B. Guo; Jingwu Zang; | Checkpoint blockade; Coinhibition; T cell |
| P672 | Discovery and development of a humanized monoclonal antibody targeting the CD73 immune checkpoint for cancer immunotherapy | H. Toni Jun, Ph.D.; Fen Pei, Ph.D.; Hui Zou, Ph.D.; Ming Wang, Ph.D.; | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; Immune tolerance; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P673 | Preliminary results from an ongoing phase 1 study of AB122, an anti-programmed cell death-1 (PD-1) monoclonal antibody, in patients with advanced solid tumors | Paul de Souza, MBBS, MPH, PHD, FRACP; Chee Khoon Lee; Katrin Sjoquist; Shu Pan; Amanda Idan; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Lisa Seitz, MSc; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P674 | Defining Tim-3 signaling and localization during T cell activation | Shunsuke Kataoka, Ph.D; Lawrence P. Kane, Ph.D. | Antigen presenting cells; Costimulation; T cell |
| P675 | Mechanisms of primary resistance to immune checkpoint blockade | Duane Moogk, PhD; Michelle Krogsgaard, PhD; Kaitao Li, PhD; Zhou Yuan, PhD; Shi Zhong, PhD; Zhiya Yu; Ivan Liadi; William Rittase, PhD; Victoria Fang, BS; Janna Dougherty, BS; Arianne Perez-Garcia, PhD; Iman Osman; Jeffrey S. Weber, MD, PhD; Navin Varadarajan, PhD; Nicholas P. Restifo, MD; Alan Frey, PhD; Cheng Zhu, PhD; | Biomarkers; Checkpoint blockade; Immune suppression; Proteomics; T cell; Targeted therapy |
| P676 | Targeting the sialoglycan/Siglec pathway in combination with checkpoint inhibitors for cancer immunotherapy | Michal Stanczak; Natalia Rodrigues Mantuano; Adam Petrone; Melissa Anne Gray; Carolyn Bertozzi; Li Peng, PhD; Alfred Zippelius, MD; Heinz Läubli, MD PhD | Checkpoint blockade; Coinhibition; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P677 | The antitumor efficacy of TIM-3 blockade in a murine model of sarcoma | Kristen McEachern, PhD; Geeta Sharma; Srimoyee Ghosh, PhD; Sridhar Ramaswamy, MD; David Jenkins, PhD | Checkpoint blockade; Coinhibition |
| P678 | Targeting Siglec-15 with NC318, a novel therapeutic antibody to enhance anti-tumor immunity | Linda N. Liu, PhD; Jun Wang, PhD; Jingwei Sun, PhD; Dallas Flies, PhD; Chang Song, PhD; Melissa Zarr, PhD; Kristina Archer, PhD; Alison McGuire, BS; Tom O'Neill, MS; Karla Maloveste, MS; Xinxin Nie, PhD; Agedi Boto, MD/PhD; Ron Copeland, PhD; Sathya Janardhanan, MS; Tete Obot, BS; Jim Bingham, PhD; Kevin N. Heller, MD; Sol Langermann, PhD; Lieping Chen, MD, PhD; | Antibody; Checkpoint blockade; Coinhibition; Costimulation; Immune suppression; Monocyte/Macrophage; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P679 | Neuropilin-1 is a T cell memory checkpoint limiting long-term tumor immunity | Chang Liu, PhD; Ashwin Somasundaram, MD; Tullia C. Bruno, PhD; Creg Workman, PhD; Dario A. Vagnali | Checkpoint blockade; Immune suppression; T cell; Tumor evasion |
| P681 | A translational platform using primary human immune cells in vitro, syngeneic and humanized models in vivo to support and advance immune-oncology drug discovery | Shilina Roman; Gary Salmon; Julie Hawkins; Jonathan White, PhD; Julia Lloyd; Ria Goodwin; Arunima A. Ganguli, PhD; Omar Aziz; Julia Schueler; Ian Waddell; Martin O'Rourke; Edgar R. Wood, Ph.D. | Antibody; Checkpoint blockade; Cytokine; Immune adjuvant; Immune monitoring; Inflammation; Monocyte/Macrophage; Stem cell/cancer-initiating cell; T cell; Tumor microenvironment |
| P682 | Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy | Saman Maleki Vareki; Steven F. Gameiro; Farhad Ghasemi; John W. Barrett; James Koropatnick; Anthony C. Nichols; Joe S. Mymryk | Bioinformatics; Biomarkers; Checkpoint blockade; Costimulation; Dendritic cell; Immune monitoring; Solid tumors; Surgery; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P683 | The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation | Anne Mansson Kvarnhammar, PhD; Niina Veitonmäki; Karin Hagerbrand, PhD; Mia Thagesson; Doreen Werchau, BS; Kristine Smedenfors; Anna Dahlman; Anna Rosen, MSc; Maria Johansson; Ida Åberg; Per Norlen, MD, PhD; Christina Furebring, PhD; Peter Ellmark, PhD | Antibody; Checkpoint blockade; Costimulation; Regulatory T cell (Treg cell); T cell |
| P684 | Preclinical studies of TIM-3 blockade supporting clinical development of BMS-986258, an anti‒TIM-3 monoclonal antibody | Xiao Min Schebye, PhD; Minhua Han; Hong-An Truong; Andy Deng; Alan J. Korman, PhD; Mark Selby, PhD; Christine Bee | Antibody; Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs) |
| P685 | CD226 impact on TIGIT blockade in T-cell rejuvenation | Katherine G. MacDonald, PhD; Yoon Park; Padma Perkins; Eric Boyer; Salvatore Santino; Michael Hamilton; Ishita Barman; Pavel Strop; Alan J. Korman, PhD; Bryan Barnhart, PhD | Antibody; Checkpoint blockade; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| P686 | The number of metastatic compartments involved at immunotherapy initiation may influence survival in stage-IV non-small cell lung cancer. | Abdul Rafeh Naqash, MD; Mahvish Muzaffar, MD; Paul R. Walker, MD; Li V. Yang, PhD | Antibody; Checkpoint blockade; Clinical study; Tumor microenvironment |
| P687 | Single-cell analysis of human T cells in the bladder tumor microenvironment reveals novel cytotoxic CD4s that are modulated by anti-PD-L1 therapy | David Y. Oh, MD, PhD; Serena Kwek; Siddharth S. Raju, BS; Tony Li, BS; Eric Chow, PhD; Arun Burra, BS; Chien-Chun S. Pai, PhD; Chiara Rancan, PhD; Yang Sun, PhD; Jacky Li, BS; Dvir Aran, PhD; Matthew Spitzer, PhD; Serghei Mangul, PhD; Sima Porten, MD; Maxwell V. Meng, MD; Terence Friedlander, MD; Chun Jimmie Ye, PhD; Lawrence Fong, MD | Bioinformatics; Biomarkers; Immune contexture; Immune monitoring; Solid tumors; Systems biology; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P688 | Peripheral blood profiling to identify predictors of sensitivity to anti–PD-1 blockade in non-small cell lung cancer | Akio Osa; shohei koyama, MD PhD; Yujiro Naito; Takeshi Uenami; Masahide Mori; Atsushi Kumanogoh | Checkpoint blockade; Immune monitoring; T cell |
| P690 | Pharmacokinetics (PK) and dosing regimen selection of the PD-1 Inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary Phase 1 results from study M15-891 | Apurvasena Parikh, PhD; Sreeneeranj Kasichayanula, PHD; Rajeev Menon; Daniel Afar, PhD; Stacie L. Lambert; Benjamin Engelhardt; Sven Mensing; | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell |
| P691 | Correlating skin toxicity and steroid treatment with outcomes of Anti-PD-1 therapy | Henry Quach, BS; Anna K. Dewan, MD; Douglas B. Johnson, MD, MSCI; | Autoimmunity; Checkpoint blockade; Coinhibition; Immune suppression; Immune toxicity; Inflammation; Solid tumors; Targeted therapy |
| P692 | Effect of steroids in metastatic non-small cell lung cancer (mNSCLC) patients treated with nivolumab after initial platinum therapy in community practices in the United States | Jenine K. Sanzari, PhD; Marc Monté; David A. Smith; Mark Danese; Michelle Gleeson; Deborah Lubeck; James White; Pranav Abraham; Beata Korytowsky; Brian Ulrich | Checkpoint blockade; Clinical study; Solid tumors |
| P693 | Efficacy of ex-vivo PD-1 blockade in cervical tumor draining lymph nodes is related to a CD8+FoxP3+ T-cell subset with high levels of multiple immune checkpoints and superior effector functions | Jossie Rotman, MD; Marijne Heeren, MSc; Anita Stam; Noëlle Pocorni, MsC; Awa Gassama; Sanne Samuels, MD, PhD; Maaike Bleeker; Stijn Mom, MD PhD; Henry Zijlmans, MD PhD; Gemma G. Kenter, MD,PhD; Ekaterina S. Jordanova, PhD; Tanja D. de Gruijl, PhD; | Biomarkers; Checkpoint blockade; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P694 | An orally bioavailable small molecule dual antagonist of TIGIT and PD-L1 pathways shows immune-mediated anti-tumor activity | Pottayil Sasikumar, PhD; Sudarshan Naremaddepalli, PhD; Sandeep Patil, PhD; Chennakrishnareddy Gundala; Raghuveer K. Ramachandra, PhD; Nagesh Gowda, PhD; Saikrishna Tangela; Sreenivas Adurthi, PhD; Amit Dhudashia, MSc; Dodheri Samiulla, PhD; Nagaraj Gowda, PhD; Kavitha Nellore; Murali Ramachandra, PhD | Checkpoint blockade; Coinhibition |
| P695 | Differential expression of microRNAs in immune cell subpopulations during checkpoint inhibitor treatment | Barbara Seliger, MD, PhD; Rolf Kiessling, MD, PhD | Antigen presenting cells; Checkpoint blockade; Immune monitoring; T cell |
| P696 | Combined anti-PD-1 and anti-LAG-3 checkpoint blockade enhances CD8+ TIL effector function while reducing Tregs leading to reduced immune suppression and improved overall survival | Elizabeth R. Sturgill, PhD; Courtney Mick, BS; Elizabeth R. Sturgill, PhD; David Jenkins, PhD; Johanna K. Kaufmann, PhD, MSc; William L. Redmond, PhD; | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P697 | Preclinical characterization of AB154, a fully humanized anti-TIGIT antibody, for use in combination therapies | Joanne BL. Tan, PhD; Amy Anderson, PhD; Daniel DiRenzo, PhD; Annette Becker, PhD; Susan J. Lee, PhD; Lisa Seitz, MSc; Rick Stanton, MSEE; Hema Singh; Sharon Zhao; Nigel PC. Walker, PhD; Matthew J. Walters, PhD | Checkpoint blockade; Coinhibition; Gene expression; Immune monitoring; NK/NK T cell; Regulatory T cell (Treg cell); T cell |
| P698 | Outcomes of advanced triple negative breast cancer patients enrolled in immune oncology clinical trials | Tira Tan, MBBS; Lisa Wang; David Cescon; Eitan Amir; David Warr; Christine Elser; Marcus O. Butler, MD; Albiruni R. Razak; Aaron Hansen; Anna Spreafico, MD PhD; Lillian Siu, MD; Philippe Bedard, MD; | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors |
| P699 | MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), increases T cell effector function and depletes regulatory T cells in blood and tumor | Katie Streicher, PhD; Keith E. Steele, DVM, PhD; Steven Eck, Ph.D.; Yanan Zheng, PhD; Farzad Sekhavati, PhD; Han Si; Fernanda Pilataxi; Song Wu, PhD; Brandon W. Higgs, PhD; Danielle Townsley; Rakesh Kumar, PhD; Mike Sheehan, PhD; Scott Hammond, PhD; Matthew Gribbin; Victoria Chiou, MD; Maria Jure-Kunkel; Sandip P. Patel, MD; John D. Powderly, II, MD, CPI; Bonnie S. Glisson, MD; Koustubh Ranade, PhD | Clinical trial; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| P700 | Immune checkpoint inhibitors induce differential anti-tumor response and immune cell infiltration across syngeneic models | Patrick Allison, PhD; Hua-Chen Chang; Lauren B. Ursic, BA; Paul Trampont, PhD; Lindsey Standarski; Jennifer L. Rusk, NA; Brandy Wilkinson, PhD | Checkpoint blockade; Myeloid cells; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P701 | Off-label use of immunotherapy in advanced malignancies | David Xu; Kathryn Gold, MD; Lyudmila Bazhenova, MD; Sandip P. Patel, MD | Checkpoint blockade |
| P702 | Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab | Hao Chi Zhang, MD; Wenyi Luo, MD; Yinghong Wang, MD, PhD; | Checkpoint blockade; Immune toxicity; Inflammation |
| P703 | Exploration of PD-1/PD-L1 spatial interaction and T cells functionality to predict anti-PD-1 treatment outcome in GI tract tumors using automated quantitative fluorescence multiplexed IHC | Xiangxue Wang, B.S.; Shizen Moh, B.S.; José L. Muñoz-Rodríguez, PhD; Antony Hubbard, BS; Mehrnoush Khojasteh, PhD; Qingfeng Zhu, PhD; Robert A. Anders, MD, PhD; Luis A. Diaz, MD; Lidija Pestic-Dragovich; Lei Tang, PhD; Wenjun Zhang, MD, PhD; | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P704 | Batf3 dendritic cells within the tumor microenvironment are necessary during the effector phase of the immune response for anti-PD-L1 efficacy through a mechanism involving the 4-1BB/4-1BB ligand axis | Andrea Ziblat, PhD; Brendan L. Horton; Philip C. He, BA; Thomas F. Gajewski, MD, PhD; | Checkpoint blockade; Costimulation; Dendritic cell; T cell |
| P705 | Time to GoInVivo(TM), validated checkpoint functional antibodies for cancer research | Miguel Tam, PhD; Josh Croteau; | Antibody; Cytokine; Immune monitoring; Immune suppression; T cell; Tumor antigens |
